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A B S T R A C T
Background
Oral poisoning is a major cause of mortality and disability worldwide, with estimates of over 100,000 deaths due to unintentional
poisoning each year and an overrepresentation of children below five years of age. Any effective intervention that laypeople can apply
to limit or delay uptake or to evacuate, dilute or neutralize the poison before professional help arrives may limit toxicity and save lives.
Objectives
To assess the effects of pre-hospital interventions (alone or in combination) for treating acute oral poisoning, available to and feasible
for laypeople before the arrival of professional help.
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, ISI Web of Science, International
Pharmaceutical Abstracts, and three clinical trials registries to 11 May 2017, and we also carried out reference checking and citation
searching.
Selection criteria
We included randomized controlled trials comparing interventions (alone or in combination) that are feasible in a pre-hospital setting
for treating acute oral poisoning patients, including but potentially not limited to activated charcoal (AC), emetics, cathartics, diluents,
neutralizing agents and body positioning.
Data collection and analysis
Two reviewers independently performed study selection, data collection and assessment. Primary outcomes of this review were incidence
of mortality and adverse events, plus incidence and severity of symptoms of poisoning. Secondary outcomes were duration of symptoms
of poisoning, drug absorption, and incidence of hospitalization and ICU admission.
Main results
We included 24 trials involving 7099 participants. Using the Cochrane ’Risk of bias’ tool, we assessed no study as being at low risk of
bias for all domains. Many studies were poorly reported, so the risk of selection and detection biases were often unclear. Most studies
reported important outcomes incompletely, and we judged them to be at high risk of reporting bias.
All but one study enrolled oral poisoning patients in an emergency department; the remaining study was conducted in a pre-hos-
pital setting. Fourteen studies included multiple toxic syndromes or did not specify, while the other studies specifically investigated
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paracetamol (2 studies), carbamazepine (2 studies), tricyclic antidepressant (2 studies), yellow oleander (2 studies), benzodiazepine
(1 study), or toxic berry intoxication (1 study). Eighteen trials investigated the effects of activated charcoal (AC), administered as a
single dose (SDAC) or in multiple doses (MDAC), alone or in combination with other first aid interventions (a cathartic) and/or
hospital treatments. Six studies investigated syrup of ipecac plus other first aid interventions (SDAC + cathartic) versus ipecac alone.
The collected evidence was mostly of low to very low certainty, often downgraded for indirectness, risk of bias or imprecision due to
low numbers of events.
First aid interventions that limit or delay the absorption of the poison in the body
We are uncertain about the effect of SDAC compared to no intervention on the incidence of adverse events in general (zero events
in both treatment groups; 1 study, 451 participants) or vomiting specifically (Peto odds ratio (OR) 4.17, 95% confidence interval
(CI) 0.30 to 57.26, 1 study, 25 participants), ICU admission (Peto OR 7.77, 95% CI 0.15 to 391.93, 1 study, 451 participants) and
clinical deterioration (zero events in both treatment groups; 1 study, 451 participants) in participants with mixed types or paracetamol
poisoning, as all evidence for these outcomes was of very low certainty. No studies assessed SDAC for mortality, duration of symptoms,
drug absorption or hospitalization.
Only one study compared SDAC to syrup of ipecac in participants withmixed types of poisoning, providing very low-certainty evidence.
Therefore we are uncertain about the effects on Glasgow Coma Scale scores (mean difference (MD) −0.15, 95% CI −0.43 to 0.13,
1 study, 34 participants) or incidence of adverse events (risk ratio (RR) 1.24, 95% CI 0.26 to 5.83, 1 study, 34 participants). No
information was available concerning mortality, duration of symptoms, drug absorption, hospitalization or ICU admission.
This review also considered the added value of SDAC or MDAC to hospital interventions, which mostly included gastric lavage. No
included studies investigated the use of body positioning in oral poisoning patients.
First aid interventions that evacuate the poison from the gastrointestinal tract
We found one study comparing ipecac versus no intervention in toxic berry ingestion in a pre-hospital setting. Low-certainty evidence
suggests there may be an increase in the incidence of adverse events, but the study did not report incidence of mortality, incidence or
duration of symptoms of poisoning, drug absorption, hospitalization or ICU admission (103 participants).
In addition, we also considered the added value of syrup of ipecac to SDAC plus a cathartic and the added value of a cathartic to SDAC.
No studies used cathartics as an individual intervention.
First aid interventions that neutralize or dilute the poison
No included studies investigated the neutralization or dilution of the poison in oral poisoning patients.
The review also considered combinations of different first aid interventions.
Authors’ conclusions
The studies included in this review provided mostly low- or very low-certainty evidence about the use of first aid interventions for
acute oral poisoning. A key limitation was the fact that only one included study actually took place in a pre-hospital setting, which
undermines our confidence in the applicability of these results to this setting. Thus, the amount of evidence collected was insufficient
to draw any conclusions.
P L A I N L A N G U A G E S U M M A R Y
First aid treatments for oral poisoning
Review question
We reviewed the evidence on the effects of first aid treatments for poisoning that could be feasibly given by people who are not health
professionals.
Background
Many first aid treatments are recommended for treating people who have ingested poisonous substances. Some treatments, such as
activated charcoal (AC), bind to the poison, limiting the body’s absorption of it. Others may induce vomiting (such as syrup of ipecac)
or dilute or neutralize the poison (such as drinking water, milk or juices). Adjusting the person’s body position may also have an effect.
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Study characteristics
In May 2017 we searched for high-quality studies (randomly dividing participants into different treatment groups) investigating
treatments for poisoning that laypeople can perform. We found 24 studies with 7099 participants. All but one study took place in
hospitals; the remaining one was in a home setting.
Fourteen studies either did not specify the type of poison or studied different kinds. The others investigated overdoses of specific
medicines (paracetamol, carbamazepine, antidepressant, benzodiazepine) or poisonous plants (yellow oleander or poisonous berries).
Eighteen trials studied different treatments with activated charcoal: as a single dose or multiple doses, with or without other first aid
treatments (a substance to speed up bowel transit), and with or without hospital treatments. Six studies compared syrup of ipecac, with
or without other first aid treatments (single-dose activated charcoal plus bowel transit enhancing substance) versus no treatment. We
found no studies that investigated the neutralization or dilution of the poison or the use of certain body positions.
Key results
Two studies compared a single dose of activated charcoal to no treatment following poisoning with paracetamol or different kinds of
poisoning. We are uncertain about the treatment’s side effects, admission to intensive care or worsening of the patient, and there was
no information about effects on death, symptom duration, poison uptake or hospitalization.
One study compared a single dose of activated charcoal to ipecac in mixed types of poisoning. We are uncertain about the effect of
activated charcoal compared to ipecac, on the patient’s level of coma or the number of unwanted effects. There was no information
about effects on death, symptom duration, poison uptake, hospitalization or intensive care admission.
One study compared ipecac to no treatment in children who ate poisonous berries at home. There may be an increase in the number
of unwanted effects for ipecac. There was no information about effects on death, poisoning symptoms, symptoms duration, poison
uptake, hospitalization or intensive care admission.
We also investigated the use of single-dose or multi-dose activated charcoal, with or without hospital treatment, compared to each
other or no treatment. Furthermore, we investigated the added value of ipecac to single-dose activated charcoal and the added value of
adding bowel transit enhancing substances to AC.
Certainty of the evidence
All but one study took place in a hospital setting, which means that the results cannot be directly applied to the lay setting. Because
studies did not always report the methods they used, we are uncertain about the quality of the research conduct for many. Outcomes
important to patients and pre-specified by us as important outcomes for this review were often absent or incompletely reported. Our
certainty about the results of this review is mostly low to very low. Therefore future research is highly likely to change the findings.
Conclusion
Based on the identified evidence, we cannot draw any conclusions about the effects of any of the investigated first aid treatments in a
lay setting.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
SDAC versus no intervention for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (paracetamol or not specif ied)
Setting: hospital sett ing
Intervention: single-dose act ivated charcoal (SDAC)
Comparison: no intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evidence
(GRADE)
Comments
Risk with no interven-
tion
Risk with SDAC
Incidence of mortality No studies collected or reported this outcome
Incidence of adverse
events
Control group: 0/ 236; intervent ion group:
4/ 240 (Peto OR 4.17, 95% CI 0.30 to 57.
26)
- 476
(2 RCTs)
⊕©©©
Very lowa,b,c
We are uncertain of the
ef fect of SDACon the inci-
dence of adverse events
Incidence and severity
of symptoms of poison-
ing: incidence of clini-
cal deteriorat ion during
stay in the hospital
- - 451
(1 RCT)
⊕©©©
Very lowa,b,d
The relat ive ef fect was
not est imable due to the
absence of events in the
intervent ion (0/ 220) and
the control group (0/ 231)
. We are uncertain of the
ef fect of SDAC on inci-
dence and severity on poi-
soning
Durat ion of toxic symp-
toms
No studies collected or reported this outcome
Drug absorpt ion No studies collected or reported this outcome
Incidence of hospital-
izat ion
No studies collected or reported this outcome
4
F
irst
a
id
in
te
r
v
e
n
tio
n
s
b
y
la
y
p
e
o
p
le
fo
r
a
c
u
te
o
ra
l
p
o
iso
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Incidence of ICU admis-
sion
Control group: 0/ 231; intervent ion group:
1/ 220 (Peto OR 7.77, 95% CI 0.15 to 391.
93)
- 451
(1 RCT)
⊕©©©
Very lowa,b,c
We are uncertain of the
ef fect of SDAC on the in-
cidence of ICU admission
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ICU: intensive care unit ; MD: mean dif ference; RCT : randomized controlled trial; RR: risk rat io; SDAC: single-dose act ivated charcoal; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious lim itat ions in study design: high risk of select ion bias.
bDowngraded one level for serious indirectness: study conducted in a hospital sett ing.
cDowngraded one level for serious imprecision: low number of events and wide conf idence intervals.
dDowngraded one level for serious imprecision: low number of events.
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B A C K G R O U N D
Description of the condition
Poisoning can be defined as exposure of the body to exogenous
substances, in sufficiently large amounts to cause harm to the
individual. This canhappen through chronic exposure to lowdoses
of a substance, or more acutely through sudden exposure to a
harmful dose. Acute poisoning can happen either accidentally or
voluntarily, as a way to end one’s own or another’s life or as a ’cry
for help’.
Poisoning inflicts a major burden of morbidity and mortality
worldwide. The World Health Organization (WHO) estimates
that 108,000 deaths a year are caused by unintentional poisoning
(WHO 2016), accompanied by the loss of a staggering 6,558,000
disability adjusted life years (DALYs) (WHO 2016). In addition
to this, auto-intoxication is one of the most common methods to
attempt suicide. Yearly, around 800,000 people worldwide com-
mit suicide, and around 30% of their attempts occur through the
intake of pesticides, a phenomenon typically occurring in rural
areas in lower- and middle-income countries (WHO 2018). As
most attempted suicides are unsuccessful, the actual burden will
be much higher (Albert 2015). Poisoning can happen via differ-
ent routes of exposure, such as through inhalation, injection or
dermal absorption, but by far the most common is through delib-
erate or accidental ingestion of a toxic substance (Mowry 2016),
which is the focus of this review. An important patient group to
suffer from unintentional poisoning are young children. Roughly
20% of all accidental poisonings are thought to occur in children
aged under 5 years (WHO 2016). In high-income countries, this
proportion is even larger: up to 47% of the incoming calls to the
American Poison Control Centers concern exposures in this age
group (Mowry 2016). This is most likely because young children
are curious to explore their environment and do not realize the
dangers of putting unknown and potentially harmful things in
their mouth. Indeed, large numbers of exposures are to cosmetics
and household products (25% of all reported exposures in chil-
dren aged 5 years or younger; Mowry 2016).
Hospital treatment of acute oral poisoning focuses initially on
supportive therapy: hypertonic glucose infusion, maintaining the
victim’s vital parameters and keeping poison-induced symptoms
under control (Isbister 2016; Nelson 2011). If practitioners can
identify a toxin syndrome, they can administer a poison-specific
antidote, for example N-acetylcysteine for a paracetamol overdose
or naloxone for an opioid overdose (Brok 2006;Wilkerson 2016).
Third-line treatment options include gastrointestinal decontam-
ination procedures: activated charcoal can adsorb the poisonous
substance (Corcoran 2016), while gastric lavage or whole bowel ir-
rigation are procedures that attempt to eliminate the poison out of
the gastrointestinal tract before absorption into the blood (Donkor
2016;Thanacoody 2015). A final treatment strategy is to eliminate
toxins that have already been absorbed through multiple doses of
activated charcoal, haemodialysis or blood/urinary alkalinization
(Decker 2015; Gaudreault 2005; Proudfoot 2003; Roberts 2005).
In cases of acute oral poisoning, a swift reaction is crucial. For
activated charcoal (AC), experimental studies have shown that its
efficacy in limiting drug absorption decreases dramatically over
time (Chyka 2005). Therefore, treatment guidelines recommend
using AC within an hour after ingestion of the poison, although
AC may still produce effects after that time, especially in drugs
administered in a delayed release formula (Chyka 2005; Juurlink
2015). However, it is difficult to adhere to these guidelines in
emergency services, mainly due to the delay between ingestion
and presentation at the emergency department (Karim 2001;
LoVecchio 2007; Tuuri 2009). Thus, any effective first aidmeasure
thatwouldneutralize, limit or delay uptake, or promote evacuation
from the gastrointestinal tract in case of acute oral poisoning,
could save precious time for professionals, potentially making the
difference between life and death, or serious morbidity, for the
poisoned patient.
First aid, as defined by the International Liaison Committee On
Resuscitation (ILCOR), is the immediate help provided to a sick
and injured person until professional help arrives. First aid inter-
ventions seek to preserve life, alleviate suffering, prevent further
illness or injury and promote recovery (Zideman 2015). This def-
inition implies that a first aid intervention must be both available
to and feasible for a layperson in a pre-hospital setting. Of the pre-
viously mentioned hospital interventions, only activated charcoal,
which is relatively easy to administer orally and available with-
out prescription, is feasible. In addition to these, other suggested
first aid techniques include administering emetics, such as syrup
of ipecac (or ipecacuanha) (Quang 2000); using cathartics, such
as sorbitol (Keller 1990), drinking water, milk, vinegar or citrus
juice to dilute and/or neutralize the poison (Rumack 1977); or
adjusting the poisoned victim’s body position to slow down the
uptake of the poison (Vance 1992).
In case of ingestion of toxic alcohols (e.g. methanol, ethylene gly-
col), ethanol could be considered a potential home remedy due to
its wide availability. However, the use of large volumes of ethanol
is dangerous and needs to be monitored carefully (Rietjens 2014).
Therefore, it is not recommended for use in a lay setting without
professional guidance.Current recommendations for laypeople are
limited to placing the victim in the lateral decubitus position and
seeking professional help (e.g. contacting poison control centres
if available) and following their advice (IFRC 2016).
Description of the intervention
The focus of this Cochrane Review is any intervention that is read-
ily available to and administrable by laypeople before professional
help arrives, targeted at neutralizing, limiting or delaying the ab-
sorption, or promoting the evacuation of a poison.
Limiting the absorption of a poison can be achieved by adminis-
tering an adsorbent, such as activated charcoal. This black pow-
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der is produced through pyrolysis of carbon-rich materials and
activation by steam to remove already adsorbed substances (Olson
2010). This process results in a material with a very large surface
area and hence adsorbing capacity. It needs to be mixed with water
to form a slurry that can be ingested.
Placing the poisoning victim on their left side might be another
method to decrease absorption of the poison (Vance 1992).
Substances that can promote the evacuation of a poison from the
gastrointestinal tract firstly include emetics. The best known and
most recommended is syrup of ipecacuanha, or ipecac. This syrup
is derived from the roots and rhizome of Cephaelis ipecacuanha
(Lee 2008). Other suggested emetics are apomorphine and copper
sulphate. Apomorphine is believed to induce vomiting faster than
ipecac (MacLean 1973), but it is not feasible to administer in a
home setting and can cause central nervous depression, so it is not
recommended, especially in children (MacLean 1973). Copper
sulphate has also been used to induce vomiting in people with
oral poisoning due to its action as a local irritant in the stomach
(Karlsson 1965). However, it is a common source of intoxication
itself, hence its use is also discouraged (Nastoulis 2017).
A second class of substances that can theoretically speed up the
evacuation of an ingested poison from the gastrointestinal tract
are cathartics. Patients who have ingested slow-absorbing mate-
rials might benefit most from these treatments, although current
guidelines suggest not using cathartics without activated charcoal
(American Academy of Clinical Toxicology 2004). Examples of
suggested cathartics include sugars, such as mannitol, lactulose
and sorbitol, or salts, including magnesium sulphate, magnesium
citrate and sodium sulphate.
In addition, diluting and neutralizing poisons, especially caustic
substances such as lye, could occur through the intake of water,
milk, vinegar or citrus juice (Rumack 1977). Milk might also have
some adsorbing capacity (Chin 1969).
How the intervention might work
First aid interventions to treat poisoning can be categorized in four
groups:
• those that either limit or delay absorption of the poison in
the body, such as activated charcoal or certain body positions;
• interventions that evacuate the poison from the
gastrointestinal tract, either by vomiting or by defecation;
• combinations of first aid interventions that limit uptake
and promote evacuation of the poison, e.g. sorbitol and activated
charcoal;
• first aid interventions that neutralize or dilute the poison,
such as drinking water, milk, vinegar or citrus juice.
Furthermore, other combinations of first aid interventions may
also be used.
A. First aid interventions that limit or delay the
absorption of the poison in the body
One way to limit the absorption of a poison is to administer a
substance that binds to the poison, thus preventing it from being
absorbed by the body. Activated charcoal (AC) is one such ad-
sorbent. Its enormous surface area can adsorb large quantities of
drugs through the generation of Van derWaals forces between the
charcoal and the adsorbed molecule (Olson 2010). Not all sub-
stances are equally effectively bound by AC. For example, lithium,
iron, cyanide or alcohols bind to AC only to a minor extent, which
means its appropriateness needs to be carefully considered in these
cases (Bateman 1999; Juurlink 2015; Olson 2010). The optimal
dose regimen for activated charcoal administration is not entirely
clear, but 25 g to 100 g is considered to be a standard dose for
adults (Chyka 2005). In practice, ingesting more than 50 g seems
to be difficult to achieve for patients.
A certain body position might also slow down the uptake of the
poison. The primary site of absorption for most pharmacologic
substances is the small intestine, because of its large surface area
and thin epithelium. Therefore, any factor that would delay gastric
emptying into the small intestine should decrease the rate of ab-
sorption and limit the potential toxic effects of the ingested drug.
Studies indicate that laying on the right side accelerates gastric
emptying (Loots 2013; Valeur 2015; VanWijk 2007). In contrast,
placing the patient in the left lateral decubitus position might slow
the rate of absorption of the ingested poison, because the anatomy
of the stomach, combined with gravity, would allow the gastric
content to stay in the greater curvature of the stomach (Vance
1992).
B. First aid interventions that evacuate the poison
from the gastrointestinal tract
Evacuation of the poison from the gastrointestinal tract as quickly
as possible can be achieved by inducing vomiting or accelerating
defecation. Two types of drugs can be considered: emetics induce
vomiting, while cathartics accelerate defecation.
As mentioned before, syrup of ipecac is the best known type of
emetic. The main active substances of the ipecacuanha plant are
emetine and cephaeline, which induce emesis and diarrhoea by
acting both as a local irritant in the upper gastrointestinal tract
and by targeting the chemoreceptor trigger zone in the medulla
oblongata of the brain, the body’s vomiting centre (Lee 2008).
A potential risk associated with the use of emetics is lung injury
through vomit aspiration (Höjer 2013).
Cathartics draw water into the large intestine, thereby stimulating
bowel movements and thus accelerating defecation (American
Academy of Clinical Toxicology 2004).
C. First aid interventions that limit uptake and
promote evacuation of the poison from the
gastrointestinal tract
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Cathartics can be used with activated charcoal. This combination
is thought to reduce drug uptake by accelerating evacuation out of
the small bowel (Moon 2015). Furthermore, cathartics counteract
the constipating effects of AC (James 1995). On the other hand,
in vitro studies have suggested that cathartics might influence the
adsorbing capacity of AC (Orisakwe 2001).
D. First aid interventions that neutralize or dilute the
poison
A commonly used home remedy for poisoning by caustic sub-
stances is drinking large amounts of fluids, such as water, milk,
vinegar or citrus juice (Rumack 1977). The rationale behind this
is not only to dilute the poison, but also to change the pH in the
stomach, thereby neutralizing the caustic effects of the ingested
poison. Considerations that need to be made when using this ap-
proach are the chemical properties of the ingested substance (acidic
or basic), the heat production that might occur during neutral-
ization and sufficient availability of the neutralizing substance. In
addition to its potential neutralizing effect, in vitro data suggest
that milk has some adsorbing capacity (Chin 1969). However, in-
creasing the volume of fluids in the stomach might also increase
the rate of emptying into the small bowel, where the absorption of
the poison takes place (Blain 2011). Furthermore, drinking large
amounts of water might cause water intoxication (Lai 2016). A
final consideration is that drinking large volumes of fluids might
increase the risk of vomiting, which could be problematic in cases
of caustic poisoning, as the caustic substance would contact the
oesophagus for a second time.
Why it is important to do this review
There are several Cochrane Reviews concerning the treatment and
prevention of poisoning. Kendrick 2012 provided evidence on in-
terventions to prevent injuries at home, including cases of oral
poisoning, while Hawton 2015 investigated potential interven-
tions to decrease self-harm in children, adolescents and adults. A
review by Nussbaumer-Streit 2016 documented potential house-
hold interventions to prevent domestic lead exposure in children.
In addition, numerous Cochrane Reviews have investigated the
use of hospital interventions to treat a range of specific intoxica-
tions, such as for example paracetamol or lithium poisoning (Brok
2006; Lavonas 2015).
This Cochrane Review fills the gap between prevention and hos-
pital treatment of poisoning, by investigating which pre-hospi-
tal interventions, available and feasible for a lay person in a non-
healthcare setting, are effective in cases of acute oral poisoning.
Identified interventions can be used in first aid guidelines targeted
at lay people, to be applied before arrival of professional help. As
time is a crucial factor in acute oral poisoning, effective interven-
tions conducted by laypeople would save valuable time and could
therefore be crucial to survival (Chyka 2005; Juurlink 2015).
O B J E C T I V E S
To assess the effects of pre-hospital interventions (alone or in com-
bination) for treating acute oral poisoning, available to and feasi-
ble for laypeople before the arrival of professional help.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered randomized controlled trials (RCTs) in actual poi-
soning patients. We excluded studies involving healthy volunteers
and preclinical studies (animal studies, in vitro research).
In order to be eligible for inclusion in the review, all RCTs taking
place after 2010 must have been prospectively registered (Roberts
2015). All RCTs conducted prior to 2010 were eligible for inclu-
sion.
Types of participants
We included participants poisoned via oral ingestion, both delib-
erately and accidentally. In addition to studies in a community
setting, we considered studies conducted in a healthcare setting,
including a hospital setting or ambulatory care, as most studies
identified would likely have been performed in a controlled set-
ting. Although this may be a source of indirectness, we feel that
excluding these studies would result in selection bias.
Types of interventions
All identified first aid interventions, alone or in combination and
feasible for a layperson in a pre-hospital setting, were eligible.
These included, among others, activated charcoal and other ad-
sorbents (single- or multi-dose); syrup of ipecac and other emet-
ics (single or multi-dose); cathartics (single or multi-dose); body
positioning; and water, milk, vinegar or citrus juice.
We compared the interventions to each other or to no interven-
tion. We did not compare them to typical hospital interventions
such as gastric lavage, whole bowel irrigation or the use of anti-
dotes. However, if pre-hospital treatments were used in adjuvant
to an established hospital treatment, we included these studies.
The reason for not considering established hospital treatments as
comparisons is that we are interested in the most efficacious treat-
ments in a non-healthcare setting. It is likely that these would be
less efficient than a hospital treatment, but they might still be use-
ful as a first aid measure, which typically takes place before pre-
sentation to a healthcare facility.
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Co-interventions were allowed if all groups received them in equal
doses. We separately explored interventions aiming to limit or de-
lay absorption of poison, evacuate poison, limit uptake and evac-
uate poison, and neutralize or dilute poison.
Types of outcome measures
Timings of outcomes are defined as early (within 24 h after poi-
soning), intermediate (24 h to one week after poisoning) and late
(more than one week and less than one year after poisoning).
Primary outcomes
• Incidence of mortality
• Incidence of adverse events due to the intervention
• Incidence and severity of symptoms of poisoning, reported
for example with the Poisoning Severity Score (PSS) (Persson
1998)
Secondary outcomes
• Duration of toxic symptoms
• Drug absorption: measured as maximal concentration of
drug in the blood (Cmax ), time to Cmax (Tmax ) or area under the
curve (AUC) of drug concentration versus time
• Incidence of hospitalization
• Incidence of intensive care unit (ICU) admission
Search methods for identification of studies
Electronic searches
We searched the following databases on 11 May 2017, without
any language restrictions or date limits.
• The Cochrane Library (2017, Issue 5, searched 11 May
2017; www.cochranelibrary.com), including the following
databases.
◦ The Cochrane Database of Systematic Reviews.
◦ The Cochrane Central Register of Controlled Trials
(CENTRAL), for reports of RCTs from MEDLINE, Embase
and records submitted from Cochrane Specialized Registers,
including the Cochrane Injuries Group.
◦ DARE (Database of Abstracts of Reviews of Effect).
• MEDLINE, using the PubMed interface (1966 to 11 May
2017).
• Embase, using the Embase.com interface (1947 to 11 May
2017).
• CINAHL, using the EBSCO host interface (1982 to 11
May 2017).
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) and Conference Proceedings Citation Index-
Science (CPCI-S) (1900 to 11 May 2017).
• International Pharmaceutical Abstracts, using the Ovid
interface (1970 to 11 May 2017).
• Clinicaltrials.gov (clinicaltrials.gov).
• EU Clinical Trials Register ( www.clinicaltrialsregister.eu).
• WHO International Clinical Trials Registry Platform (
ICTRP) ( www.who.int/ictrp/en/).
For each of the articles included, we did a search in MEDLINE
(via the PubMed interface) and screened the first 20 similar arti-
cles for additional relevant publications. Search strategies can be
found in Appendix 1. Furthermore, we searched previously pub-
lished systematic reviews and evidence-based guidelines that were
identified during the database searches (Table 1).
We included relevant conference abstracts retrieved from searches
in the above-mentioned databases in the review.
Searching other resources
We searched the reference list of included articles, retrieved with
the above searches, to identify other studies.
Data collection and analysis
Selection of studies
Two authors (BA and VB) independently screened the titles and
abstracts of all references yielded by the search. Subsequently, we
retrieved full texts of selected articles, using a study selection form
to assess eligibility.We resolved any discrepancies between authors
through discussion. In cases where no consensus could be reached,
we consulted a third author (EDB or AV). We documented the
included studies in the appropriate sections within the review and
summarized studies that were excluded after full-text assessment
in the Characteristics of excluded studies table, together with the
reason for exclusion. We describe identified studies that were se-
lected based on study design, study population and intervention
of interest, but which reported no outcome of interest or outcome
data, in the Results section of the review. We tried to contact the
authors to ascertain whether the data for our outcomes of interest
were unavailable due to lack of measurement or lack of reporting.
Data extraction and management
Two authors (BA, VB and/or AV) independently extracted data
from all studies using a standardized and piloted data extraction
form.
They extracted the following information from each study.
• General information: author, year of publication, year of
study, country of author.
• Study characteristics.
◦ Study design.
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◦ Information on study population: number of
participants, age, sex, country of study and poisoning
characteristics (type and dose of intoxication, deliberate or
accidental intoxication, time elapsed between intoxication and
intervention, experimental or community setting).
◦ Details of the intervention and the comparison: type
of intervention, dose, route of administration, duration of the
treatment.
◦ Outcome(s) measured.
• Study findings.
◦ Effects of the intervention on the outcome: effect
measure, confidence interval, P value.
◦ Number of events and participants in intervention and
comparison groups.
Assessment of risk of bias in included studies
Two authors (BA, VB and/or AV) independently assessed risk of
bias in the included studies using Cochrane’s ’Risk of bias’ tool
(Higgins 2011). They assessed the domains of sequence genera-
tion, allocation concealment, blinding of participants and person-
nel, blinding of outcome assessment, incomplete outcome data
addressed, selective reporting and possible other bias, rating each
domain as being at low, high or unclear risk of bias.
Measures of treatment effect
We used Review Manager 5 (RevMan 5) to manage data and con-
duct analyses (RevMan 2014). We reported continuous outcomes
as mean differences (MD) with 95% confidence intervals (CIs)
and dichotomous outcomes as risk ratios (RR) with 95% CIs, or
Peto odds ratios (OR) when events were rare and criteria were sat-
isfied.
Unit of analysis issues
We identified studies that had a multi-arm design. We were cau-
tious during the analysis of these data, ensuring that the same
group of participants was not included twice in the meta-analy-
sis. We achieved this by ensuring that separate interventions were
not included in a single meta-analysis. Secondly, if multiple doses
or administration times of an intervention were compared to a
control group, we combined groups to create a single pair-wise
comparison in the case of dichotomous outcomes, according to
the recommendations of the Cochrane Handbook for Systematic Re-
views of Interventions on the analysis of multi-arm trials (Higgins
2011). We did not identify multi-arm trials reporting continuous
outcomes.
Dealing with missing data
In case of missing data, we attempted to contact the authors to
obtain these data at least twice, if contact details were available.
Where possible, we calculated missing values (such as SDs) from
the available data (P values, t values, CIs or standard errors) (
Higgins 2011).
If insufficient data were available to calculate missing values, we
only analysed the available data. We narratively described results
from studies with missing data. We addressed the issue of the
missing data and their potential impact on the findings of the
study in the Discussion.
Assessment of heterogeneity
The target population of this review, patients with oral poison-
ing, is inherently heterogeneous with respect to the type, dose and
timing of poison intake. However, the target audience for deliv-
ering this intervention, laypeople, are likely not capable of differ-
entiating between these differences. Therefore, a certain degree of
heterogeneity in the results is unavoidable.
Our analyses are stratified based on type of intervention. We as-
sessed heterogeneity by inspection of the forest plot and by using
the Chi²-test and the I² statistic. We considered the Chi² statis-
tic to be significant at P < 0.10. For interpretation of the I², we
followed the guidance of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
When I² was at least 80% and the P value of the Chi² test was less
than 0.1, we considered heterogeneity to be substantial, whereas
for I² values below 40%, we considered heterogeneity to be unim-
portant. When heterogeneity was substantial, we examined the
direction of the effects before making a decision whether to report
the pooled result or describe the effects narratively.
Assessment of reporting biases
We planned methods for assessing reporting biases, but we could
not perform them (New Reference). See Differences between
protocol and review section.
Data synthesis
Where possible, we performed meta-analyses. We pooled data if
there were two or more studies on the same intervention that as-
sessed the same outcome and provided sufficient data. We did not
combine outcomes with different timings into a single meta-anal-
ysis. We analysed different comparisons as separate analyses. We
performed meta-analyses using a random-effects model, given the
anticipated variation between studies. For dichotomous outcomes,
we used the Mantel-Haenszel method, while for continuous out-
comes, we used the inverse variance method. In case of dichoto-
mous outcomes with no or few events in one of the test groups,
we used the Peto ORmethod, if criteria were met according to the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). Given the large number of interventions in this review,
we considered the possibility of a network meta-analysis (NMA).
However, due to the paucity of data and the heterogeneity in re-
ported outcomes, this was not an option. In future updates of this
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review, we will consider this possibility again if there are sufficient
data.
Subgroup analysis and investigation of heterogeneity
To investigate potential heterogeneity, we could have theoretically
performed four possible subgroup analyses.
• Different drugs taken. We hypothesized that for the
intervention activated charcoal, drugs with a higher or a lower
affinity for activated charcoal would be taken up to a lesser or
higher extent in the body, while for cathartics, drugs that are
absorbed faster would be less effectively flushed out of the body
than drugs with a slower absorption rate.
• Time point of the intervention. We hypothesized that the
later an intervention is performed, the less efficacious it is in
lowering the uptake of the drug.
• Co-interventions administered. We hypothesized that
differing co-interventions, such as the administration of a
hospital treatment (e.g. gastric lavage), could influence the
efficacy of the intervention investigated.
• Type of adverse event experienced. We hypothesized that
for the combined outcome ’occurrence of adverse events’,
different types of adverse events might be experienced to a
different degree for a certain intervention.
Of these potential analyses, we could perform only the latter two
because of the paucity of data.
Sensitivity analysis
We had planned to perform a sensitivity analysis by excluding
studies at high or unclear risk of bias for sequence generation,
allocation concealment, incomplete outcome reporting or other
sources of bias, and then comparing the results with the initial
analysis. However, we were not able to combine sufficient studies
into a meta-analysis for this analysis based on risk of bias of the
individual studies.
We had also planned to perform sensitivity analyses in case we
were required to impute data for some studies to enable meta-
analysis. We would have excluded the studies with imputed data
and compared the results to the initial analysis. However, we were
not able to impute data.
See Differences between protocol and review section.
’Summary of findings’ table
Weassessed the certainty of the body of evidence from the included
studies according to the methodology described by the GRADE
working group (Atkins 2004). The GRADE approach assesses the
certainty of evidence for separate outcomes across the different
studies in five domains: limitations in study design, consistency,
imprecision, indirectness and publication bias. RCTs start with
a level of high-certainty evidence, which can be downgraded by
one (serious limitations) or two (very serious limitations) levels for
each of these domains. The certainty of evidence can therefore be
high,moderate, low or very low. For the assessment of theGRADE
domain ’limitations in study design’, we decided to downgrade
the certainty of evidence for an outcome if we judged one of the
studies contributing to this outcome to be at high risk of bias in one
of following domains: selection bias, detection bias, attrition bias
or other bias. We decided not to take into account domains with
unclear risk of bias to make this judgment. For the assessment of
theGRADEdomain ’imprecision’ according to the guidance of the
GRADEworking group (Guyatt 2011), we decided to downgrade
the certainty of evidence for an outcome:
• if the optimal information size criterion was not met and
total sample size of studies contributing to the outcome was low
(fewer than 400 participants) for continuous outcomes or there
was a low number of events (fewer than 300 events) for
dichotomous outcomes;
• if the CIs were wide (including both the line of no effect
and an appreciable benefit or harm, i.e. a 25% increase or
decrease in risk for dichotomous outcomes or a 50% increase or
decrease in mean difference for continuous outcomes); or
• if there was a lack of data to judge the prior two criteria.
We created a ’Summary of findings’ table, using the online
GRADEpro Guideline Development Tool (GRADEpro GDT
2015), for the most relevant comparison of interventions in a first
aid setting: single-dose activated charcoal (SDAC) versus no inter-
vention. We created additional ’Summary of findings’ tables for
the other most clinically relevant comparisons involving single-
and multi-dose activated charcoal: SDAC plus hospital interven-
tion versus hospital intervention alone, MDAC plus hospital in-
tervention versus SDAC plus hospital intervention, MDAC plus
hospital intervention versus hospital intervention alone, and syrup
of ipecac versus no intervention. We also created ’Summary of
findings’ tables for the other identified comparisons, but we placed
these in the Appendices.
We have included all primary and secondary outcomes of this re-
view in our ’Summary of findings’ tables. For outcomes such as
severity of symptoms, studies reported multiple outcomes (e.g. in-
cidence of clinical improvement, incidence of intubation require-
ment, incidence of convulsions etc.). As ’Summary of findings’
tables should include no more than seven outcomes, we chose the
clinically most relevant outcomes together with a clinical expert
(PD).
R E S U L T S
Description of studies
Results of the search
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Our search strategies identified a total of 11,582 references. After
removing 1859 duplicates and screening titles and abstracts, we
assessed 292 full-text records for eligibility. At this stage we in-
cluded 20 studies, reported in 27 records, and we then included an
additional four studies after screening reference lists of included
studies and systematic reviews retrieved with the database searches
and similar articles in PubMed. Figure 1 shows the flowchart of
the study selection.
Figure 1. Study selection flow diagram.
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Included studies
We included 24 studies reported in 31 publications and involving
a total of 7099 participants randomized to different treatment
groups. Only one study took place in a pre-hospital setting (Wax
1999), whereas the rest were in hospitals.
Nineteen studies assessed the effects of single-dose activated char-
coal (SDAC), either administered alone (Amigó Tadín 2002;
Merigian 1990; Underhill 1990), in adjuvant to hospital treat-
ment (Behnoush 2009; Brahmi 2006; Comstock 1982; Cooper
2005; Crome 1983; De Silva 2003; Eddleston 2008; Hultén
1988; Merigian 2002; Roberts 2006), combined with a cathartic
(James 1995; Passeron 1989), or combined with syrup of ipecac
(Albertson 1989; Kornberg 1991; Kulig 1985; Pond 1995).
Seven studies looked at the effect of multi-dose activated charcoal
(MDAC) either in adjuvant to hospital treatment (Behnoush
2009; Bouget 1989; Brahmi 2006; De Silva 2003; Eddleston
2008; Roberts 2006), or combined with cathartics and in adjuvant
to hospital treatment (Montoya-Cabrera 1999).
Six studies investigated syrup of ipecac alone (Amigó Tadín 2002;
Wax 1999), or followed by SDACand a cathartic (Albertson 1989;
Kornberg 1991; Kulig 1985; Pond 1995).
Table 2 contains an overview of the comparisons made in the
different studies.
Excluded studies
We excluded 47 studies after full-text evaluation (Characteristics
of excluded studies). We excluded 11 studies because of an ineligi-
ble study population (not oral poisoning patients or patients with
chronic poisoning), 30 studies because of an intervention that did
not meet our selection criteria and 5 because of an inappropri-
ate comparison. Furthermore, we excluded one recent study, pub-
lished as an abstract only (Escalante 2016), because of a lack of
prospective trial registration, in accordance to the editorial policies
of the Cochrane Injuries review group.
Risk of bias in included studies
We did not judge any study to be at low risk of bias on all domains
investigated. We scored two studies as having a low risk of bias
for all but one domain: in one study there was a risk of selective
reporting (De Silva 2003), and in the other there was a risk of
performance bias (Eddleston 2008). All other studies were at high
or unclear risk of bias for two or more domains. Six studies were
at high risk of bias in at least four domains (Albertson 1989;
Crome 1983; Kornberg 1991; Merigian 2002; Pond 1995; Wax
1999), whereas 12 studies were at unclear risk of bias in three
or more domains (Amigó Tadín 2002; Behnoush 2009; Bouget
1989; Brahmi 2006; Comstock 1982; Crome 1983;Hultén 1988;
Ilett 1977; Montoya-Cabrera 1999; Passeron 1989; Sue 1994;
Underhill 1990). Figure 2 and Figure 3 provide an overview of the
risk of bias across domains and studies, and detailed judgments by
domain can be found for each included study in theCharacteristics
of included studies table.
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Figure 2.
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Figure 3.
Allocation
In general, randomization and allocation concealment was inad-
equately performed or poorly reported. The population was suf-
ficiently randomized and adequately reported in six studies only
(Bouget 1989; De Silva 2003; Eddleston 2008; Hultén 1988; Ilett
1977; Roberts 2006). In four studies the allocation concealment
was adequate (Cooper 2005; De Silva 2003; Eddleston 2008;
Roberts 2006).
Blinding
Most studies either did not blind or did not report on blinding
of the participants and personnel. This is likely due to the nature
of the interventions, which makes it difficult to perform adequate
blinding. However, this might lead to performance bias, for exam-
ple, because of differential administration of co-interventions.One
study that combined activated charcoal with different cathartics
reported blinding both participants and personnel (James 1995),
while another study testingmultiple versus single doses of activated
charcoal blinded the treating physicians by making sure research
assistants cleaned the participants and their bedclothes after each
activated charcoal treatment (De Silva 2003). Blinding of outcome
assessors was not common, but eight studies did take this step
(Comstock 1982; De Silva 2003; Eddleston 2008; James 1995;
Merigian 2002;Montoya-Cabrera 1999; Roberts 2006; Underhill
1990).
Incomplete outcome data
Only three studies were at high risk of attrition bias (Comstock
1982; Crome 1983; Passeron 1989), and three were at unclear
risk (Amigó Tadín 2002; Behnoush 2009; Bouget 1989). All other
studies showed no evidence of incomplete outcome data.
Selective reporting
Overall there was a high risk of reporting bias. Only a third of
the studies were at low risk (Amigó Tadín 2002; Cooper 2005;
Eddleston 2008; Hultén 1988; Kornberg 1991; Merigian 1990;
Roberts 2006; Wax 1999).
Other potential sources of bias
F ifteen studies were at low risk of other potential sources of bias,
and we assessed nine studies as being at high risk of bias for reasons
other than those mentioned above.
In Albertson 1989, actual poisoning was not verified for 25% of
the participants by means other than history. Furthermore, inWax
1999, there was no confirmation of actual ingestion or uptake of
the drug.
In another study, investigators suspected a clinical difference be-
tween the groups receiving the MDAC intervention versus the
SDAC control, based on divergent carbamazepine kinetics during
the initial six hours of the treatment period, when both groups
had received only one dose of activated charcoal (Brahmi 2006).
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Also inMontoya-Cabrera 1999, the hepatic toxicity marker values
suggest there might be a clinically meaningful difference between
the two treatment groups. This could create a bias in effectiveness
of the treatment, because of differences in degree and type of poi-
soning.
In Comstock 1982 there was a potential bias in the selection of the
study population since participants were selected at the discretion
of the attending physician.
Crome 1983 did not find significant amounts of any drugs in 11
of the 48 participants, and 7 of them had not taken any tricyclic
antidepressant (although this was a criterion for inclusion). Fur-
thermore, the role of the study funder was not clear.
Two studies included only asymptomatic participants, who are less
likely to experience a benefit from any treatment (Merigian 1990;
Wax 1999).
Merigian 2002 performed only post hoc analyses according to
clinical severity, and there was no follow-up after discharge from
the hospital.
In Roberts 2006 it is not entirely clear, even to the authors, what
exactly is measured with the digoxin assay used in the study. The
fact that both active cardenolides and metabolites might bind the
assay compromise the results of these analyses, potentially explain-
ing the wide variability observed. Furthermore, only participants
with mild intoxication were included in this analysis, as the severe
cases were treated with Fab antitoxin or transferred to a tertiary
hospital, but these patients might have shown the biggest effect
(Roberts 2006).
In Wax 1999, the authors reported dichotomous outcomes but
performed measurement using an ordinal scale.
Effects of interventions
See: Summary of findings for the main comparison SDAC
versus no intervention for first aid in patients with acute oral
poisoning; Summary of findings 2 SDAC + hospital intervention
versus hospital intervention alone for first aid in patients with
acute oral poisoning; Summary of findings 3MDAC + hospital
intervention versus SDAC + hospital intervention for first aid
in patients with acute oral poisoning; Summary of findings
4 SDAC versus syrup of ipecac for first aid in patients with
acute oral poisoning; Summary of findings 5MDAC + hospital
intervention versus hospital intervention for first aid in patients
with acute oral poisoning; Summary of findings 6 Syrup of ipecac
versus no intervention for first aid in patients with acute oral
poisoning
See Summary of findings for the main comparison; Summary
of findings 2; Summary of findings 3; Summary of findings 4;
Summary of findings 5; Summary of findings 6; Appendix 2;
Appendix 3; Appendix 4; Appendix 5; Appendix 6; Appendix 7.
A. First aid interventions that limit or delay the
absorption of the poison in the body
1. Single-dose activated charcoal versus no intervention
Two studies compared a single dose of activated charcoal ver-
sus no intervention (Merigian 1990; Underhill 1990). Underhill
1990 included 25 participants presenting in the emergency de-
partment with acute paracetamol overdose. Recruitment in the
control group was stopped early for ethical reasons, as blood levels
of paracetamol kept rising over time. Merigian 1990 included 820
participants presenting at the emergency department with self-
reported oral overdose in general. This study subdivided partici-
pants into a symptomatic and an asymptomatic group, for which
treatments differed.Only the 451 asymptomatic participants, who
received either a single dose of activated charcoal or were kept for
observation, were within scope of this review. For a detailed sum-
mary of the outcomes, we refer to the Data and analyses section.
Below we provide a narrative overview. See Summary of findings
for the main comparison.
Primary outcomes
Incidence of mortality
The identified studies either did not collect or did not report
outcomes related to mortality.
Adverse events
The only adverse event Underhill 1990 reported in response to
SDAC was vomiting, which occurred in 4/20 participants com-
pared to 0/5 in the control group (Peto OR 4.17, 95% CI 0.30 to
57.26; Analysis 1.1). Merigian 1990 reported no adverse events in
any treatment group (451 participants). We assessed this evidence
as being of very low certainty because of limitations in study de-
sign, imprecision due to a low event number and indirectness.
Incidence and severity of poisoning symptoms
Only Merigian 1990 reported an outcome related to symptom
severity. In 451 asymptomatic participants presenting to the emer-
gency department, no participants experienced events of clinical
deterioration in either group (Table 3). We assessed this evidence
as being of very low certainty because of limitations in study de-
sign, imprecision due to a low event number and indirectness.
Secondary outcomes
Duration of symptoms
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The identified studies either did not collect or did not report
outcomes related to symptom duration.
Drug absorption
Underhill 1990 measured drug levels of paracetamol before treat-
ment and at several time points after treatment. However, the
study reported none of the pre-defined outcomes of interest in
our protocol, nor could we derive them from the data provided;
therefore we could make no reliable estimation of drug absorption
from the available data.
Incidence of hospitalization
The identified studies either did not collect or did not report
outcomes related to incidence of hospitalization.
Incidence of ICU admission
Merigian 1990 reported the number of participants admitted to
the ICU department, which was 1/220 in the intervention group
and 0/231 participants in the control group (Peto OR 7.77; 95%
CI 0.15 to 391.93; Table 3). We assessed this evidence as being
of very low certainty, downgraded for limitations in study design,
imprecision due to a low number of events and indirectness.
Summary for this comparison
We were uncertain about the effect of SDAC compared to no
intervention on the incidence of ICU admission or the incidence
of clinical deterioration (very low certainty due to limitations in
study design, imprecision and indirectness). One study described a
single type of adverse event in response to the treatment, vomiting,
but we are uncertain about the effect (very low-certainty evidence
due to limitations in study design, imprecision and indirectness).
2. Single-dose activated charcoal plus hospital intervention
versus hospital intervention alone
Seven trials used single-dose activated charcoal (SDAC) in adju-
vant to established hospital treatments (Comstock 1982; Cooper
2005; Crome 1983; Eddleston 2008; Hultén 1988; Merigian
2002; Roberts 2006). These hospital treatments consisted of sup-
portive treatments to maintain vital parameters plus poison-spe-
cific treatments, but in most studies this also included gastric
lavage (Comstock 1982; Crome 1983; Eddleston 2008; Hultén
1988; Roberts 2006). Crome 1983 and Hultén 1988 specifically
included participants with tricyclic antidepressant overdose, while
the other studies did not define a specific toxic syndrome. Roberts
2006 investigated drug uptake in a subpopulation of participants
entering the Eddleston 2008 study, with yellow oleander seed poi-
soning. For a detailed summary of the outcomes, we refer to the
Data and analyses section. Below we provide a narrative overview.
See Summary of findings 2.
Primary outcomes
Incidence of mortality
Two studies reported the impact of SDAC on mortality (Cooper
2005; Eddleston 2008). Both studies included participants with a
variety of toxic syndromes, so we considered it appropriate to pool
these results. Moreover, from a layperson’s perspective, it is usually
impossible to distinguish different toxic syndromes, let alone to
decide on the appropriateness of administering SDAC in case of a
specific syndrome. The statistical results were mainly determined
by the large study, Eddleston 2008 (Peto OR 1.04, 95% CI 0.79
to 1.37; 3425 participants; 2 studies; Analysis 2.1). We did not
identify important heterogeneity (P = 0.30, I² = 7%). Evidence
was of low certainty, downgraded for imprecision due to wide
confidence intervals and indirectness.
Adverse events
Three studies reported on adverse events in relation to adminis-
tering SDAC (Cooper 2005; Eddleston 2008; Merigian 2002).
Two studies reported the occurrence of vomiting (Cooper 2005;
Merigian 2002), while Eddleston 2008 reported the absence of
bowel sounds as a proxy for constipation. We considered a com-
bined estimate of adverse events to be appropriate, given the wide
variety in toxic syndromes included in the different studies and
the inability of laypeople to distinguish between different toxic
syndromes. However, this resulted in considerable heterogeneity
(P = 0.002, I² = 83%) with different directions of effect. We per-
formed a subgroup analysis by reported symptom, showing be-
tween-group differences (P = 0.02, I² = 83%), which decreased
but did not fully eliminate the heterogeneity. The risk ratio for
the outcome occurrence of vomiting was 1.44 (95% CI 0.88 to
2.37; 1806 participants; 2 studies) and still showed substantial
unexplained heterogeneity (P = 0.08, I² = 68%). The RR for the
sub-outcome, absence of bowel sounds, was 0.41 (95% CI 0.17
to 1.00; 3098 participants; 1 study; Analysis 2.2). The evidence
on adverse events was of very low certainty because of inconsis-
tency between studies, imprecision (low number of events) and
indirectness.
Incidence and severity of symptoms of poisoning
17First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
One study evaluated the incidence of clinical deterioration, which
was absent in both an intervention group of 455 participants and
a control group of 1075 participants (Merigian 2002; Table 3).
This evidence was of very low certainty, downgraded due to lim-
itations in study design, imprecision (low number of events) and
indirectness.
Crome 1983 and Hultén 1988 expressed the grade of coma using
the Matthew-Lawson coma scale at 4 h, 8 h and 24 h after hospi-
tal admission. The median coma score scales of intervention and
control groups were similar in the study of 16 participants (Crome
1983; Table 3). The proportion of participants with a coma scale
of III or IV were also similar in Hultén 1988, with 77 partici-
pants (Table 3). Evidence was of very low certainty, downgraded
for limitations in study design, imprecision due to a low number
of events and a low sample size and indirectness.
Eddleston 2008 reported the incidence of participants with yel-
low oleander seed poisoning, who needed specialized treatment,
namely cardiac pacing or Fab antitoxin treatment (Eddleston
2008). The risk ratio was 1.01 (95% CI 0.79 to 1.30, P = 0.93,
1104 participants; Table 3). This evidence was of low certainty,
downgraded for imprecision due to a low number of events and
indirectness.
Four studies reported on the need for intubation and/or ventilation
(Cooper 2005; Eddleston 2008; Hultén 1988; Merigian 2002).
In Merigian 2002 these data were only available for participants
admitted to the ICU. We considered it appropriate to combine
the results, given the multiple or unspecified toxic syndromes in-
cluded in three out of four individual studies, and the inability of
laypeople to distinguish between ingested toxins.The combined
result showed substantial heterogeneity and different directions of
effect, so we do not present it (P = 0.04; I² = 63%; Analysis 2.3). A
possible reason for the observed heterogeneity may have been the
co-interventions, i.e. whether participants received gastric lavage
as part of the hospital treatments. A subgroup analysis suggested
there may be between-group differences between participants who
received gastric lavage prior to receiving SDAC and those who
did not (P = 0.005, I² = 87.6%). The summary estimate in the
subgroup with gastric lavage was RR 0.95 (95% CI 0.70 to 1.27,
3175 participants, 2 studies, P = 0.71). In the subgroup without
gastric lavage the RR was 2.61 (95% CI 1.38 to 4.93, 387 par-
ticipants, 2 studies, P = 0.003), in favour of not receiving SDAC.
In addition, Hultén 1988 made a subcomparison of the need for
ventilation with a respirator (RR 0.28, 95% CI 0.06 to 1.22, 77
participants, P = 0.09; Table 3). Evidence on ventilation was of
low certainty, downgraded for imprecision (low number of events
and wide confidence intervals) and indirectness.
Two studies, Eddleston 2008 and Hultén 1988, studied the inci-
dence of convulsions. We considered combining these outcomes
appropriate, given the inability of laypeople to make a distinc-
tion between different toxic syndromes. A combined estimate of
these studies, however, had substantial heterogeneity (P = 0.03; I²
= 79%) and a different direction of effect, so we only report the
individual study results. The individual estimates were RR 1.87
(95% CI 0.75 to 4.67, 3098 participants; Eddleston 2008) and
RR 0.28 (95% CI 0.06 to 1.22, 77 participants; Hultén 1988;
Analysis 2.4). Exploring heterogeneity in ameta-analysis with only
two studies is difficult, so explanations for the observed differences
between studies remain speculative. Possible reasons might be the
small study sample in Hultén 1988. Alternatively, true differences
in patient population might explain the differences, as Hultén
1988 specifically recruited participants with tricyclic antidepres-
sant poisoning, while most participants in Eddleston 2008 took
an overdose of pesticides or yellow oleander seeds. This evidence
was of very low certainty, downgraded for inconsistency between
studies, imprecision (wide confidence intervals and low number
of events) and indirectness.
Hultén 1988 recorded some additional clinical parameters in their
77 participants, as measures of poisoning severity: systolic blood
pressure, heart rate and incidence of cardiac arrhythmias, at 4 h,
8 h and 24 h after treatment (Table 3). These numbers were not
shown to differ between treatments. The certainty of evidence for
these parameters was rated as very low, due to limitations in study
design, imprecision (low number of events and wide confidence
intervals) and indirectness.
Secondary outcomes
Duration of symptoms
Three studies measured length of intubation (Eddleston 2008;
Hultén 1988;Merigian 2002). Combination of the studies’ results
in a meta-analysis was not feasible, due to differences in reporting.
Eddleston 2008 reported medians with interquartile ranges, and
there was no demonstrable difference. Authors did not report the
number of participants in this analysis. Merigian 2002 reported
length of intubation as means without a measure of spread or the
number of participants in the analysis, and likewise, authors could
not show a difference between intervention and control (Analysis
2.5). Hultén 1988 reported the proportion of participants that
were intubated for longer than 8 h, which was similar between
intervention and control (RR 0.56, 95% CI 0.19 to 1.67, 77
participants, P = 0.30; Hultén 1988; Table 3). This evidence was
rated to be of low certainty, downgraded for imprecision due to a
low number of events or lack of data, plus indirectness.
Drug absorption
Three included studies measured drug absorption (Comstock
1982; Hultén 1988; Roberts 2006). Comstock 1982, with 339
participants, only reported increases in blood drug concentrations
over time, without reporting any of our pre-specified outcomes of
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interest. Hultén 1988 presented the course of tricyclic antidepres-
sant levels in the blood of 77 participants graphically, and reported
narratively that there was no demonstrable difference in AUC,
Cmax or T1/2 between treatments (Hultén 1988). Therefore, the
only numeric data available were on the AUC, Cmax and Tmax
of cardenolides from yellow oleander seeds, measured by Roberts
2006 in a subset of 68 participants from the Eddleston study. Au-
thors reported results as median with interquartile ranges (IQR)
and could not show a difference between treatments (Analysis 2.6;
Analysis 2.7; Analysis 2.8). The evidence on the pharmacokinetic
parameters was of very low certainty, due to limitations in study
design, imprecision (low sample size) and indirectness.
Incidence of hospitalization
Merigian 2002 reported the incidence of hospitalization. The re-
sults favoured no treatment over SDAC (RR 1.57, 95% CI 1.22
to 2.02, 1479 participants, P < 0.001; Analysis 2.9). We assessed
this evidence as being of very low certainty, downgraded for lim-
itations in study design, imprecision (low number of events) and
indirectness.
Incidence of ICU admission
Merigian 2002 reported the incidence of ICU admission in favour
of no treatment with SDAC (RR 2.33, 95% CI 1.42 to 3.82,
1479 participants, P < 0.001; Analysis 2.10). This evidence was
of very low certainty, downgraded for limitations in study design,
imprecision (low number of events) and indirectness.
Summary for this comparison
SDAC as adjuvant to supportive hospital treatments may have
little or no influence on one of our primary outcomes, incidence
of mortality, while we are uncertain about its effect on another
primary outcome, adverse events due to the intervention. In ad-
dition, SDAC plus hospital treatments may have little or no in-
fluence on the primary outcomes of need for intubation, need for
cardiac pacing or antitoxin treatment in cases of yellow oleander
poisoning, or the secondary outcome, length of intubation. We
are uncertain about the effect of SDAC in addition to hospital
treatments on the incidence of clinical deterioration, Matthew-
Lawson coma scale scores, incidence of convulsions, blood pres-
sure, heart rate, cardiac arrhythmias, and the secondary outcomes
of drug absorption and incidence of hospital or ICU admission.
The evidence collected is of low to very low certainty, due to lim-
itations in study design, indirectness and/or imprecision.
3. Multi-dose activated charcoal plus hospital intervention
versus single-dose activated charcoal plus hospital
intervention
Five trials compared single-dose (SDAC) versus multi-dose ac-
tivated charcoal (MDAC), in adjuvant to hospital treatments
(Behnoush 2009; Brahmi 2006; De Silva 2003; Eddleston 2008;
Roberts 2006). The identified trials studied the following toxic
overdoses: carbamazepine (Behnoush 2009; Brahmi 2006), yellow
oleander (De Silva 2003; Roberts 2006), and a combination of
toxic syndromes (Eddleston 2008). In all studies except for Brahmi
2006, supportive treatments included gastric lavage. Behnoush
2009 did not report any outcomes of interest for this review. See
Summary of findings 3.
Primary outcomes
Incidence of mortality
Incidence of mortality was an outcome of interest inDe Silva 2003
and Eddleston 2008.We considered it appropriate to combine the
findings given the similar populations studied. Nevertheless, the
meta-analysis resulted in an estimate with substantial heterogene-
ity (P = 0.04, I² = 76%), albeit the same direction of effect. The
pooled risk ratio was 0.59 (95% CI 0.21 to 1.63; 3476 partici-
pants; 2 studies; Analysis 4.1). Reasons for the observed hetero-
geneity were not immediately clear, as both the provided interven-
tions and the population studied are remarkably similar. Eddleston
2008 included a broader range of toxic syndromes; however, in-
cluding only the subpopulation of participants with yellow olean-
der poisoning (SDAC: 26/549 and MDAC: 23/541) would not
change the conclusions made (P = 0.06, I² = 71%). There are
some factors that might explain the differences observed, such as
a longer treatment in De Silva 2003 (activated charcoal up to 72
h) compared to Eddleston 2008 (activated charcoal up to 24 h)
or differences in the compliance rate with the treatment (reported
to drop to 66% by the final dose by Eddleston 2008 but claimed
to be ensured in all cases by De Silva 2003). However, these ex-
planations remain speculative, and if there are more studies in a
future update, we may be able to show more robust evidence and
clarify the heterogeneity issue. We considered the evidence here
to be of very low certainty, due to inconsistency between studies,
imprecision (wide confidence intervals) and indirectness.
Adverse events
Two studies reported the incidence of adverse events in response
to the intervention (De Silva 2003; Eddleston 2008). We consid-
ered combining the results of these studies appropriate, given the
similar study population. The combined result (Peto OR 3.55,
95% CI 1.85 to 6.79; 3476 participants; 2 studies) contained a
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substantial degree of heterogeneity (P = 0.08, I² = 66.8%), but
with the same direction of effect. Reasons for this heterogeneity
remain speculative, but it could be due to differing definitions and
diagnostic methods for adverse events, for example absent bowel
sounds in Eddleston 2008 (Peto OR 2.34, 95% CI 1.05 to 5.21;
3075 participants, P = 0.04) versus abdominal discomfort/diar-
rhoea in De Silva 2003 (Peto OR 7.82, 95% CI 2.59 to 23.58;
401 participants, P < 0.001; Analysis 4.2). Both studies suggest
that the number of adverse events may increase in case of MDAC,
compared to SDAC. This evidence was of low certainty, down-
graded for imprecision (lownumber of events andwide confidence
intervals) and indirectness.
Incidence and severity of symptoms of poisoning
Both De Silva 2003 and Eddleston 2008 reported on the need
for cardiac pacing or administration of a Fab antitoxin, treatments
used in severe cases of yellow oleander poisoning. We considered
it appropriate to combine results, given the similar patient popu-
lations studied. The combined effect estimate (RR 0.26, 95% CI
0.02 to 4.18; 1490 participants; 2 studies) resulted in considerable
heterogeneity (P = 0.005, I² = 87%; Analysis 4.3). As for mor-
tality, the reasons for the observed heterogeneity are not immedi-
ately clear and remain speculative. We considered evidence to be
of very low certainty, due to imprecision (low numbers of events
and wide confidence intervals), inconsistency between studies and
indirectness.
De Silva 2003 also recorded the incidence of life-threatening ar-
rhythmias after 24 h, which may be lower for the group receiv-
ing SDAC (RR 0.21, 95% CI 0.06 to 0.71, 385 participants, P
= 0.01; Analysis 4.4). Evidence was of low certainty, downgraded
for imprecision due to a low number of events and indirectness.
Another outcome De Silva 2003 reported in their study with
401 participants was the need for atropine, expressed as both the
amount of atropine administered and the number of boluses ad-
ministered. Both the amount (mg) of atropine administered (MD
−1.60, 95% CI−2.25 to−0.95, P < 0.001; Analysis 4.5) and the
median number of boluses (Analysis 4.6) were higher in the group
receiving SDAC. We assessed the evidence as being of moderate
certainty, downgraded for indirectness.
Two studies reported the need for intubation (Brahmi 2006;
Eddleston 2008). We decided to combine these results, as from
the point of view of laypeople, the focus of this review, it is usually
impossible to distinguish between toxic syndromes or adapt the
provided intervention accordingly. There may be little or no effect
on the need for intubation (RR 1.01, 95% CI 0.75 to 1.38, 3097
participants, P = 0.93; Analysis 4.7). There was no heterogeneity
between studies (P = 0.98, I² = 0%). The evidence was of low
certainty, downgraded due to imprecision (low number of events
and wide confidence intervals) and indirectness.
Finally, Eddleston 2008 reported the incidence of convulsions (RR
1.09, 95% CI 0.52 to 2.32, 3085 participants, P = 0.82; Analysis
4.8). Evidence was of low certainty, downgraded due to impre-
cision (low number of events and wide confidence intervals) and
indirectness.
Secondary outcomes
Duration of symptoms
One study in six participants reported the duration of coma as
a measure of symptom duration (Brahmi 2006). The mean dif-
ference was −9.00 h (95% CI −14.79 to −3.21, P = 0.002), in
favour ofMDAC (Analysis 4.9).We considered this to be evidence
of very low certainty, downgraded for limitations in study design,
imprecision (small sample size) and indirectness.
Brahmi 2006 and Eddleston 2008 also reported duration of in-
tubation. Due to differences in reporting, it was not possible to
combine the estimates. The mean difference reported by Brahmi
2006 is −12.30 h (95% CI −18.56 to −6.04, 6 participants, P
< 0.001). Eddleston 2008 reported medians with IQR; however,
authors made no statement of effectiveness. The number of par-
ticipants in the analysis was not clear either (Analysis 4.10). This
evidence was of very low certainty, downgraded for inconsistency
between studies, imprecision (low sample size and lack of data)
and indirectness.
Drug absorption
Two studies, Brahmi 2006 and Roberts 2006, reported on phar-
macokinetic parameters as measures of drug absorption. Differ-
ences in reporting precluded meta-analysis.
Both studies reported the Cmax . The mean difference reported
by Brahmi 2006 was 0.40 mg/L (95% CI −4.89 to 5.69, 6 par-
ticipants, P = 0.88). Roberts 2006 reported Cmax , as medians
with IQR, demonstrating no difference between intervention and
control (participants = 64, P > 0.05; Analysis 4.11). AUC and
Tmax were similar between treatments (64 participants, P > 0.05;
Analysis 4.12; Analysis 4.14). In addition, Brahmi 2006 measured
the T1/2 which was in favour of MDAC (MD−15.32 h (95% CI
−21.84 to −8.80, 6 participants, P < 0.001; Analysis 4.13). The
evidence was of very low certainty, downgraded for limitations in
study design, imprecision (low sample size) and indirectness.
Incidence of hospitalization
The identified studies either did not collect or did not report
outcomes related to incidence of hospitalization.
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Incidence of ICU admission
De Silva 2003 reported the incidence of ICU admissions. The risk
ratio suggests MDAC may have a strong effect on reducing ICU
admissions (RR 0.31, 95% CI 0.12 to 0.83, 401 participants, P =
0.02; Analysis 4.15). The presented evidence was of low certainty,
downgraded for imprecision (low number of events) and indirect-
ness.
Summary for this comparison
The evidence that we have collected concerning the use of single-
versus multi-dose activated charcoal in adjuvant to hospital treat-
ments is of moderate to very low certainty. There may be little or
no difference in the incidence of convulsions and the need for intu-
bation between MDAC plus hospital treatments and SDAC plus
hospital treatments. On the other hand, there may be a favourable
effect for MDAC on the incidence of life-threatening cardiac ar-
rhythmias and ICU admissions, while it probably decreases the
number of atropine boluses and total amount of atropine adminis-
tered. Low-certainty evidence suggests, however, thatMDACmay
come with an increased risk of adverse events. We are uncertain
about the effects of MDAC plus hospital treatments on mortality,
the need for cardiac pacing or antitoxin treatment, symptom du-
ration and drug absorption.
4. Single-dose activated charcoal versus syrup of ipecac
One study with 34 participants compared SDAC versus syrup of
ipecac in oral poisoning participants with mild levels of intoxi-
cation (defined as a Glasgow Coma Scale score of more than 12;
Amigó Tadín 2002). The study specifically included participants
presenting with oral overdoses of anti-inflammatory, psychotropic
or analgesic drugs. Participants received no additional treatments.
See Summary of findings 4.
Primary outcomes
Incidence of mortality
The identified study did not collect outcomes related to mortality.
Adverse events
Amigó Tadín 2002 reported the incidence of adverse events en-
countered (RR 1.24, 95% CI 0.26 to 5.83, 34 participants, P =
0.79; Analysis 3.1). Evidence was of very low certainty, down-
graded for limitations in study design, imprecision (low number
of events and wide confidence intervals) and indirectness.
Incidence and severity of symptoms of poisoning
The identified study measured participants’ poisoning symptoms
1 h after treatment (Amigó Tadín 2002). The mean difference
in Glasgow Coma Scale scores between treatments was −0.15
(95% CI −0.43 to 0.13, 34 participants, P = 0.29; Analysis 3.2).
Furthermore, the study reportedmean arterial bloodpressure (MD
7.00 mmHg, 95% CI −3.56 to 17.56, 34 participants, P = 0.19;
Analysis 3.3), heart rate (MD −2.39 bpm, 95% CI −15.58 to
10.80, 34 participants, P = 0.72; Analysis 3.4) and respiratory rate
(MD 1.12 breaths/min, 95% CI −1.69 to 3.93, 34 participants,
P = 0.44; Analysis 3.5) as measures of intoxication. The collected
evidence was of very low certainty, downgraded for limitations in
study design, imprecision (low sample size) and indirectness.
Secondary outcomes
Duration of symptoms
The identified study did not collect outcomes related to symptom
duration.
Drug absorption
The identified study did not collect outcomes related to drug ab-
sorption.
Incidence of hospitalization
The identified study did not collect outcomes related to incidence
of hospitalization.
Indicence of ICU admission
The identified study did not collect outcomes related to incidence
of ICU admission.
Summary for this comparison
We identified evidence of very low certainty, originating from one
study (Amigó Tadín 2002).We are uncertain about any difference
between SDAC and syrup of ipecac concerning poisoning symp-
toms or incidence of adverse events.
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5. Multi-dose activated charcoal plus hospital treatment
versus hospital treatment alone
We found three studies comparing the administration of MDAC
in adjuvant to hospital treatments versus hospital treatments alone
(Bouget 1989; Eddleston 2008; Roberts 2006). For most partici-
pants in Eddleston 2008, who had a variety of intoxications, hos-
pital treatments included gastric lavage. Roberts 2006 studied a
subgroup of participants from the Eddleston study, those with yel-
low oleander seed poisoning. Bouget 1989 included 36 partici-
pants with benzodiazepine poisoning, but no numeric outcomes
were reported in this study. See Summary of findings 5.
Primary outcomes
Incidence of mortality
Eddleston 2008 reported the incidence of mortality, which may
not differ between intervention and control (RR 0.94, 95% CI
0.72 to 1.22, 3085 participants, P = 0.64; Analysis 5.1). The
evidence was of low certainty, downgraded for imprecision (low
number of events and wide confidence intervals) and indirectness.
Adverse events
Eddleston 2008 reported one adverse event, incidence of absent
bowel sounds (RR 1.02, 95% CI 0.52 to 1.98, 3085 participants,
P = 0.97; Analysis 5.2). Evidence was of low certainty, downgraded
for imprecision (low number of events and wide confidence inter-
vals) and indirectness.
Incidence and severity of symptoms of poisoning
Eddleston 2008 reported several markers of intoxication, includ-
ing the need for intubation (RR 0.97, 95% CI 0.71 to 1.33, 3085
participants, P = 0.87; Analysis 5.3), seizures (RR 2.03, 95% CI
0.82 to 5.02, 3085 participants, P = 0.12; Analysis 5.4) and need
for cardiac pacing/Fab antitoxin treatment in participants with
yellow oleander poisoning (RR 0.86, 95% CI 0.66 to 1.13, 1095
participants, P = 0.28; Analysis 5.5). Evidence was of low certainty,
downgraded for imprecision (low number of events and wide con-
fidence intervals) and indirectness.
Secondary outcomes
Duration of symptoms
Eddleston 2008 reported length of intubation as a measure of
symptom duration. It was expressed as a median plus IQR, and it
may not be different between groups (Analysis 5.6). The evidence
was of low certainty, downgraded for imprecision (lack of data)
and indirectness.
Drug absorption
Roberts 2006 analysed cardenolide pharmacokinetic parameters
in a subgroup of 76 participants from the Eddleston study, with
yellow oleander poisoning. AUC, Cmax and Tmax were reported
as medians with IQR, and there was no demonstrable difference
between treatment groups (Analysis 5.7; Analysis 5.8; Analysis
5.9). Evidence was of very low certainty due to limitations in study
design, imprecision (low sample size) and indirectness.
Incidence of hospitalization
The identified studies either did not collect or did not report
outcomes related to incidence of hospitalization.
Incidence of ICU admission
The identified studies either did not collect or did not report
outcomes related to incidence of ICU admission.
Summary for this comparison
The identified evidence on the use of MDAC in addition to hos-
pital treatment is of low to very low certainty and originates from
two studies, one of which is a subgroup analysis of the larger study
(Eddleston 2008; Roberts 2006). MDAC plus hospital treatments
may not be better than hospital treatments alone for mortality,
symptoms of intoxication (need for intubation, seizures, cardiac
pacing or antitoxin treatment), duration of intubation or absence
of bowel sounds as adverse events. We are uncertain about the
effects of MDAC on pharmacokinetic parameters of cardenolides.
B. First aid interventions that evacuate the poison
from the gastrointestinal tract
B1. Emetics
6. Syrup of ipecac versus no intervention
One study compared ipecac versus observation in 103 cases of
paediatric, asymptomatic toxic berry ingestion (Wax 1999). This
study took place in a pre-hospital setting and did not include any
other treatments. See Summary of findings 6.
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Primary outcomes
Incidence of mortality
The identified study did not collect outcomes related to incidence
of mortality.
Adverse events
The identified study reported on the incidence of several adverse
events separately. As it was likely that one patient could encounter
multiple adverse events, it was not possible to combine these into
a composite outcome. Therefore, we present the risk ratios for
the individually described adverse events. Participants receiving
ipecac may show an increased risk of diarrhoea (RR 4.08, 95%
CI 1.66 to 10.04, 103 participants, P = 0.002; Analysis 6.1) and
sedation (RR 5.10, 95% CI 1.17 to 22.13, 103 participants, P =
0.03; Analysis 6.3), while there may be little or no difference for
abdominal pain (RR 1.02, 95% CI 0.07 to 15.87, 103 partici-
pants, P = 0.99; Analysis 6.2) or agitation (RR 1.53, 95% CI 0.27
to 8.77, 103 participants, P = 0.63; Analysis 6.4). The evidence
was of low certainty, downgraded for limitations in study design
and imprecision (low number of events and wide confidence in-
tervals).
Incidence and severity of symptoms of poisoning
The identified study did not collect outcomes related to incidence
and severity of poisoning symptoms.
Secondary outcomes
Duration of symptoms
The identified study did not collect outcomes related to duration
of poisoning symptoms.
Drug absorption
The identified study did not collect outcomes related to drug ab-
sorption.
Incidence of hospitalization
One patient in the intervention group was referred to the emer-
gency department, compared to none in the control group (Wax
1999). The Peto OR was 7.54 (95% CI 0.15 to 379.83, 103 par-
ticipants, P = 0.31; Table 3). None of the 103 participants were
hospitalized (Table 3). The evidence was of low certainty, down-
graded for limitations in study design and imprecision due to a
small sample size and wide confidence intervals.
Incidence of ICU admission
As none of the participants were hospitalized, none could have
been admitted to the ICU.
Summary for this comparison
We identified one study that compared syrup of ipecac versus
home observation (Wax 1999). Authors did not report any clinical
outcomes, but there may be little or no difference in emergency
department referrals. In contrast, the incidence of adverse events
(diarrhoea and sedation)may be larger. Evidence is of low certainty
(downgraded for limitations in study design and imprecision).
7. Syrup of ipecac plus single-dose activated charcoal plus
cathartics versus single-dose activated charcoal plus
cathartics
We identified four studies that compared SDAC plus a cathartic
(sorbitol or magnesium sulphate), preceded or not preceded by
syrup of ipecac in participants presenting to an emergency depart-
ment (Albertson 1989; Kornberg 1991; Kulig 1985; Pond 1995).
None of the studies selected participants on a specific toxic syn-
drome. Kornberg 1991 focused on children under 6 years old,
while Albertson 1989 and Pond 1995 included adults (specified
as more than 18 years old or more than 13 years old, respectively).
Kulig 1985 did not specify a certain age range. See Appendix 2.
Primary outcomes
Incidence of mortality
Two of the included studies reported on incidence of mortality,
but neither study noted any events in the 573 participants across
treatment groups (Kornberg 1991; Kulig 1985; Analysis 7.1). We
considered this evidence to be of very low certainty, downgraded
for limitations in study design, imprecision (lownumber of events)
and indirectness.
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Adverse events
Two studies reported the incidence of adverse events (Albertson
1989; Pond 1995), while one study reported the number of ac-
tivated charcoal that was vomited as an adverse event (Kornberg
1991). We combined these outcomes, as all studies included a
wide variety of toxic syndromes. The meta-analysis favoured not
using ipecac (RR 2.59, 95% CI 1.37 to 4.91, 764 participants,
3 studies, P = 0.003). We found no important heterogeneity (P
= 0.29, I² = 19%; Analysis 7.2). This was evidence of very low
certainty, downgraded for limitations in study design, imprecision
(low number of events) and indirectness.
Incidence and severity of symptoms of poisoning
Three studies reported on the incidence of participants with clin-
ical improvement during their stay in the emergency department
(Kornberg 1991; Kulig 1985; Pond 1995). We considered a meta-
analysis appropriate, given the wide variety of toxic syndromes
included in the individual studies. The combined risk ratio was
1.00 (95% CI 0.83 to 1.21, 989 participants, 3 studies, P = 0.98),
without evidence of important heterogeneity (P = 0.21, I² = 36%;
Analysis 7.3). The evidence was of low certainty, downgraded for
limitations in study design and indirectness.
Two trials studied the incidence of clinical deterioration during the
emergency department stay (Kulig 1985; Pond 1995); we com-
bined these in a meta-analysis, given the wide variety of toxic syn-
dromes included in the individual studies. The pooled RR was
0.88 (95% CI 0.46 to 1.69, 970 participants, 2 studies, P = 0.70),
with no apparent heterogeneity (P = 0.38, I² = 0%; Analysis 7.4).
We considered this to be evidence of very low certainty, down-
graded for limitations in study design, imprecision (low number
of events and wide confidence intervals) and indirectness.
Secondary outcomes
Duration of symptoms
The identified studies either did not collect or did not not report
outcomes related to duration of poisoning symptoms.
Drug absorption
The identified studies either did not collect or did not report
outcomes related to drug absorption.
Incidence of hospitalization
The incidence of hospitalization was an outcome of interest in
three studies (Albertson1989;Kornberg 1991;Kulig 1985).Given
the wide variety of toxic syndromes included in the individual
studies, and the inability of laypeople to distinguish between in-
gested toxins, we considered ameta-analysis appropriate. The Peto
OR was 1.17 (95% CI 0.69 to 1.98, 746 participants, 3 studies,
P = 0.56), without any important heterogeneity (P = 0.15, I² =
47%; Analysis 7.5). We considered this evidence to be of very
low certainty, due to limitations in study design, imprecision (low
number of events and wide confidence intervals) and indirectness.
Incidence of ICU admission
One trial, Albertson 1989, reported the incidence of ICU admis-
sion (RR 1.38, 95%CI 0.44 to 4.38, 200 participants, 1 study, P =
0.58; Analysis 7.6). We considered this evidence to be of very low
certainty, downgraded for limitations in study design, imprecision
(low number of events or low sample size, and wide confidence
intervals) and indirectness.
Summary for this comparison
Evidence from four studies suggests that adding syrup of ipecac to
SDAC plus cathartics may make little difference for clinical im-
provement. On the other hand, we are uncertain about its impact
on mortality, adverse events, clinical deterioration, hospitalization
or ICU admission. Evidence was of low to very low certainty,
downgraded for limitations in study design, imprecision and/or
indirectness.
8. Syrup of ipecac versus syrup of ipecac (different doses)
We found one study using different types and doses of ipecac (Ilett
1977). This study involved 120 participants presenting to the
emergency department of a hospital with various intoxications.
Primary outcomes
Incidence of mortality
The identified study either did not collect or did not report on
outcomes related to incidence of mortality.
Adverse events
The identified study either did not collect or did not report on
outcomes related to adverse events due to the intervention.
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Incidence and severity of symptoms of poisoning
The identified study either did not collect or did not report on
outcomes related to incidence and severity of poisoning symptoms.
Secondary outcomes
Duration of symptoms
The identified study either did not collect or did not report on
outcomes related to duration of poisoning symptoms.
Drug absorption
The identified study either did not collect or did not report on
outcomes related to drug absorption.
Incidence of hospitalization
The identified study either did not collect or did not report on
outcomes related to incidence of hospitalization.
Incidence of ICU admission
The identified study either did not collect or did not report on
outcomes related to incidence of ICU admission.
Summary for this comparison
We identified one study that compared the use of different doses
of syrup of ipecac (Ilett 1977), but it did not report any outcome
of interest to our review.
B2. Cathartics
9. Single-dose activated charcoal plus cathartics versus
single-dose activated charcoal alone
Two trials compared SDAC plus cathartics versus SDAC alone
(James 1995; Sue 1994). Both trials studied children presenting to
the emergency department following various or unspecified toxic
ingestions, requiring SDAC. See Appendix 3.
Primary outcomes
Incidence of mortality
The identified studies either did not collect or did not report
outcomes related to incidence of mortality.
Adverse events
In Sue 1994 the only measured adverse event due to the inter-
vention was lethargy during follow-up. Authors reported no cases
of lethargy in the SDAC plus magnesium citrate group (50 par-
ticipants) or in the SDAC group (14 participants). James 1995
recorded the incidence of participants vomiting upon receiving
activated charcoal with or without sorbitol, magnesium citrate or
magnesium sulphate. The pooled RR was 1.46 (95% CI 0.61 to
3.49, 116 participants, P = 0.39; Analysis 8.1). We considered the
evidence to be of very low certainty, due to limitations in study
design, imprecision (low number of events) and indirectness.
Incidence and severity of symptoms of poisoning
The identified studies either did not collect or did not report out-
comes related to occurrence and severity of symptoms of poison-
ing.
Secondary outcomes
Duration of symptoms
The identified studies either did not collect or did not report
outcomes related to symptom duration.
Drug absorption
The identified studies either did not collect or did not report
outcomes related to drug absorption.
Incidence of hospitalization
Sue 1994 studied the incidence of hospitalization. Three partici-
pants required hospitalization in the group receiving SDAC plus
either 4 mL/kg, 6 mL/kg or 8 mL/kg of magnesium citrate, versus
one patient in the activated charcoal group (RR0.84, 95%CI 0.09
to 7.46, 64 participants, P = 0.88; Analysis 8.2). The evidence was
of very low certainty, downgraded for limitations in study design,
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imprecision (low number of events and wide confidence intervals)
and indirectness.
Incidence of ICU admission
The identified studies did not report outcomes related to incidence
of ICU admission.
Summary for this comparison
We are uncertain if adding SDAC to a cathartic has an effect on
adverse events or hospitalization. The evidence was of very low
certainty, downgraded for limitations in study design, imprecision
and indirectness.
10. Single-dose activated charcoal plus different doses of
cathartics
Sue 1994 assessed SDAC with different doses of cathartics. This
trial studied 64 children presenting to the emergency department
following an unspecified toxic ingestion requiring SDAC. See
Appendix 4.
Primary outcomes
Incidence of mortality
The identified study either did not collect or did not report out-
comes related to incidence of mortality.
Adverse events
The only measured adverse event due to the intervention was
lethargy during follow-up. Authors reported no cases of lethargy in
any of the treatment groups (Table 3).We considered this evidence
to be of very low certainty, downgraded for limitations in study
design, imprecision (low number of events) and indirectness.
Incidence and severity of symptoms of poisoning
The identified study either did not collect or did not report out-
comes related to incidence and severity of symptoms of poisoning.
Secondary outcomes
Duration of symptoms
The identified study either did not collect or did not report out-
comes related to symptom duration.
Drug absorption
The identified study either did not collect or did not report out-
comes related to drug absorption.
Incidence of hospitalization
No patient required hospitalization in the group receiving 4 mL/
kg of magnesium citrate plus SDAC compared to one participant
in the 6 mL/kg magnesium citrate plus SDAC group and two
participants in the 8 mL/kg magnesium citrate plus SDAC group.
When comparing 6 mL/kg or 8 mL/kg magnesium citrate versus
4 mL/kg, the ORs were 7.39 (95% CI 0.15 to 372.38, 32 partic-
ipants, P = 0.32; Table 3) and 7.01 (95% CI 0.42 to 117.63, 34
participants, P = 0.18; Table 3), respectively. The RR when com-
paring 6 mL/kg to 8 mL/kg magnesium citrate was 1.78 (95%
CI 0.18 to 17.80, 34 participants, P = 0.62; Analysis 9.1). We
considered this to be evidence of very low certainty, due to lim-
itations in study design, imprecision (low number of events and
wide confidence intervals) and indirectness.
Incidence of ICU admission
The identified study either did not collect or did not report out-
comes related to incidence of ICU admission.
Summary for this comparison
We are uncertain about the effects of higher doses of magnesium
citrate combined with SDAC, compared to lower doses combined
with SDAC, with respect to the incidence of adverse events or hos-
pitalization. These results were of very low certainty, downgraded
for limitations in study design, imprecision and indirectness.
11. Single-dose activated charcoal plus different types of
cathartics
One trial compared SDAC plus different types of cathartics,
namely sorbitol, magnesium citrate and magnesium sulphate
(James 1995). This trial studied 119 children who ingested a
variety of toxins (analgesics, anticonvulsants, antihistamines and
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decongestants, asthma therapies, automotive products, cardio-
vascular drugs, gastrointestinal preparations, insecticides, mush-
rooms, psychotropic drugs, rodenticides, topicals, or miscella-
neous drugs). See Appendix 5.
Primary outcomes
Incidence of mortality
The identified study either did not collect or did not report out-
comes related to incidence of mortality.
Adverse events
Emesis occurred in 13of 32 children receiving SDACplus sorbitol;
6 of 33 children receiving SDAC plus magnesium citrate, and 4
of 23 children receiving SDAC plus magnesium sulphate.
When comparing sorbitol with magnesium sulphate, the RR was
2.34 (95% CI 0.87 to 6.25, 55 participants, P = 0.09; Analysis
10.1). Sorbitol versus magnesium citrate resulted in an RR of 2.23
(95% CI 0.97 to 5.16, 55 participants, P = 0.06; Analysis 10.2).
For magnesium sulphate versus magnesium citrate, the RR is 0.96
(95% CI 0.30 to 3.01, 55 participants, P = 0.94; Analysis 10.3).
We considered this evidence to be of very low certainty, due to
limitations in study design, imprecision (low number of events
and wide confidence intervals) and indirectness.
Incidence and severity of symptoms of poisoning
The identified study either did not collect or did not report out-
comes related to incidence and severity of symptoms of poisoning.
Secondary outcomes
Duration of symptoms
The identified study either did not collect or did not report out-
comes related to symptom duration.
Drug absorption
The identified study either did not collect or did not report out-
comes related to drug absorption.
Incidence of hospitalization
The identified study either did not collect or did not report out-
comes related to incidence of hospitalization.
Incidence of ICU admission
The identified study either did not collect or did not report out-
comes related to incidence of ICU admission.
Summary for this comparison
Only one study assessed the effect of different types of cathartics in
combination with SDAC in the treatment of poisoning. The only
relevant outcome measured is incidence of emesis as an adverse
event, for which any effect of using different types of cathartics
is uncertain. Evidence is of very low certainty, downgraded for
limitations in study design, imprecision and indirectness.
C. Combined first aid interventions that limit uptake
and promote evacuation of the poison from the
gastrointestinal tract
12. Single-dose activated charcoal plus cathartic plus
hospital intervention versus hospital intervention alone
One study compared SDACplus a cathartic plus hospital interven-
tions versus hospital interventions alone (Passeron 1989). Passeron
1989 included participants presenting with a confirmed overdose
of benzodiazepines, barbiturates or imipramine. All participants in
this study received gastric lavage prior to the SDAC plus sorbitol
or no additional intervention. See Appendix 6.
Primary outcomes
Incidence of mortality
The identified study either did not collect or did not report out-
comes related to incidence of mortality.
Adverse events
The included study reported the incidence of vomiting (Passeron
1989). The RR was 11.00 (95% CI 0.66 to 183.79, 32 partici-
pants, P = 0.10; Analysis 11.1). The level of evidence was very low,
downgraded due to limitations in study design, imprecision (low
number of events and wide confidence intervals) and indirectness.
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Incidence and severity of symptoms of poisoning
Passeron 1989 monitored participants’ symptoms using the Glas-
gow Coma Scale. They did not report any numeric data but re-
ported no difference for the course of the Glasgow Coma Scale
scores between treatments (P = 0.49). The evidence was of very
low certainty, downgraded for limitations in study design, impre-
cision due to a lack of data and indirectness.
Secondary outcomes
Duration of symptoms
The identified study either did not collect or did not report out-
comes related to symptom duration.
Drug absorption
Passeron 1989 measured drug levels in their participants, but did
not report any of our pre-defined outcomes of interest (AUC,
Cmax , Tmax ), so we could not make a reliable estimate of effect
on drug absorption.
Incidence of hospitalization
The identified study either did not collect or did not report out-
comes related to incidence of hospitalization.
Incidence of ICU admission
The identified study either did not collect or did not report out-
comes related to incidence of ICU admission.
Summary for this comparison
We found only evidence of very low certainty (downgraded for
limitations in study design, imprecision and indirectness) concern-
ing the use of SDAC plus a cathartic, in adjuvant to established
hospital treatments. Thus we are uncertain about the effect on
Glasgow Coma Scale scores or incidence of vomiting.
13. Multi-dose activated charcoal plus cathartic plus hospital
intervention versus hospital intervention alone
One study in 14 participants compared MDAC plus mag-
nesium sulphate as an adjuvant to oral N-acetylcysteine ver-
sus N-acetylcysteine alone for paediatric paracetamol overdose
(Montoya-Cabrera 1999). See Appendix 7.
Primary outcomes
Incidence of mortality
The identified study either did not collect or did not report out-
comes related to incidence of mortality.
Adverse events
Montoya-Cabrera 1999 reported that no adverse events occurred
in any treatment group (Table 3). This is evidence of very low
certainty, downgraded for limitations in study design, imprecision
(low number of events) and indirectness.
Incidence and severity of symptoms of poisoning
The identified study either did not collect or did not report out-
comes related to occurrence and severity of poisoning symptoms.
Secondary outcomes
Duration of symptoms
The identified study either did not collect or did not report out-
comes related to symptom duration.
Drug absorption
Montoya-Cabrera 1999 measured T1/2 of paracetamol in the
plasma, reporting a decrease (P < 0.05; Table 3). However, they
failed to report any measure of spread, so we cannot report any
summary estimate with 95%CI.We consider the evidence to be of
very low certainty due to limitations in study design, imprecision
(low sample size and lack of data) and indirectness.
Incidence of hospitalization
The identified study either did not collect or did not report out-
comes related to incidence of hospitalization.
Incidence of ICU admission
The identified study either did not collect or did not report out-
comes related to incidence of ICU admission.
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Summary for this comparison
We identified one study, which provided evidence of very low cer-
tainty (downgraded for limitations in study design, imprecision
and indirectness) (Montoya-Cabrera 1999). Any effect on the inci-
dence of adverse events or plasma half-life of paracetamol after re-
ceiving MDAC in adjuvant to oral administration of N-acetylcys-
teine, compared to oral administration of N-acetylcysteine alone
is uncertain.
D. First aid interventions that neutralize or dilute the
poison
We identified no studies comparing interventions aiming at neu-
tralizing or diluting orally ingested poisons in a patient setting.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
SDAC + hospital intervention versus hospital intervention alone for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (not specif ied, tricyclic ant idepressants, combinat ions of dif f erent drugs or yellow oleander)
Setting: hospital sett ing
Intervention: single-dose act ivated charcoal (SDAC) + hospital intervent ion
Comparison: hospital intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with hospital in-
tervention
Risk with SDAC + hos-
pital intervention
Incidence of mortality Study populat ion Peto OR 1.04
(0.79 to 1.37)
3425
(2 RCTs)
⊕⊕©©
Lowa,b
SDAC in addit ion to hos-
pital t reatments may
make lit t le or no dif -
ference on incidence of
mortality
62 per 1000 64 per 1000
(49 to 85)
Incidence of adverse
events
Incidence of vomit ing: intervent ion group: 118/
570 and control group: 163/ 1236 (RR 1.44, 95%
CI 0.88 to 2.37; 1806 part icipants; 2 studies)
Incidence of absent bowel sounds: intervent ion
group: 7/ 1544 and control group: 17/ 1554 (RR
0.41, 95% CI 0.17 to 1.00, 1 study, 3098 part ici-
pants)
- 4904
(3 RCTs)
⊕©©©
Very lowa,c,d
Stat ist ically signif icant
heterogeneity was
found,which may be ex-
plained part ially by sub-
group analyses per type
of adverse event.
We are uncertain about
the ef fect of SDAC
in addit ion to hospi-
tal t reatments on in-
cidence of adverse
events
Incidence and severity
of symptoms of poison-
ing: incidence of need
for intubat ion
Patients that received gastric lavage prior to
SDAC: intervent ion group: 80/ 1578 and control
group: 87/ 1597 (RR 0.95, 95% CI 0.70 to 1.27, 2
studies, 3175 part icipants)
- 3562
(4 RCTs)
⊕©©©
Very lowa,b,c
Stat ist ically signif icant
heterogeneity was
found, which may be
explained by subgroup3
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Patients that did not receive gastric lavage prior
to SDAC: intervent ion group: 24/ 194 and control
group: 10/ 193 (RR 2.61, 95% CI 1.38 to 4.93, 1
study, 387 part icipants)
analyses in pat ients re-
ceiving or not receiving
gastric lavage.
We are uncertain about
the ef fect of SDAC on
incidence of need for
intubat ion
Durat ion of toxic symp-
toms: durat ion of intu-
bat ion (h)
Eddleston 2008: intervent ion group median (IQR):
112.0 (36.6 to 234.9) h and control group median
(IQR): 88.5 (38.5 to 203.1) h (median dif ference:
23.5 h, P > 0.05)
Merigian 2002: intervent ion group mean: 54.6 h
and control group mean: 39.9 h (MD: 14.7 h, P =
0.70)
- (2 RCTs) ⊕⊕©©
Lowa,e
Data were reported as
median with IQR in one
or means without mea-
sure of spread in an-
other study, without in-
formation on part ici-
pant numbers
SDAC in addit ion to hos-
pital t reatments may
make lit t le or no dif fer-
ence on the durat ion of
intubat ion
Drug absorpt ion: carde-
nolide: AUC (µg/ L) × h
Follow-up: 1 days
The median (IQR) in intervent ion group was 17.7
(11.1 to 21.8) (µg/ L) × h and in the control group
19.0 (13.7 to 24.3) (µg/ L) × h (median dif ference:
−1.3 h, P > 0.05)
- 68
(1 RCT)
⊕©©©
Very lowa,f,g
We are uncertain about
the ef fect of SDAC
in addit ion to hospital
t reatments on cardeno-
lide absorpt ion
Incidence of hospital-
izat ion
125 per 1000 196 per 1000 (152 to
252)
RR 1.57 (1.22 to 2.02) 1479
(1 RCT)
⊕©©©
Very lowa,g,h
We are uncertain about
the ef fect of SDAC
in addit ion to hospi-
tal t reatments on in-
cidence of hospitaliza-
t ion
Incidence of ICU admis-
sion
30 per 1000 69 per 1000 (42 to 114) RR 2.33 (1.42 to 3.82) 1479
(1 RCT)
⊕©©©
Very lowa,g,h
We are uncertain about
the ef fect of SDAC
in addit ion to hospi-
tal t reatments on inci-3
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dence of ICU admission
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ICU: intensive care unit ; IQR: interquart ile range; RCT : randomized controlled trial; RR: risk rat io; SDAC: single-dose act ivated charcoal; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious indirectness: study conducted in a hospital sett ing.
bDowngraded one level for serious imprecision: low number of events and wide conf idence intervals.
cDowngraded one level for serious inconsistency: large and stat ist ically signif icant heterogeneity present (I² > 60%, P < 0.10).
dDowngraded one level for serious imprecision: wide conf idence intervals.
eDowngraded one level for serious imprecision: lack of data on the number of pat ients analysed.
fDowngraded one level due to serious lim itat ions in study design: high risk of other bias: it is not ent irely clear what is
measured with the assay used. The fact that both act ive cardenolides and (inact ive) metabolites might bind the assay
compromise the results of these analyses, as they might explain the wide variability observed.
gDowngraded one level for serious imprecision: low number of events.
hDowngraded one level for serious lim itat ions in study design: high risk of select ion bias.
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MDAC + hospital intervention versus SDAC + hospital intervention for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (carbamazepine, yellow oleander, or combinat ions of dif f erent drugs)
Setting: hospital sett ing
Intervention: mult iple dose of act ivated charcoal (MDAC) + hospital intervent ion
Comparison: single-dose act ivated charcoal (SDAC) + hospital intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with SDAC + hos-
pital intervention
Risk with MDAC + hos-
pital intervention
Incidence of mortality Study populat ion RR 0.59 (0.21 to 1.63) 3476
(2 RCTs)
⊕©©©
Very lowa,b,c
Combining the studies
resulted in stat ist ically
signif icant heterogene-
ity, for which explana-
t ions remain specula-
t ive
We are uncertain about
the ef fects of MDAC
in addit ion to hospital
t reatment, compared to
SDAC, in addit ion to
hospital t reatment
72 per 1000 42 per 1000
(15 to 117)
Incidence of adverse
events
Study populat ion Peto OR 3.55
(1.85 to 6.79)
3476
(2 RCTs)
⊕⊕©©
Lowb,c
There was stat ist ically
signif icant heterogene-
ity, which may be at-
tributable to dif f erent
adverse events mea-
sured in individual stud-
ies
MDAC in addit ion
to hospital t reatment
may increase abdom-
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inal discomfort / diar-
rhoea and absent bowel
sounds, compared to
SDAC in addit ion to hos-
pital t reatment
4 per 1000 14 per 1000
(7 to 27)
Incidence and severity
of symptoms of poison-
ing: incidence of need
for intubat ion
Study populat ion RR 1.01
(0.75 to 1.38)
3097
(2 RCTs)
⊕⊕©©
Lowb,c
MDAC in addit ion to
hospital t reatment may
make lit t le or no dif fer-
ence in the incidence
of need for intuba-
t ion, compared to SDAC
in addit ion to hospital
t reatment
49 per 1000 49 per 1000
(37 to 67)
Durat ion of toxic symp-
toms: durat ion of intu-
bat ion (h)
Brahmi 2006: intervent ion group: 24.1 (SD 4.2 h
and control group 36.4 (SD 3.6 h (MD: 12.30 h
lower, 95%CI −18.56 to −6.04, 6 part icipants)
Eddleston 2008: intervent ion group median (IQR)
: 83.8 (35.0 to 173.0) h and control group median
(IQR): 112.0 (36.6 to 234.9) h (median dif ference:
28.2 h), unclear number of part icipants
- (2 RCTs) ⊕©©©
Very lowb,d,e
Data were reported as
means with SD in one
study or medians with
IQR in another study,
without information on
part icipant numbers or
statement of signif i-
cance
We are uncertain about
the ef fects of MDAC
in addit ion to hospi-
tal t reatment on dura-
t ion of intubat ion, com-
pared to SDAC in ad-
dit ion to hospital t reat-
ment
Drug absorpt ion: carde-
nolide: AUC (µg × L/ h)
Follow-up: 1 days
The median (IQR) in intervent ion group was 17.3
(12.8 to 21.7) (µg/ L) × h and in the control group
17.7 (11.1 to 21.8) (µg/ L) × h (median dif ference
−0.4, P > 0.05)
- 64
(1 RCT)
⊕©©©
Very lowb,e,f
We are uncertain about
the ef fects of MDAC
in addit ion to hospi-
tal t reatment on car-
denolide drug absorp-
3
4
F
irst
a
id
in
te
r
v
e
n
tio
n
s
b
y
la
y
p
e
o
p
le
fo
r
a
c
u
te
o
ra
l
p
o
iso
n
in
g
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
t ion, compared to SDAC
in addit ion to hospital
t reatment
Incidence of hospital-
izat ion
No studies collected or reported this outcome
Incidence of ICU admis-
sion
Study populat ion RR 0.31
(0.12 to 0.83)
401
(1 RCT)
⊕⊕©©
Lowb,g
MDAC in addit ion to
hospital t reatment may
result in a decreased
incidence of ICU ad-
mission, compared to
SDAC in addit ion to hos-
pital t reatment
80 per 1000 25 per 1000
(10 to 66)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
AUC: area under the receiver operat ing curve; CI: conf idence interval; ICU: intensive care unit ; IQR: interquart ile range; MDAC: mult i-dose act ivated charcoal; RCT : randomized
controlled trial; RR: risk rat io; SD: standard deviat ion; SDAC: single-dose act ivated charcoal; OR: odds rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious inconsistency: combining results resulted in a considerable and stat ist ically signif icant
degree of heterogeneity (I² > 60%, P < 0.10).
bDowngraded one level for serious indirectness: study conducted in a hospital sett ing.
cDowngraded one level for serious imprecision: low number of events and wide conf idence intervals.
dDowngraded one level for other lim itat ions: inconsistent conclusions made by the studies.
eDowngraded one level for serious imprecision: low sample size and lack of data.
fDowngraded one level for serious study lim itat ions: high risk of other bias: it is not ent irely clear what is measured with the
assay used. The fact that both act ive cardenolides and (inact ive) metabolites might bind the assay compromise the results
of these analyses, as they might explain the wide variability observed.
gDowngraded one level for serious imprecision: low number of events.
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SDAC versus syrup of ipecac for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (ant i-inf lammatory drugs, analgesics or psychotropic drugs)
Setting: hospital sett ing
Intervention: single-dose act ivated charcoal (SDAC)
Comparison: syrup of ipecac
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with syrup of
ipecac
Risk with SDAC
Incidence of mortality No studies collected this outcome
Incidence of adverse
events
Study populat ion RR 1.24
(0.26 to 5.83)
34
(1 RCT)
⊕©©©
Very lowa,b,c
We are uncertain about
the ef fect of SDAC,
compared to syrup of
ipecac on incidence of
adverse events
154 per 1000 191 per 1000
(40 to 897)
Incidence and severity
of symptoms of poi-
soning: level of coma
assessed with Glasgow
Coma Scale
Scale f rom: 3 to 15
Follow-up: 1 h
The mean incidence
and severity of symp-
toms of poisoning: level
of coma was 14.91
MD 0.15 lower
(0.43 lower to 0.13
higher)
- 34
(1 RCT)
⊕©©©
Very lowa,b,d
We are uncertain about
the ef fect of SDAC,
compared to syrup of
ipecac on the level of
coma
Durat ion of toxic symp-
toms
No studies collected this outcome
Drug absorpt ion No studies collected this outcome
Incidence of hospital-
izat ion
No studies collected this outcome
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Incidence of ICU admis-
sion
No studies collected this outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ICU: intensive care unit ; MD: mean dif ference; RCT : randomized controlled trial; RR: risk rat io; SDAC: single-dose act ivated charcoal.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious study lim itat ions: high risk of select ion bias.
bDowngraded one level for serious indirectness: study conducted in a hospital sett ing.
cDowngraded one level for serious imprecision: low number of events and wide conf idence intervals.
dDowngraded one level for serious imprecision: low sample size.
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MDAC + hospital intervention versus hospital intervention for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (benzodiazepines, yellow oleander or combinat ions of dif f erent drugs)
Setting: hospital sett ing
Intervention: mult i-dose act ivated charcoal (MDAC) + hospital intervent ion
Comparison: hospital intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with hospital in-
tervention
Risk with MDAC + hos-
pital intervention
Incidence of mortality Study populat ion RR 0.94
(0.72 to 1.22)
3085
(1 RCT)
⊕⊕©©
Lowa,b
MDAC in addit ion to
hospital t reatment may
make lit t le or no dif -
ference in incidence of
mortality
68 per 1000 64 per 1000
(49 to 82)
Incidence of adverse
events
Study populat ion RR 1.02
(0.52 to 1.98)
3085
(1 RCT)
⊕⊕©©
Lowa,b
MDAC in addit ion to
hospital t reatment may
make lit t le or no dif fer-
ence in incidence of ad-
verse events
11 per 1000 11 per 1000
(6 to 22)
Incidence and severity
of symptoms of poison-
ing: incidence of need
for intubat ion
Study populat ion RR 0.97
(0.71 to 1.33)
3085
(1 RCT)
⊕⊕©©
Lowa,b
MDAC in addit ion to
hospital t reatment may
make lit t le or no dif -
ference in incidence of
need for intubat ion
49 per 1000 47 per 1000
(35 to 65)
Durat ion of toxic symp-
toms: length of intuba-
t ion (h)
The median (IQR) length of intubat ion in the
intervent ion group was 83.8 (35.0 to 173.0) h
and 88.5 (38.5 to 203.1) h in the control group
and was reported not to dif f er signif icant ly (P >
0.05); unclear number of part icipants
- (1 RCT) ⊕⊕©©
Lowa,c
The number of part ici-
pants analysed was not
reported.
MDAC in addit ion to
hospital t reatment may
make lit t le or no dif fer-
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ence in length of intu-
bat ion
Drug absorpt ion: carde-
nolide: AUC (µg/ L × h)
Follow-up: 1 day
The median (IQR) cardenolide AUC in the inter-
vent ion group was 17.3 (12.8 to 21.7) (µg/ L) × h
and 19.0 (13.7 to 24.3) (µg/ L) × h in the control
group
- 76
(1 RCT)
⊕©©©
Very lowa,c,d
We are uncertain about
the ef fects of MDAC
in addit ion to hospital
t reatment on cardeno-
lide drug absorpt ion
Incidence of hospital-
izat ion
No studies collected or reported this outcome
Incidence of ICU admis-
sion
No studies collected or reported this outcome
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
AUC: area under the receiver operat ing curve; CI: conf idence interval; ICU: intensive care unit ; IQR: interquart ile range; MDAC: mult i-dose act ivated charcoal; RCT : randomized
controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious indirectness: study conducted in a hospital sett ing.
bDowngraded one level for serious imprecision: low number of events and wide conf idence interval.
cDowngraded one level for serious imprecision: low sample size and lack of data.
dDowngraded one level for serious study lim itat ions: high risk of other bias: it is not ent irely clear what is measured with the
assay used. The fact that both act ive cardenolides and (inact ive) metabolites might bind the assay compromise the results
of these analyses, as they might explain the wide variability observed.
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Syrup of ipecac versus no intervention for first aid in patients with acute oral poisoning
Patient or population: f irst aid in pat ients with acute oral poisoning (toxic berries)
Setting: pre-hospital sett ing
Intervention: syrup of ipecac
Comparison: no intervent ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no interven-
tion
Risk with Syrup of
ipecac
Incidence of mortality No studies collected this outcome
Incidence of adverse
events: diarrhoea
Follow-up: 1 day
Study populat ion RR 4.08
(1.66 to 10.04)
103
(1 RCT)
⊕⊕©©
Lowa,b
Syrup of ipecac may re-
sult in an increased in-
cidence of diarrhoea96 per 1000 392 per 1000
(160 to 965)
Incidence and severity
of symptoms of poison-
ing
No studies collected this outcome
Durat ion of toxic symp-
toms
No studies collected this outcome
Drug absorpt ion No studies collected this outcome
Hospitalizat ion: inci-
dence of hospitaliza-
t ion
Follow-up: 1 days
- - 103
(1 RCT)
⊕⊕©©
Lowa,b
The ef fect was not es-
t imable due to the ab-
sence of events in the
intervent ion (0/ 52) and
the control group (0/ 51)
ICU admission No studies collected this outcome
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; ICU: intensive care unit ; RCT : randomized controlled trial; RR: risk rat io.
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded one level for serious study lim itat ions: high risk of select ion bias, high risk of detect ion bias, and high risk of
other bias (no conf irmation of actual ingest ion or uptake, report ing of dichotomous outcomes while measuring with an
ordinal scale).
bDowngraded one level for serious imprecision: low number of events.
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D I S C U S S I O N
Summary of main results
Out of a total of 11,582 potentially relevant references, we iden-
tified 24 studies reported in 31 publications. All but one study
took place in a hospital setting (Wax 1999 was in a pre-hospital
setting). A total of 7099 participants were randomized to different
treatment groups.
A. First aid interventions that limit or delay the
absorption of the poison in the body
Activated charcoal
A commonly used intervention in poisoning is activated charcoal.
Due to its enormous surface area it can adsorb large quantities
of drugs, thus preventing the absorption of the poison by the
body. Included studies made different comparisons, either using
single-dose activated charcoal (SDAC) alone, combinedwith other
pre-hospital treatments, or in adjuvant to hospital interventions.
Furthermore, multi-dose activated charcoal (MDAC) was used in
adjuvant to hospital interventions.
We found very low-certainty evidence from two studies, involv-
ing 476 participants and comparing single-dose activated char-
coal to no intervention, which is our main comparison (Merigian
1990; Underhill 1990). These studies included participants with
unspecified exposures in Merigian 1990 or paracetamol overdoses
in Underhill 1990. Any effect on the incidence of adverse events,
clinical deterioration or ICU admission is uncertain. See Summary
of findings for the main comparison.
Seven trials, providing evidence of low to very low certainty and
including 5383 participants, investigated the effect of SDAC in
adjuvant to established hospital interventions such as support-
ive treatment and in most cases also gastric lavage (Comstock
1982; Cooper 2005; Crome 1983; Eddleston 2008; Hultén 1988;
Merigian 2002; Roberts 2006). All but three studies either did
not specify a toxic syndrome or recruited participants with differ-
ent toxic syndromes (Crome 1983; Hultén 1988; Roberts 2006).
Theremay be little or no difference in the incidence ofmortality or
the need for and length of intubation. We are uncertain about the
effects of SDAC in addition to hospital treatments with regard to
adverse events, drug absorption and incidence of hospitalization
or ICU admission. See Summary of findings 2.
Five trials including 3568 participants compared MDAC ver-
sus SDAC, all in adjuvant to hospital interventions (Behnoush
2009; Brahmi 2006; De Silva 2003; Eddleston 2008; Roberts
2006). Two trials included participants with carbamazepine over-
dose (Behnoush 2009; Brahmi 2006), and two trials studied par-
ticipants with yellow oleander poisoning (De Silva 2003; Roberts
2006). Eddleston 2008 included participants with different types
of overdose, including yellow oleander and pesticide poisoning.
There were some discrepancies between studies, preventing us
from drawing any conclusions regarding incidence of mortality.
This is evidence of very low certainty. In addition, low-certainty
evidence suggests that MDAC may result in decreased incidence
of ICU admissions and an increase in abdominal discomfort or
diarrhoea, but it may have no influence on the need for intuba-
tion. Furthermore, we are uncertain about the effects of MDAC
on drug absorption or length of intubation, evidence of very low
certainty. See Summary of findings 3.
We identified one study, involving 34 participants, with very low-
certainty evidence that compared SDAC with syrup of ipecac
in participants with anti-inflammatory, analgesic or psychotropic
drug overdose (Amigó Tadín 2002). We are uncertain about the
effect of SDAC versus ipecac on the incidence of adverse events
or Glasgow Coma Scale scores. See Summary of findings 4.
We identified three studies comparing MDAC in adjuvant to hos-
pital intervention versus hospital intervention alone in 3121 par-
ticipants (Bouget 1989; Eddleston 2008; Roberts 2006). This low-
to very low-certainty evidence suggests there may be no difference
in the incidence of mortality, symptoms of intoxication or length
of intubation, while we are uncertain about its effects on pharma-
cokinetic parameters. See Summary of findings 5.
None of the above-mentioned evidence could showadded value for
the use of activated charcoal, either administered as a single dose or
as multiple doses, or in adjuvant or not to hospital interventions.
Body position
Another possible intervention to slow down the uptake of the
poison is a certain body position. The theory is that placing a
patient on the left lateral decubitus positionwould allow the gastric
content to stay in the greater curvature of the stomach, due to the
combination of gravity and the anatomy of the stomach, which
might slowdown the rate of absorption of the poison.However, we
did not identify any studies performed in poisoning participants
that compared different kinds of body position.
B. First aid interventions that evacuate the poison
from the gastrointestinal tract
Vomiting or accelerated defecation might induce the quick evac-
uation of the poison from the gastrointestinal tract. Interventions
that might obtain this effect are emetics, which induce vomiting,
or cathartics, for the acceleration of defecation.
Emetics
Five included studies looked at the effectiveness of syrup of ipecac
as a first aid measure for poisoning.
One study including 103 participants provided evidence of low
certainty on the use of ipecac versus no intervention in asymp-
tomatic participants with toxic berry ingestion (Wax 1999). This
42First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
study took place in a pre-hospital setting and reported no clinical
outcomes. While there may be little or no difference in emergency
department referral, there may be an increase in adverse events.
See Summary of findings 6.
Four studies, involving 1240 participants, assessed the addition
of syrup of ipecac to SDAC plus a cathartic (Albertson 1989;
Kornberg 1991; Kulig 1985; Pond 1995). All studies either did
not specify or included multiple types of overdose. Low-certainty
evidence suggests there may be little or no difference in the in-
cidence of clinical improvement. On the other hand, we are un-
certain about any effect on the incidence of mortality, adverse
events, clinical deterioration, hospitalization or ICU admission.
See Appendix 2.
We identified one study with 120 participants comparing different
doses of ipecac (Ilett 1977), but it did not report any outcomes of
interest.
One study compared syrup of ipecac versus SDAC. We describe
this study above (interventions that limit or delay the absorption
of the poison in the body). See Summary of findings 4.
None of the evidence on the use of syrup of ipecac as a first aid
intervention shows any benefit, and it may even cause harm.
Cathartics
Cathartics are often used in combination with activated char-
coal, where activated charcoal is used to adsorb the poison and
the cathartic to accelerate the evacuation from the gastrointestinal
tract. We identified two studies in 183 participants that looked
at the combination of different types or doses of cathartic with
SDAC in childrenwith unspecified or various intoxications (James
1995; Sue 1994).
These trials provided evidence of very low certainty comparing
the use of SDAC plus a cathartic versus SDAC alone in either
unspecified ormultiple toxic syndromes.We are uncertainwhether
adding a cathartic to the treatment influences the incidence of
adverse events or the incidence of hospitalization. See Appendix
3.
Sue 1994 assessed SDACplus different doses of magnesium citrate
in 64 participants, but we are uncertain whether this would result
in a difference regarding the incidence of hospitalization. See
Appendix 4.
James 1995 studied the effects of different types of cathartics (sor-
bitol, magnesium citrate or magnesium sulphate) in combination
with SDAC, in 119 participants. We are uncertain whether a dif-
ferent type of cathartic in adjuvant to SDAC influences the inci-
dence of vomiting as an adverse event. See Appendix 5.
In summary, we did not identify any trials that looked at the use of
cathartics alone compared with no intervention. Cathartics were
always used in combination to SDAC. From the limited evidence
available, we are not able to draw conclusions regarding the use of
cathartics in addition to SDAC.
C. Combinations of first aid interventions
One study including 32 participants looked at the effects of com-
bining SDAC with cathartics as an adjuvant to hospital inter-
vention, compared to hospital intervention alone in participants
with overdoses of benzodiazepines, barbiturates or imipramine
(Passeron 1989). The study provided evidence of very low cer-
tainty, so we are uncertain about the impact of adding SDAC plus
cathartics in adjuvant to a hospital intervention onGlasgowComa
Scale scores or the incidence of vomiting. See Appendix 6.
One study in 14 participants used MDAC in combination with
magnesium sulphate as a cathartic, in adjuvant to hospital treat-
ment (Montoya-Cabrera 1999). The evidence of very low cer-
tainty precluded us from drawing conclusions about the effects
of MDAC and magnesium sulphate in adjuvant to hospital treat-
ments on the plasma half-life of paracetamol. See Appendix 7.
D. First aid interventions that neutralize or dilute the
poison
We did not identify any studies in poisoning patients that looked
at the effects of commonly used home remedies such as drinking
milk, water, vinegar or citrus juice to neutralize or dilute the poi-
son.
Overall completeness and applicability of
evidence
The objective of this review was to assess the effects of pre-hospital
interventions, alone or in combination, that laypeople could fea-
sibly provide victims of acute oral poisoning before professional
help arrives. We identified only one study from a pre-hospital set-
ting (Wax 1999). As we anticipated that this would be the case in
advance, we also included studies performed in a hospital setting
as indirect evidence. Furthermore, half of the studies compared
the intervention of interest in adjuvant to a hospital intervention
versus hospital interventions alone. These considerations limit the
applicability of our findings.
With regard to the interventions of interest, about two-thirds of
the identified studies looked at SDAC and MDAC alone or in
combination with cathartics, and sometimes in adjuvant to hos-
pital treatment. We identified six studies assessing syrup of ipecac.
We found little evidence on the use of cathartics, and in the two
studies we did identify cathartics were used in adjuvant to another
treatment (i.e. SDAC), making it difficult to make a judgment on
the use of cathartics by themselves for oral poisoning. Finally, we
found no studies of the effect of body position or interventions
that might dilute or neutralize the poison, such as drinking water
or milk.
The 24 identified studies described a wide range of outcomes.
However, the primary outcomes of interest, mortality, severity of
symptoms due to poisoning and adverse events, were very variably
and often incompletely reported. Useable data on these outcomes
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were thus limited. This also precluded combining the different
interventions in this review in a network meta-analysis (NMA),
which would have allowed us to compare the relative efficacy of
different interventions and potentially rank the interventions for
efficacy.Wewill performanNMA for future updates of this review,
if more useable data becomes available.
Furthermore, most studies were over 10 years old, with the oldest
study being performed in 1977 (Ilett 1977).Only two studies took
place in the past decade (Behnoush 2009; Eddleston 2008).
A major limitation in most of the identified studies is the substan-
tial heterogeneity of the included participants. This might obscure
potential benefits in subgroups of participants, for example par-
ticipants with severe poisoning, specific toxic syndromes or those
presenting early (Juurlink 2015). On the other hand, in a first aid
setting it might often be unclear what type of patient a caregiver
is dealing with, with regard to the type, dose and timing of intox-
ication, further complicating conclusions with respect to the lay
setting.
Overall, the identified evidence is scarce and of low to very low
certainty, which precludes any firm conclusions about the added
value of any of the first aid interventions discussed in this review.
However, almost all of these studies were performed in a hospital
setting, which means there is a delay in presentation and thus
treatments are started at a later time than when given in a home
setting. It could therefore be possible that treatments were not
effective because of their delayed administration.
In addition, evidence is too scarce to be able to draw conclusions
about the safety of most of the first aid interventions. The excep-
tion is syrup of ipecac, for which low-certainly evidence suggests
that the number of complications increases when using it com-
pared to no intervention.
Quality of the evidence
A key methodological limitation in the included studies is that
most studies used inappropriate or unclear methods of random-
ization. Furthermore, most studies reported outcomes poorly, and
the reporting format was highly heterogeneous. This makes the
studies difficult to compare with one another. The variation be-
tween and within studies with respect to the population further
complicates the comparison of different studies.
First aid interventions that limit or delay the
absorption of the poison in the body
For most of the comparisons including single- or multi-dose ac-
tivated charcoal, the evidence is of low to very low certainty. In
most cases, we downgraded the evidence for indirectness (since
most studies were performed in a hospital setting), imprecision
(limited sample size, low number of events and/or wide confidence
intervals) and limitations in study design.
In the comparison of SDAC versus MDAC (both in adjuvant to
hospital interventions), we identified two studies at low risk of bias;
however, there was inconsistency between the studies’ findings,
which makes it difficult to draw any conclusions. There is no clear
cause of this inconsistency, but possible explanations might be
that De Silva 2003 included participants up to 72 h after poison
ingestion, whereas Eddleston 2008 included participants only up
to 24 h after ingestion. Furthermore, Eddleston 2008 included
less severely poisoned participants than De Silva 2003 (Glasgow
Coma Scale of less than 13).
First aid interventions that evacuate the poison from
the gastrointestinal tract
For interventions that promote the evacuation of the poison from
the gastrointestinal tract, we found themost evidence on the use of
syrup of ipecac. However, all studies were at high risk of selection
bias, and most were at high or unclear risk of detection bias. We
further downgraded studies due to imprecision and indirectness,
leading to low or very low certainty evidence.
The evidence on the use of cathartics was limited and of very low
certainty due to a high risk of reporting bias, indirectness and im-
precision. The identified studies always used cathartics in combi-
nation with other interventions, making it difficult to draw con-
clusions about cathartics alone as a treatment for oral poisoning.
First aid interventions that neutralize or dilute the
poison
There are no available data that we identified on interventions that
neutralize or dilute the poison.
Potential biases in the review process
This review intended to assess interventions that are feasible for
laypeople to use in situations of oral poisoning. This means that
the interventions should be feasible to use in a pre-hospital setting
by people without any medical knowledge. According to these
criteria, we excluded interventions such as gastric lavage or intra-
venous drug administrations.
Most identified studies took place in a hospital setting, which
means that we had to downgrade the level of evidence due to in-
directness. Only one included study was in a pre-hospital com-
munity setting, but it included only asymptomatic poisoning pa-
tients.
Although the interventions were mostly in a hospital setting, we
included only studies that used interventions feasible by laypeo-
ple. We only allowed comparisons with hospital interventions if
the treatment group received the same hospital interventions in
adjuvant to the possible first aid treatment under investigation.
We did not include themany available volunteer studies. These are
studies in which healthy volunteers receive a drug in a therapeutic
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or supratherapeutic dose, in a controlled setting such as a labora-
tory environment, mostly without co-ingestion of other drugs or
alcohol, on an empty stomach. We believed this was even more
indirect than including studies performed in actual oral poisoning
patients, although they were performed in a hospital setting.
As mentioned earlier, most studies were over 10 years old, with the
oldest study from 1977. Only two studies took place within 10
years of our literature search. Many of the studies were poorly re-
ported: data weremissing, and our attempts to contact the authors
were often unsuccessful because no contact details were available,
authors did not respond, or data were no longer available. This
could introduce a bias on the completeness of the data and the
risk of bias assessment, leading to perhaps a more strict judgment
of bias for some studies.
Agreements and disagreements with other
studies or reviews
An existing Cochrane Review on interventions for paracetamol
(acetaminophen) overdose included not only possible first aid in-
terventions such as activated charcoal or syrup of ipecac, but also
hospital interventions such as gastric lavage, charcoal haemoper-
fusion, antidotes such as N-acetylcysteine or cimetidine, and liver
transplantations (Brok 2006). The review included randomized
controlled trials as well as observational studies, and studies per-
formed in healthy volunteers as well as in patients. In our review,
the focus is on first aid interventions feasible for laypeople. This
excludes all types of hospital interventions. Furthermore, we did
not focus on a specific toxin, and since sufficient studies in patients
were available, we decided to exclude studies performed in healthy
volunteers. We agree with the conclusions of Brok 2006 that the
use of activated charcoal seems a safer option than syrup of ipecac
to reduce uptake, although research still needs to demonstrate a
clear clinical benefit.
There might be some overlap with the different position papers
published on the use of SDAC (American Academy of Clinical
Toxicology 2005), MDAC (American Academy of Clinical
Toxicology 1999), cathartics (American Academy of Clinical
Toxicology 2004), and syrup of ipecac (Höjer 2013). These pa-
pers give a comprehensive overview of the interventions and dis-
cuss the published literature, from preclinical to clinical research.
However, most are out of date, and it is not clear if the literature
search was systematic. Our systematic review does highlight that
in the decade preceding publication, there has been very little re-
search on this important topic.
Furthermore, the position papers only give a description of the
different identified studies, whereas in our review we combined
studies in a meta-analysis where possible, to give an overall effect
size. In any case, our conclusions are largely similar: there is in-
sufficient evidence for a clinical benefit and thus for the routine
use of any of the investigated treatments. Few studies have been
published since the publication of these position papers, and while
our review includes them, all fail to show a clear clinical benefit for
the use of these first aid treatments in a hospital setting. However,
one important difference is that the recommendations made in
these position papers were designed for a professional care setting.
The relevance for a pre-hospital setting remains unclear.
A systematic literature search and meta-analysis on the effect of
activated charcoal in healthy volunteers showed that administra-
tion of activated charcoal was most effective when administered
immediately after drug intake, but it was still effective up until
four hours after drug ingestion (Jürgens 2009). There was no in-
formation on adverse events due to the intervention. This meta-
analysis demonstrates the theoretical capacity of activated charcoal
to reduce uptake of a variety of toxins. However, the actual clinical
benefit for oral poisoning patients remains speculative, as demon-
strated by the studies included in our review, which fail to show a
clear clinical benefit. Reasons for the discrepancy between data col-
lected from healthy volunteers and actual patients might include
the time passed between ingestion of the drugs and the start of the
treatment. Also, the meta-analysis looked at activated charcoal as
the only treatment. It did not assess any combination treatments,
such as activated charcoal plus a cathartic. Furthermore, the con-
trolled setting where studies in healthy volunteers take place ex-
cludes certain confounding variables, for example ingesting the
drugs with alcohol, intake of a cocktail of different kinds of drugs
or not knowing which drugs were taken. These considerations im-
ply that the use of activated charcoal is still a therapeutic option in
emergency departments, but clinicians should carefully consider
its use for individual patients (Juurlink 2015). From the available
evidence, it is unclear whether a layperson would be capable of
making these considerations in a pre-hospital setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We are unsure about the effects of activated charcoal, syrup of
ipecac or cathartics for pre-hospital management by laypeople of
acute oral poisoning, due to the low- or very low-certainty evi-
dence.Datamostly came fromemergency care departments, where
the added value of first aid interventions is uncertain. Given the
indirectness of these results, it is not possible to draw any conclu-
sions concerning the use of these interventions for the pre-hospital
setting.
Implications for research
There are many studies available on the use of activated char-
coal, cathartics, syrup of ipecac or combinations of these interven-
tions. Studies are performed either in oral poisoning patients or
in healthy volunteers, mostly in a healthcare or controlled setting.
However, there is very little up-to-date evidence. Researchers may
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feel hampered by practical issues to further investigate these in-
terventions; nevertheless, the most recent studies show that high
methodological quality can be feasible and ethical. The identified
evidence, however, is indirect.
On the other hand, the clinical benefit of the one recommendation
that is being made in practice in a pre-hospital setting (IFRC
2016), the use of the left lateral decubitus position, remains to be
demonstrated. If researchers are designing future studies on the
effectiveness of first aid measures for acute oral poisoning, these
could take place in a pre-hospital setting to avoid the delay that is
inherent to hospital studies. This delay precludes firm conclusions
about interventions whose effectiveness decreases over time, as is
clearly the case for interventions that try to limit the uptake of a
poisonous substance.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Albertson 1989
Methods Study design: randomized controlled trial
Study duration: 24 months ending December 1987
Setting: emergency department (ED) at UC Davis Medical Center
Country: USA
Number of individuals randomized: 200
Number of individuals receiving the intervention: 93
Number of individuals receiving the control: 107
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: 113 women, 87 men
Age: 30.1 (SEM 0.8), range 18-77 years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: all participants with mild or moderate oral overdose,
56% had mixed overdoses, most frequently with ethanol, timing could not be reliably
obtained in most participants
Inclusion criteria: awake with gag reflex, > 18 years, cooperative
Exclusion criteria: rapidly deteriorating level of consciousness, previous vomiting, re-
ceived ipecac syrup at home or en route, ingested substance with contraindication for
ipecac syrup, ingested strong acids or bases, camphor, volatile petroleum distillates and
strychnine, ingested large amounts of iron and lithium alone
Interventions Intervention arm:
Type: syrup of ipecac followed with activated charcoal-sorbitol after vomiting subsided
Timing:
Syrup of ipecac: no information
AC-sorbitol: after induced vomiting
Dose: 30 mL ipecac syrup + 1 g/kg AC (50 g AC-sorbitol-water suspension
Frequency: 1× ipecac unless no response then repeated after 30 min + 1× AC
Integrity: no information
Control arm:
Type: activated charcoal-sorbitol
Timing: no information
Dose: 1 g/kg AC (50 g AC-sorbitol-water suspension)
Frequency: 1×
Integrity: no information
Outcomes Type (unit):
Mean time in the emergency department (h) (see Table 4)
Proportion requiring hospitalization
Number of days hospitalized (see Table 4)
Proportion admitted to the intensive care unit
Number of days in ICU (see Table 4)
Proportion of complications
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Albertson 1989 (Continued)
Timing: during time in the hospital (early)
Funding No information
Notes 75% had toxicology screen done but was not a criterion for inclusion or exclusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “were randomized by hospital unit
numbers to two treatment groups”
Comment: not an adequate randomisation
method
Allocation concealment (selection bias) High risk Quote: “were randomized by hospital unit
numbers to two treatment groups”
Comment: allocation scheme does not al-
low allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied (e.g. mean time spend in the emergency
department)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No specific information, but no failure to
adhere to intervention reported
Selective reporting (reporting bias) High risk No assessment of symptom severity
Other bias High risk Quote: “Most patients (75%) had partial
or complete toxicological analysis of blood
and/or urine performed, although this was
not a requirement of the study.”
Comment: for 25% of the participants, ac-
tual poisoning was not verified by means
other than history
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Amigó Tadín 2002
Methods Study design: randomized controlled trial
Study duration: 11 December 2000 to 12 March 2001
Setting: emergency department of a tertiary healthcare facility (El Hospital Clinic,
Barcelona)
Country: Spain
Number of individuals randomized: 34
Number of individuals receiving the intervention: 21
Number of individuals receiving the control: 13
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex:
Ipecac: 17 females, 4 males
AC: 10 females, 3 males
Age:
Ipecac: 35 (SD 13) years
AC: 27 (SD 6) years
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants presenting at the emergency department with an oral overdose of either anti-
inflammatory drugs, analgesics or psychotropic drugs. 91% were psychotropics, mostly
benzodiazepines, followed by tricyclic antidepressants. In 35% of cases, more than 1
drug was taken. 18% were taken with alcohol
Selection criteria:
Inclusion criteria: > 15 years and Glasgow score > 12
Exclusion criteria: participants with a medical indication for gastric lavage or if it had
previously been performed by a medical service in an out-of-hospital setting. Presenting
more than 2 h after intoxication unless they had taken antidepressants, neuroleptics,
salicylates or opioids in which the interval was extended to 4 h. Participants for whom,
due to their potential severity, was presumed that 1-2 doses of SOI or AC would be
insufficient to effectively decontaminate the digestive tract
Interventions Intervention arm:
Type: syrup of ipecac
Timing: 8.65 (SD 8.4) min after arriving at the ED or 113.46 (SD 80.29) min after
ingestion
Dose: 30 mL, followed by 240 mL of water
Frequency: 1×
Integrity: dose was repeated after 20 minutes if no vomiting occurred in that time
Time to vomiting: 32 (SD 25.17) min, mean number of vomiting episodes: 2.05 (SD
1.68). 38% of vomits contained rests of tablets. 3 people did not vomit
Control arm:
Type: activated charcoal
Timing: 10.68 (SD 9.48) min after arriving at the ED or 112.35 (SD 81.48) min after
ingestion
Dose: 25 g in 200 mL of water
Frequency: 1×
Integrity: in order to mask the black color of the AC and so that its oral administration
did not pose problems of acceptability, it was given in the same jar in which it is marketed
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Amigó Tadín 2002 (Continued)
or in a glass with a cane
Outcomes Type (unit):
Mean arterial blood pressure (mmHg)
Heart rate (bpm)
Breathing rate (breaths/min)
Glasgow Coma Scale score
Length of stay ED (min) (see Table 4)
Workload nurses (data not extracted)
Adverse events
Timing:
Clinical parameters: 1 h after initial assessment of patient (early)
Rest: during ED stay (early)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients entering on even days re-
ceives syrup of ipecac and patients entering
on uneven days received activated charcoal.
”
Comment: no adequate randomization
Allocation concealment (selection bias) High risk Quote: “Patients entering on even days re-
ceives syrup of ipecac and patients entering
on uneven days received activated charcoal.
”
Comment: randomization schemedoes not
allow allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied (e.g. Glasgow Coma Scale assessment)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “The rest were excluded because
they had a Glasgow coma score < 12, did
not meet the inclusion criteria or because
caregivers were not able to complete the
forms”
Comment: of the 97 potentially eligible
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Amigó Tadín 2002 (Continued)
participants, only 34 were included, due to
justified reasons as “Glasgow coma score
<12” or “not meeting inclusion criteria”,
but also due to staff business. Not clear how
many participants were lost because of this
Selective reporting (reporting bias) Low risk No indication of a risk of reporting bias
Other bias Low risk No indication of other risk of bias
Behnoush 2009
Methods Study design: randomized controlled trial
Study duration: July 2003 to September 2004
Setting: hospital setting (poisoning ward of the Loghman Hospital, Tehran)
Country: Iran
Number of individuals randomized: 68
Number of individuals receiving the intervention: 38
Number of individuals receiving the control: 30
Number of individuals lost to follow-up: unclear, as loss to follow-up was considered an
exclusion criterion for the study
Sample size calculated: yes, but methods are not clearly reported: “The sample size was
measured according to the descriptive studies formula, and the P value was calculated
based on the number of controls with carbamazepine poisoning in Loghman Hospital,
in previous years.”
Participants Sex: 28 males and 40 females
Age: 24.2 years, range 13-65 years
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants admitted to the poisoning ward with history of carbamazepine poisoning:
Dose average (range): 6.8 g (1.2-24 g)
Delay between drug intake and admission average (range): 7.44 h (0.5 h to 15 h)
Inclusion criteria: poisoning confirmed by clinical examination and paraclinical tests
Exclusion criteria: taken other drugs or unknown drugs, hospitalization not needed, left
hospital before completion of treatment, not possible to confirm poisoning by carba-
mazepine
Interventions Intervention arm:
Type: MDAC via nasogastric tube + supportive treatment (including gastric lavage)
Timing: every 4 h
Dose: 100 g AC per dose
Frequency: several, but unknown number of doses
Integrity: no information
Control arm:
Type: SDAC via nasogastric tube + supportive treatment (including gastric lavage)
Timing: no information provided, presumably after poisoning confirmation
Dose: not specified, but likely 100 g AC
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Behnoush 2009 (Continued)
Frequency: 1×
Integrity: no information
Outcomes Type (unit): duration of hospitalization (h) (see Table 4)
Timing: no information
Funding No information
Notes All 8 ICU participants, with grade III or IV level of unconsciousness received the multi-
dose treatment, thus seem not to have been randomized and were therefore not included
in the analysis of hospitalization duration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “In all patients admitted to I.C.U.
and 30 patients of the ward, multiple doses
of charcoal were administered, whereas the
resting 30 patients -who were chosen ran-
domly- received single doses of charcoal”
Comment: not enough information to
make a judgment
Allocation concealment (selection bias) Unclear risk Quote: “In all patients admitted to I.C.U.
and 30 patients of the ward, multiple doses
of charcoal were administered, whereas the
resting 30 patients -who were chosen ran-
domly- received single doses of charcoal”
Comment: not enough information to
make a judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “The following patients were ex-
cluded from the study: those who left the
hospital before the treatment process was
completed”
Comment: participants that did not com-
plete the treatment process were excluded
and no data is available on the number of
people
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Behnoush 2009 (Continued)
Selective reporting (reporting bias) High risk Occurrence of complications not clearly
described: unclear in which group they oc-
curred. Drug and symptommonitoring are
crucial outcomes that are lacking in this
study. Especially for symptom monitoring,
which was described as being the criterion
for hospital discharge, this is problematic
Other bias Low risk No other risk of bias detected
Bouget 1989
Methods Study design: randomized controlled trial
Study duration: one month
Setting: hospital setting (emergency department of a regional hospital)
Country: France
Number of individuals randomized: 36
Number of individuals receiving the intervention: 19
Number of individuals receiving the control: 17
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex:
MDAC group: 16 female and 3 male
Control group: 12 female and 5 male
Age:
MDAC group: 31 (SD 3.6) years
Control group: 30 (SD 3.5) years
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants presenting with a deliberate overdose of benzodiazepines, with or without
concomitant alcohol ingestion
Inclusion criteria: overdose of benzodiazepines of any sort, with or without alcohol
Exclusion criteria: pregnant women, participants < 18 years old, concomitant ingestion
of other drugs
Interventions Intervention arm:
Type: MDAC (Carbomix) + supportive treatment including gastric lavage and infusion
of a an isotonic solution (5% glucose, enriched with 2 g/L KCl & 4 g/L NaCl)
Timing: after gastric lavage, and after 4 h, 8 h, 12 h
Dose: 50 g
Frequency: 4×
Integrity: no information
Control arm:
Type: supportive treatment including gastric lavage and infusion of a an isotonic solution
(5% glucose, enriched with 2 g/L KCl and 4 g/L NaCl)
Timing: gastric lavage: upon admission. Infusion: every 12 h
Dose:
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Bouget 1989 (Continued)
Gastric lavage: 15 L
Infusion: 1 L/time
Frequency:
Gastric lavage: 1×
Infusion: every 12 h
Integrity: no information
Outcomes Type (unit):
Glasgow Coma Scale score
Heart rate
Blood pressure
Diuresis
Temperature
Benzodiazepine concentration
Timing:
At 0 h and 12 h after intervention (early)
Blood samples were drawn every 4 h until discharge (early)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “By drawing of a lot”
Comment: adequate method of randomi-
sation
Allocation concealment (selection bias) Unclear risk Quote: “By drawing of a lot”
Comment: not enough information to
make a judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect certain out-
comes at study (e.g. Glasgow Coma Scale
scores)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information about incomplete out-
comes
Selective reporting (reporting bias) High risk Outcomes are not reported in such a way
that any interpretation is possible
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Bouget 1989 (Continued)
Other bias Low risk No other risk of bias detected
Brahmi 2006
Methods Study design: randomized controlled trial
Study duration: January to June 2004
Setting: 8 men and 4 women
Country: hospital setting (intensive care and toxicological unit)
Number of individuals randomized: 12
Number of individuals receiving the intervention: 6
Number of individuals receiving the control: 6
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: 8 men and 4 women
Age: 27.6 (SD 12.2) years
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants admitted with a history of carbamazepine poisoning. Participants did not
receive gastric lavage and received the same symptomatic and supportive treatment, as
needed
Poisoning symptoms at admission:
SAPS II score: 16.37 (SD 8.46)
APACHE II score:
8 (SD 3.96)
Glasgow coma score of the comatose participants (6):
8.28 (SD 1.6)
CBZ concentration:
29.42 (SD 6.68) mg/L
Inclusion criteria: history of CZBG ingestion, clinical features of poisoning, and labora-
tory findings using gas chromatography
Exclusion: children, mixed poisoning
Interventions Intervention arm:
Type: MDAC via nasogastric tube
Timing: every 6 h
Dose: 50 g AC
Frequency: variable, until carbamazepine blood levels drop below 12 mg/L
Integrity: no information
Control arm:
Type: SDAC via nasogastric tube
Timing: no information
Dose: 1 g/kg AC
Frequency: 1×
Integrity: no information
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Brahmi 2006 (Continued)
Outcomes Type (unit):
Cmax (mg/L)
T1/2 (h)
Ventilation required
Duration of ventilation (h)
Duration of coma (h)
Length of stay (h) (see Table 4)
Timing: blood levelsmeasured every 3 h until the peak and then every 6 h. (intermediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Once CBZ poisoning was re-
tained, no gastric lavage was done, and pa-
tients were randomized in 2 groups.”
Comment: not enough information to
make a judgment
Allocation concealment (selection bias) Unclear risk Quote: “Once CBZ poisoning was re-
tained, no gastric lavage was done, and pa-
tients were randomized in 2 groups.”
Comment: not enough information to
make a judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect certain out-
comes studied (e.g. decision to discharge)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up described
Selective reporting (reporting bias) High risk No AUC or potential adverse events re-
ported
Other bias High risk A clinical difference is suspected between
intervention and control group, based on
the divergent carbamazepine kinetics
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Comstock 1982
Methods Study design: randomized controlled study
Study duration: October 1975 to June 1976
Setting: hospital (emergency department of the Ben Taub hospital, Houston, Texas)
Country: USA
Number of individuals randomized: 339
Number of individuals receiving the intervention: 131
Number of individuals receiving the control: 208
Number of individuals lost to follow-up:277 at the start of follow-up, 308 at the 3-5 h sample
Sample size calculated: no information
Participants Sex: no information
Age: no information
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants presenting with illness associated with acute oral drug overdose, and at the
discretion of the attending physician selected for gastric lavage
Of these, chemical evidence of intake of sedative-hypnotics or aspiring in the blood and
at least 2 blood samples (1 at lavage and 1 afterwards) were available for 62 participants
(25 AC and 37 control participants)
Inclusion criteria: taken a sedative-hypnotic or aspirin
Degree of functional decompensation: moderate - slight impairment to unconscious,
normal gag reflex and deep tendon reflexes, responsive to superficial pain; severe - un-
conscious with depressed or absent pain response, gag reflex and deep tendon reflexes to
respiratory arrest
Chemical proof of intake of sedative-hypnotics or aspirin
Interventions Intervention arm:
Type: gastric lavage + activated charcoal via nasogastric tube
Timing: no information
Dose: gastric lavage followed by 100 g AC
Frequency: 1×
Integrity: no information
Control arm:
Type: gastric lavage
Timing: no information
Dose: no information
Frequency: 1×
Integrity: no information
Outcomes Type (unit): percentage of participants showing increased blood drug concentrations (%)
(data not extracted)
Timing: blood samples were taken at the time of lavage and at 2 h to 4 h intervals
thereafter when possible (early)
Funding Supported by grant from theNational Institute ofDrugAbuse: grant 1H81DA0175301
Notes Of the initially 339 selected participants, only 62 had chemical proof of sedative-hyp-
notics or aspirin at at least 1 blood sample available, which constituted the study sample
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Comstock 1982 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Following gastric lavage, 131 pa-
tients were randomly chosen to receive a
slurry of 100 g of activated charcoal (Norit
A) via the gastric tube.”
Comment: not enough information to
make a judgment
Allocation concealment (selection bias) Unclear risk Quote: “Following gastric lavage, 131 pa-
tients were randomly chosen to receive a
slurry of 100 g of activated charcoal (Norit
A) via the gastric tube.”
Comment: not enough information to
make a judgment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information to support judgment, but
lack of blinding is not likely to affect mea-
surement of the outcomes studied
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Of the total population, 25 AC
treated patients and 37 control patients had
chemical evidence for the presence of one
of the sedative-hypnotics listed in Tables
la and lb or aspirin in the blood, and at
least one blood sample in addition to the
sample taken at lavage. These 62 patients
constituted the population under study.”
Comment: only data from 62 out 339 ran-
domized patients (18%) is presented. Loss
to follow-up increases over time
Selective reporting (reporting bias) High risk Several clinically relevant outcomes (symp-
toms, adverse events) not reported
Other bias High risk Quote: “995were ingestions by history and
339 or 34% were selected for gastric lavage
at the discretion of the attending physician.
”
Comment: potential bias during selection
of the study population
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Cooper 2005
Methods Study design: randomized controlled trial
Study duration: July 1999 to October 2000
Setting: hospital (emergency department at tertiary referral teaching hospital, the Can-
berra Hospital)
Country: Australia
Number of individuals randomized: 327
Number of individuals receiving the intervention: 166
Number of individuals receiving the control: 161
Number of individuals lost to follow-up: 0
Sample size calculated: yes, a power of 80% to detect a 33% reduction in length of stay
at the 5% level was anticipated
Participants Sex:
Control: 48 males and 113 females
Intervention: 50 males and 116 females
Age:
Control: median age 28.5 years, IQR: 21.5-42.5 years
Intervention: median age 31.5 years, IQR: 21-42 years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: participants presenting at the emergency department
with a history of oral drug overdose. Benzodiazepines and paracetamol combined ac-
counted for most of the overdoses (62-66%). 31-35% ingested more than one drug.
Most subjects (57-59%) presented within 2 h after overdose. Glasgow Coma Scale was
< 15 in 27-30% of cases
Inclusion criteria: ≥16 years, within 12 h following a deliberate oral overdose, thought
to have ingested a substance adsorbed by AC
Exclusion criteria (at discretion of treating physician): ingested a potentially toxicmodified
release preparation, presentation within 1 h of ingestion of a highly lethal substance (e.g.
large doses of tricyclic antidepressants, antineoplastic medications, aspirin, cardioactive
agents)
Exclusion criteria: transferred, ingested substances not significantly adsorbed by AC (hy-
drocarbons, acids, alkalis), contraindications (unprotected airway, non-intact gastroin-
testinal tract)
Interventions Intervention arm:
Type: activated charcoal orally or via nasogastric tube + other treatment appropriate to
the substances ingested
Timing: after randomization
Dose: 50 g (Norit-C) in 200 mL of water as slurry
Frequency: 1×
Integrity: 3 participants refused charcoal
Control arm:
Type: no activated charcoal, only other treatment appropriate to the substances ingested
Timing: after randomization
Dose: NA
Frequency: NA
Integrity: 1 received charcoal
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Cooper 2005 (Continued)
Outcomes Type (unit):
Primary:
Medical length of hospital stay (h) (see Table 4)
Secondary:
Requirement for ventilation
Vomiting after admission
Occurrence of aspiration
Occurrence of death
Timing: during hospital admission (intermediate)
Funding The study was funded by the Australian Rotary Foundation and the Private Practice
Trust Fund of The Canberra Hospital
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to AC
or no gastrointestinal decontamination, as
indicated by the sealed sequentially num-
bered envelope contents.”
Comment: not enough information to
make a judgment
Allocation concealment (selection bias) Low risk Quote: “Patients were randomized to AC
or no gastrointestinal decontamination, as
indicated by the sealed sequentially num-
bered envelope contents.”
Comment: adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “The treatingmedical staff were not
blinded to the administration of AC, as this
would be very difficult to achieve.”
Comment: not blinded, but lack of blind-
ing may affect outcomes studied
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “This decision was made by a se-
nior member of the medical staff, but this
was not usually a toxicologist or any other
member of the study team... The coordi-
nator and data manager of the study was
never involved in the decision to medically
discharge the patient.”
Comment: suggests that members of the
study team are at least in some cases in-
volved in outcome assessment
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Cooper 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analysis was based on intention to
treat...”
Comment: analysis was appropriate, and
therewas very little deviation fromprotocol
Selective reporting (reporting bias) Low risk All relevant outcomes are reported
Other bias Low risk No other risk of bias detected
Crome 1983
Methods Study design: randomized controlled trial
Study duration: no information
Setting: hospital: accident departments of multiple hospitals
Country: UK
Number of individuals randomized: 48
Number of individuals receiving the intervention: 20
Number of individuals receiving the control: 28
Number of individuals lost to follow-up: 33
Sample size calculated: no information
Participants Sex: 10 males and 38 females
Age:
10-21 years: n = 7
22-31 years: n = 12
32-41 years: n = 8
42-51 years: n = 7
52-61 years: n = 4
62-71 years: n = 2
72-81 years: n = 1
unknown: n = 7
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Presenting at the accident department with suspected overdose of tricyclic antidepres-
sants and considered required to be hospitalized. Mixed dose were okay if tricyclic an-
tidepressants were considered responsible for the symptoms
Of these 48 cases, 17 had taken tricyclic antidepressants alone, 13 in combination with
other drugs, 7 had not taken antidepressants and 11 did not have significant amounts
of any drug in their blood
Inclusion criteria: symptoms considered to be caused by tricyclic antidepressants, patient
will be admitted to hospital
Interventions Intervention arm:
Type: activated charcoal in water suspended (+ supportive care), given through a naso-
gastric tube after gastric lavage in obtunded patients and as a drink in conscious and co-
operative patients
Timing: no information
Dose: 10 g in 200 mL water
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Crome 1983 (Continued)
Frequency: 1×
Integrity: no information
Control arm: supportive care, which might include gastric lavage, otherwise not specified
Type: NA
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Grade of coma
Presence of convulsions/movement disorders
Presence of pyramidal signs
Anticholinergic signs
Airway inserted, intubated and/or ventilated
Heart rate, rhythm, ECG
Blood pressure
Respiratory rate
Timing:
Clinical information was recorded on admission and at 4 h, 8 h and 24 h and at discharge
(intermediate)
Blood samples were collected on admission and at 4, 8 and 24 h (intermediate)
Urine and gastric washings were collected.
Funding Grant from Leo Research Foundation pharmaceutical company
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Local randomisation by sealed en-
velopes” (personal communication)
Comment: not enough information to
make a judgment
Allocation concealment (selection bias) Unclear risk Quote: “Local randomisation by sealed en-
velopes” (personal communication)
Comment: sealed envelopes were kept in
emergency departments of participating
hospitals, but not specified whether these
were opaque and sequentially opened
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
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Crome 1983 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Were outcome assessors blinded?
No” (personal communication)
Comment: lack of blinding might affect
measurement of the outcomes at study
Incomplete outcome data (attrition bias)
All outcomes
High risk For themain outcome reported, coma, only
data for pure tricyclic antidepressant were
reported and not for the other subgroups.
Although 17 participants are reported to
make up this subgroup, data for 15 partic-
ipants is reported. Participants that refused
to ingest ACwere not included in the analy-
sis, no intention-to-treat analysis (personal
communication)
Selective reporting (reporting bias) High risk Pre-specified outcomes presence of con-
vulsions/movement disorders, presence of
pyramidal signs, anticholinergic signs, air-
way inserted, intubated and/or ventilated,
heart rate, heart rhythm, ECG, blood pres-
sure and respiratory rate were not reported
Other bias High risk In 11 of the 48 participants no significant
amounts of any drugs were found and 7
of them had not taken any tricyclic antide-
pressant
Role of the study funder not clarified
De Silva 2003
Methods Study design: randomized controlled trial
Study duration: November 2001 to June 2002
Setting: hospital setting (accident and emergency department of the Kurunegala Teaching
Hospital)
Country: Sri Lanka
Number of individuals randomized: 401
Number of individuals receiving the intervention: 201
Number of individuals receiving the control: 200
Number of individuals lost to follow-up: 23
Sample size calculated: yes, a sample size of 376 was calculated to detect a decrease in
death rate from 10% to 2.5% with 80% power at the 5% level
Participants Sex:
SDAC: 111 males and 89 females
MDAC: 87 males and 114 females
Age:
SDAC: 24.1 (SD 8.7) years
MDAC: 23.5 (SD 9.6) years
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De Silva 2003 (Continued)
Country (if different from study authors’): NA
Type, dose and timing of poisoning: yellow oleander seed poisoning, presenting within 24
h of ingestion
Inclusion criteria: yellow oleander tree poisoning; 12-70 years old; presenting within 24
h of poisoning
Exclusion criteria: taken another drug (e.g. alcohol, organophosphates, paracetamol, or
sedatives); debilitating disease (diabetes mellitus, hepatic or renal disease, heart failure,
or malignant disease); abdominal surgery within the past year; known hypersensitivity
to AC; severe infection; pregnant and lactating women
Interventions Intervention arm:
Type:MDAC and supportive care (which included gastric lavage, followed by a first dose
of AC, atropine and metoclopramide as required)
Timing: initial dose on admission, after gastric lavage, additional doses every 6 h for 3
days: 0 h, 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h, 66 h, 72 h
Dose: 50 g in 400 mL water
Frequency: 13×
Integrity: 16 discharged themselves before end of treatment. Although most participants
found the charcoal unpalatable, none refused to take it
Control arm:
Type: SDAC + water and supportive care (which included gastric lavage, atropine and
metoclopramide as required)
Timing: on admission, after gastric lavage
Dose: 50 g dose AC + 400 mL, followed by 400 mL water every 6 h as placebo
Frequency: 1×
Integrity: 10 discharged themselves before end of treatment
Outcomes Type (unit):
Primary outcome:
Death
Secondary outcomes:
ICU admission
Participants given anti-digoxin antibody Fab fragments
Cardiac pacing
Life-threatening arrhythmias at 24 h
Atropine administered (mg)
Boluses of atropine administered
Time in hospital (days) (see Table 4)
Patient response to treatment
Bowel sounds
Timing: data collected until death or discharge from hospital (intermediate)
Funding The University of Kelaniya gave financial support for the study
Notes Sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. The authors declared no conflict of interest
23/26 participants that left the hospital before end of treatment were confirmed to be
alive and well within 1 week of leaving the hospital. 3 that could not be contacted were
considered and analysed as being alive
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De Silva 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “6 h after admission, an investiga-
tor (AP) used a computer-generated ran-
dom-allocation table to allocate patients ..
. This investigator was not involved in care
or assessment of patients.”
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “6 h after admission, an investiga-
tor (AP) used a computer-generated ran-
dom-allocation table to allocate patients ..
. This investigator was not involved in care
or assessment of patients.”
Comment: adequate
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Investigators were unaware of pa-
tients’ treatment allocation. Three medi-
cally qualified research assistants supervised
administration of activated
charcoal or sterile water, but they did not
participate in clinical assessment or man-
agement of patients. To facilitate blinding,
research assistants also ensured that patients
and their bedclothes were cleaned thor-
oughly after each treatment.”
Comment: participants were not blinded,
but lack of blinding is not likely to affect
the outcomes studied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Investigators were unaware of pa-
tients’ treatment allocation. Three medi-
cally qualified research assistants supervised
administration of activated charcoal or ster-
ile water, but they did not participate in
clinical assessment or management of pa-
tients. To facilitate blinding, research assis-
tants also ensured that patients and their
bedclothes were cleaned thoroughly after
each treatment.”
Comment: adequate, outcome assessors
were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analysis was by intention to treat.
”, “26 (16 in the treatment group) patients
discharged themselves within 72 h of ad-
mission; all had normal heart rates at the
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De Silva 2003 (Continued)
time they left hospital, and 23 (16 in the
treatment group) reported being well when
contacted at their homes within 1 week”
Comment: low attrition rate (6%), which
was accounted for and analysed as inten-
tion-to-treat
Selective reporting (reporting bias) High risk Quote: “The most frequent adverse effects
of treatment with multiple doses of acti-
vated charcoal were diarrhoea and abdom-
inal discomfort. Three patients had diar-
rhoea and13 complained of abdominal dis-
comfort.”
Comment: potential adverse events not
clearly described for the control group and
for the outcome ’boluses of atropine ad-
ministered’ statistical analyses and reported
summary effect were not clear
Other bias Low risk No other risk of bias detected
Eddleston 2008
Methods Study design: randomized controlled trial
Study duration:
Total: 31 March 2002 to September 2004
Anuradhapura: 31 March 2002 to September 2004
Polonnaruwa: 4 June 2002 to September 2004
Kurunegala: 23 November 2002 to 3 Febrary 2003
Setting: hospital setting (medical wards of 3 Sri Lankan secondary hospitals)
Country: UK
Number of individuals randomized: 4632
Number of individuals receiving the intervention:
SDAC: 1545
MDAC: 1533
Number of individuals receiving the control: 1554
Number of individuals lost to follow-up: 3
Sample size calculated: yes, a total sample size of 4200 was calculated tomeasure a decrease
in mortality from 10% to 7%, with 80% power at the 5% level
Participants Sex:
No AC: 915 men and 639 women
SDAC: 883 men and 662 women
MDAC: 960 men and 573 women
Age:
No AC: 25 (19-35)
SDAC: 25 (19-35)
MDAC: 25 (19-36)
Country (if different from study authors’): Sri Lanka
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Eddleston 2008 (Continued)
Type, dose and timing of poisoning: participants admitted to the medical ward of 3 sec-
ondary referral hospitals with a history of oral poisoning
Median time between ingestion and admission (h, mean (IQR))
Usual care: 4.2 (2.7 to 7.0)
SDAC: 4.2 (2.7 to 7.1)
MDAC: 4.3 (2.7 to 7.1)
Type of poisoning:
Usual care:
Oleander: 555
Organophosphorus/carbamate pesticide: 441
Organochlorine: 4
Other/unknown pesticide or paraquat: 343
Medicine or unknown: 211
SDAC:
Oleander: 550
Organophosphorus/carbamate pesticide: 440
Organochlorine: 3
Other/unknown pesticide or paraquat: 340
Medicine or unknown: 212
MDAC:
Oleander: 542
Organophosphorus/carbamate pesticide: 429
Organochlorine: 3
Other/unknown pesticide or paraquat: 345
Medicine or unknown: 214
Participants were stabilized upon admission by resuscitation, by airway stabilization and
providing oxygen, atropine, fluid and antidotes, as necessary, before intervention started
Exclusion criteria: < 14 years, prior treatment with AC during this episode of poisoning,
known pregnancy, ingestion of corrosives or hydrocarbons alone, requirement for oral
medication, inability to intubate the patientwith aGlasgowcoma score <13, presentation
> 72 h after ingestion, previous recruitment, < 16 years old or unconscious without
relatives present to give consent
Interventions Intervention arm:
Type: SDAC or MDAC orally or via nasogastric tube + supportive care (see control)
Timing:
SDAC: “soon” after admission
MDAC: every 4 h
Dose: 50 g superactivated charcoal (Carbomix) in 300 mL water per dose
Frequency:
SDAC: 1×
MDAC: 6×
Integrity: first protocol intended to deliver 18 doses of AC in the multi-dose group,
this however was not feasible, so protocol was adapted to 6 doses. Compliance was
not anticipated a problem as was given while patient was under supervision; however
participants were not forced. An analysis of compliance was done in 2 of the 3 hospitals,
involving 1103 participants, showing that compliance decreased to 66% by the 6th dose
of AC. Furthermore, an estimated 8% of the first dose of AC was vomited. This amount
decreased to 1% by the sixth dose. < 5% did not receive allocated intervention (reasons
73First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eddleston 2008 (Continued)
included damaged throat and refusal)
Control arm:
Type: supportive care: resuscitated if needed, stabilized and given oxygen and antidotes
as necessary. Atropine (usually 0.3-0.6 mg/h) and intravenous fluids were administered
as needed to maintain a heart rate > 70 bpm and systolic blood pressure > 80 mm Hg.
Participants with severe cardiotoxicity either were administered antidigoxin Fab antitoxin
or treatedwith temporary pacing.Most participants, 54%and7.5% respectively, received
forced emesis or gastric lavage prior to arriving at the study hospital
Initially gastric lavage was never performed at study hospital. However, after patient
1905, in participants presenting less than 2 h with significant poisonings gastric lavage
was performed (3 × 300 mL)
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Primary outcome:
All-cause mortality
Secondary outcomes (per ingested poison):
For organophosphorus or carbamate pesticide:
Intubation
Time ventilated
Time to first ventilation
Seizures
For oleander poisoning:
Cardiac dysrhythmias needing digoxin-specific antibody fragments, serum potassium >
6.0 mmol/L or temporary pacing
Timing: participants were seen at least every 3 h and more if needed. Condition of
participants was recorded twice per day at 8:30 and 20:30. Significant events (intubation,
seizures, death) were recorded at time of the event (intermediate)
Funding Grant 063560 from the Wellcome Trust’s Tropical Interest Group to ME. The South
Asian Clinical Toxicology Research Collaboration is funded by a Wellcome Trust/Na-
tional Health andMedical Research Council International Collaborative ResearchGrant
071669
Notes The funding source had no role in study design, data collection, data analysis, and data
interpretation; or writing of the report; or in the decision to submit for publication. The
authors declared no conflict of interest
Trial registration number: ISRCTN02920054
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The random allocation sequence
was generated by computer and incorpo-
rated into a Microsoft Access programme
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written for patient recruitment, randomi-
sation and event recording (Figure 1). Strat-
ified block randomisation was performed
using the following strata:”
Comment: adequate
Allocation concealment (selection bias) Low risk Quote: “The allocation sequences were
generated independently by the study
statistician (EJ) and implemented by the
programmer (SA), neither of whom had a
role in patient recruitment, treatment or as-
sessment. Variable block sizes of 3, 6 and 9
were used to allocate patients in equal num-
bers to each treatment group... Randomi-
sation occurred after the patient’s baseline
data had been entered and receipt of con-
sent noted, and could not be manipulated
by study doctors. The recruiting doctor
was unable to predict allocation before ran-
domisation.”
Comment: adequate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Another limitation was the ab-
sence of masking. We believed that mask-
ing was difficult because of the impossi-
bility to conceal from a reviewing doctor
whether a patient had received any char-
coal. An absence of masking might have
allowed for performance bias for the sec-
ondary outcomes. To counter this poten-
tial bias, the medical team made decisions
about intubation and transfer of patients
independently of the study doctors.”
Comment: participants andpersonnel were
not blinded, which may affect outcomes
studied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Another limitation was the ab-
sence of masking. We believed that mask-
ing was difficult because of the impossi-
bility to conceal from a reviewing doctor
whether a patient had received any char-
coal. An absence of masking might have
allowed for performance bias for the sec-
ondary outcomes. To counter this poten-
tial bias, the medical team made decisions
about intubation and transfer of patients
independently of the study doctors.”
Comment: outcome assessors were not
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blinded, but primary outcome was unam-
biguous
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “We did an intention-to-treat anal-
ysis on all patients with available outcomes
data (loss to follow-up of three (< 1%) pa-
tients) analysed in the groups to which they
were allocated.”
Comment: adequate
Selective reporting (reporting bias) Low risk All pre-specified outcomes have been re-
ported
Other bias Low risk No other risk of bias detected
Hultén 1988
Methods Study design: randomized controlled trial
Study duration: no information
Setting: hospital setting
Country: Sweden
Number of individuals randomized: 91
Number of individuals receiving the intervention: 34
Number of individuals receiving the control: 43
Number of individuals lost to follow-up: 14
Sample size calculated: no information
Participants Sex: no information
Age: older than 14 years
Country (if different from study authors’): UK, Belgium, Sweden
Type, dose and timing of poisoning: 32 participants took amitriptyline, 16 clomipramine,
10 mianserin, 9 imipramine, 6 dothiepin, 2 doxepin, 2 nortriptyline, mixed overdoses
in 67% with most commonly benzodiazepines or alcohol
Inclusion criteria: participants with self-poisoning with 1 or more of 7 different TCA
(mixed overdoses also included if clinician considered 1 of 7 TCA drugs was major cause
of participants’ symptoms)
Exclusion criteria: participants < 14 years old, taken significant amount of other drugs
Plasma TCA concentration < 0.3 µg/L
Interventions Intervention arm:
Type: activated charcoal (MedicoalR) after gastric lavage
Timing: no information
Dose: 20 g
Frequency: 1×
Integrity: no information
Control arm:
Type: gastric lavage
Timing: no information
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Dose: no information
Frequency: 1×
Integrity: no information
Outcomes Type (unit):
AUC ((mg/L) × h)
Blood pressure (mmHg)
Heart rate (bpm)
Coma grade (Matthew-Lawson coma scale)
Symptoms: e.g. convulsions, arrhythmias, muscle twitching
Number of participants intubated
Time spent intubated
Time admitted to ICU (see Table 4)
Time admitted to hospital (see Table 4)
Timing:
Plasma drug concentration at 0 h, 1 h, 2 h, 4 h, 8 h and 24 h (intermediate)
Blood pressure, heart rate, coma grade and symptoms at 0 h, 4 h, 8 h and 24 h (inter-
mediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomization was performed
by using rand numbers and equilibration
made by groups of 10.”
Comment: adequate randomization
Allocation concealment (selection bias) Unclear risk Quote: “Randomization was performed
by using rand numbers and equilibration
made by groups of 10.”
Comment: not enough information to
make a judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “14 patients were excluded because
they had taken a significant amount of
other drugs”
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Comment: adequate explanation
Selective reporting (reporting bias) Low risk All pre-specified outcomes have been re-
ported
Other bias Low risk No other risk of bias detected
Ilett 1977
Methods Study design: randomized controlled trial
Study duration: no information
Setting: hospital setting (emergency centre at Royal Perth Hospital)
Country: Australia
Number of individuals randomized: 120
Number of individuals receiving the intervention:
USP 15 mL: 38
APF 15 mL: 34
Number of individuals receiving the control:
APF 30 mL: 33
Number of individuals lost to follow-up: 15
Sample size calculated: no information
Participants Sex: 100 females, 20 males
Age:
Females: 27 (SD 10) years
Males: 29 (SD 8.9) years
Range: 13-64 years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: benzodiazepine tranquillizers or hypnotics (n = 37),
other tranquillizers (n = 4), other hypnotics (n = 18), antidepressants (n = 7), analgesics
(n = 30), antihistamines (n = 3), miscellaneous drugs and chemicals (n = 26)
Exclusion criteria: only partial dose was taken (n = 2), left monitored field (n = 2),
physician in charge ordered alternative treatment because of deterioration of patient’s
condition, insufficient data collected
Interventions Intervention arm 1:
Type: syrup of ipecacuanha USP
Timing: upon admission
Dose: 15 mL followed by 200 mL of water
Frequency: 1×, participants who did not vomit within 30 minutes of the first dose were
given a second identical dose and an additional 200 mL of water
Integrity: no information
Intervention arm 2:
Type: syrup of ipecacuanha APF
Timing: upon admission
Dose: 15 mL followed by 200 mL of water
Frequency: 1×, participants who did not vomit within 30 minutes of the first dose were
given a second identical dose and an additional 200 mL of water
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Integrity: no information
Control arm:
Type: syrup of ipecacuanha APF
Timing: upon admission
Dose: 30 mL followed by 200 mL of water
Frequency: 1×, participants who did not vomit within 30 minutes of the first dose were
given a second identical dose and an additional 200 mL of water
Integrity: no information
Outcomes Type (unit):
Incidence of vomiting (data not extracted)
Time to vomit (min) (data not extracted)
Number of times vomiting occurred (data not extracted)
Volume of vomitus (mL) (data not extracted)
Timing: on occurrence (no information)
Funding No information
Notes Data for syrup of ipecacuanha USP vs syrup of ipecacuanha APF not extracted, because
not within scope of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were allocated sequen-
tially to the treatments, which had been
previously randomized by means of a table
of random numbers”
Comment: adequate
Allocation concealment (selection bias) Unclear risk Quote: “Patients were allocated sequen-
tially to the treatments, which had been
previously randomized by means of a table
of random numbers”
Comment: not enough information to
make a judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The trial was conducted at a dou-
ble blind design”
Comment: not enough information to sup-
port judgment, but lack of blinding may
affect outcomes studied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “The trial was conducted at a dou-
ble blind design”
Comment: not enough information to sup-
port judgment, but lack of blinding may
affect outcomes studied
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 15/120 (12.5%) is lost to follow-up: 2 only
took partial dose, 2 left monitored field,
6 received alternative treatment because of
deterioration of condition, 5 with insuffi-
cient data. Not a high attrition rate, ade-
quately explained
Selective reporting (reporting bias) High risk No reporting of potential adverse events.
No data on symptom severity or drug ab-
sorption/dug recovery
Other bias Low risk No other risk of bias detected
James 1995
Methods Study design: randomized controlled trial
Study duration: February 1993 to January 1994
Setting: hospital setting (emergency department)
Country: USA
Number of individuals randomized: 119
Number of individuals receiving the intervention:
Sorbitol: 32
Magnesium citrate: 33
Magnesium sulphate: 23
Number of individuals receiving the control: 28
Number of individuals lost to follow-up:3
Sample size calculated: sample size calculations determined that a minimum of 25 par-
ticipants were needed in each treatment group to detect a difference in mean time to the
first stool of 4 h, using a power of 0.80 and an α of 0.10
Participants Sex: no information
Age: 25 (SD 8) months, range 1-5 years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: variety of toxins (analgesics, anticonvulsants, anti-
histamines and decongestants, asthma therapies, automotive products, cardiovascular
drugs, gastrointestinal preparations, insecticides, mushrooms, psychotropic drugs, ro-
denticides, topicals, miscellaneous drugs)
Inclusion criteria: suspected acute ingestions in which activated charcoal and a cathartic
were indicated. Parents of participants had to have telephone access for follow-up pur-
poses
Interventions Intervention arm 1:
Type: sorbitol
All treatments were administered as a slurry with 1 g/kg activated charcoal. Participants
also received syrup of ipecac or gastric lavage
Timing: as soon as possible
Dose: 50% solution, 2 g/kg. Administered as a slurry with 1 g/kg activated charcoal per
nasogastric tube
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Frequency: 1×, if emesis occurred after administration of the cathartic/charcoal slurry,
additional doses were administered at the discretion of the attending physician in the
emergency department
Integrity: no information
Intervention arm 2:
Type: magnesium citrate
All treatments were administered as a slurry with 1 g/kg activated charcoal. Participants
also received syrup of ipecac or gastric lavage
Timing: as soon as possible
Dose: 233 mg/kg. Administered as a slurry with 1 g/kg activated charcoal per nasogastric
tube
Frequency: 1×, if emesis occurred after administration of the cathartic/charcoal slurry,
additional doses were administered at the discretion of the attending physician in the
emergency department
Integrity: no information
Intervention arm 3:
Type: magnesium sulphate
All treatments were administered as a slurry with 1 g/kg activated charcoal. Participants
also received syrup of ipecac or gastric lavage
Timing: as soon as possible
Dose: 6.25%solution, 250mg/kg. Administered as a slurry with 1 g/kg activated charcoal
per nasogastric tube
Frequency: 1×, if emesis occurred after administration of the cathartic/charcoal slurry,
additional doses were administered at the discretion of the attending physician in the
emergency department
Integrity: no information
Control arm:
Type: water
Timing: as soon as possible
Dose: no information
Frequency: 1×
Integrity: no information
Outcomes Type (unit):
Mean time to stool (h) (data not extracted)
Number of stools during 24 h (data not extracted)
Occurrence of side effects
Timing:
Telephone follow-ups at 1h, 4h, 8h and24h after completionof cathartic administration
(intermediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not enough information to make a judge-
ment
Allocation concealment (selection bias) Unclear risk Not enough information to make a judge-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Physicians, nurses and parents
were blinded. Cathartics were formulated
for delivery at a uniform volume in opaque
bottles.”
Comment: adequate
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Poison control centre staff who
conducted telephone follow-ups were
blinded”
Comment: adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants were lost to follow-up, and
not included in the analysis. Low attrition
rate: 2.5%
Selective reporting (reporting bias) High risk Important outcomes, clinical outcomes,
are not measured
Other bias Low risk No other risk of bias detected
Kornberg 1991
Methods Study design: randomized controlled trial
Study duration: 2 years (November 1987 to November 1989)
Setting: hospital setting (pediatric emergency department of the Children’s Hospital of
Buffalo)
Country: USA
Number of individuals randomized: 70
Number of individuals receiving the intervention: 32
Number of individuals receiving the control: 38
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: SOI: 39 boys, 31 girls; AC: 17 boys and 15 girls
AC: 22 boys and 16 girls
Age:
SOI and AC group: 2.5 (SD 0.2) years
AC alone group: 2.3 (SD 0.2) years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: wide variety of ingested substances, most common
was acetaminophen
Inclusion criteria: orally poisoned participants less than 6 years old presenting to the ED
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Exclusion criteria: not awake or without a definite gag reflex, deteriorating level of con-
sciousness, vomited or received SOI before ED arrival, or ingested hydrocarbons, corro-
sives, iron, ethanol alone or acetaminophen alone if more than 6 h before ED arrival
Interventions Intervention arm:
Type: SOI + 160mL tap water or apple juice + activated charcoal (Actidose) with sorbitol
Timing: SOI: on admission, AC after vomiting occurred (mean time 2.1 h after SOI)
Dose: SOI: 15 mL, AC: 1 g/kg premixed with 40% sorbitol
Frequency: 1× but repeated if no emesis occurred after 30 min
Integrity: no information.
Control arm:
Type: activated charcoal (Actidose) with sorbitol
Timing: on admission
Dose: 1 g/kg with 40% sorbitol
Frequency: 1×
Integrity: AC was presented orally, but if patient was unwilling or unable to take AC
orally, it was given by nasogastric tube
Outcomes Type (unit):
Time to ED (h) (see Table 4)
Time in ED (h) (see Table 4)
Time to receive AC (h)
Hospital admission
Improved in ED
Emesis of AC
Time in ED (if discharged) (h) (see Table 4)
Timing:
On occurrence (early)
Funding Study was not funded (personal communication)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “They were randomized into two
groups based on the date of arrival.”
Comment: randomization based on even/
odd days
Allocation concealment (selection bias) High risk Quote: “They were randomized into two
groups based on the date of arrival.”
Comment: allocation based on the date of
arrival does not allow for adequate alloca-
tion concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding (personal communication),
whichmight affect the subjective outcomes
admission to ED, improvement in ED,
time to discharge from ED
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding (personal communication)
, which might affect subjective outcome
measures, such as admission to ED, im-
provement in ED, time to discharge from
ED
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported, all subjects
included in analysis
Selective reporting (reporting bias) Low risk No reason to believe there is reporting bias
Other bias Low risk No other risk of bias detected
Kulig 1985
Methods Study design: randomized controlled trial
Study duration: 18 months (June 1981 to December 1982)
Setting: hospital setting (emergency department of Denver General Hospital)
Country: USA
Number of individuals randomized: 630
Number of individuals receiving the intervention:
214 ipecac + AC
72 gastric lavage + AC (data not extracted)
Number of individuals receiving the control:
262 AC orally
44 AC via nasogastric tube (data not extracted)
Number of individuals lost to follow-up: 38
Sample size calculated: no information
Participants Sex: 268 male and 324 female (based on 592 finally included participants)
Age: 29.3 (8 months to 80 years) (based on 592 finally included participants)
Country (if different from study authors’): NA
Type, dose and timing of poisoning: any kind over oral drug overdose not mentioned in
exclusion criteria
Exclusion criteria: emesis occurred spontaneously or after administration of activated
charcoal; ipecac had been administered prior to arrival; ingested poison was a hydrocar-
bon, corrosive, iron, strychnine or if acetaminophen was ingested alone; ethanol alone
had been ingested
Interventions Intervention arm:
Type: syrup of ipecac + activated charcoal-magnesium sulphate, in addition to vigorous
supportive care if needed (including airway support, ventilation, antidotes, anticonvul-
sants, antiarrhythmic and pressors)
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Timing: on admission
Dose:
SOI: no information
AC-magnesium sulphate: 30-50 g AC mixed with 20 g magnesium sulphate (250 mg/
kg for a child) and water
Frequency: 1×
Integrity: no information
Control arm:
Type: activated charcoal + magnesium sulphate, in addition to vigorous supportive care
if needed (including airway support, ventilation, antidotes, anticonvulsants, antiarrhyth-
mic and pressors)
Timing: on admission
Dose: 30-50 g mixed into a slurry with 20 g MgSO4 (or 250 mg/kg for a child)
Frequency: 1×
Integrity: no information
Outcomes Type (unit):
Number of admissions
Clinical deterioration
Clinical improvement
Mortality
Timing: on occurrence: ED data were collected on a standard toxicology form created
for the study, which detailed the patient’s history, physical examination, laboratory data,
and clinical course (early)
Funding McNeil Consumer Products Company
Notes Data for gastric lavage vs AC administered via nasogastric tube were not extracted,
because not within scope of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients arriving on odd-num-
bered days were treated in the traditional
manner by receiving syrup of ipecac. Pa-
tients presenting on even-numbered days
did not undergo gastric emptying proce-
dures, but only received activated charcoal
and the cathartic.”
Comment: no adequate randomization
Allocation concealment (selection bias) High risk Quote: “Patients arriving on odd-num-
bered days were treated in the traditional
manner by receiving syrup of ipecac. Pa-
tients presenting on even-numbered days
did not undergo gastric emptying proce-
dures, but only received activated charcoal
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and the cathartic.”
Comment: randomization process allows
to know in which group the next partici-
pants will be allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information on blinding, but not pos-
sible due to nature of interventions. May
affect outcomes studied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38 participants were excluded because they
were not treated according to protocol. Low
attrition rate: 38/630 = 6%
Selective reporting (reporting bias) High risk No reporting of adverse data such as nausea.
Sample sizes of subgroups not reported
Other bias Low risk No other risk of bias detected
Merigian 1990
Methods Study design: randomized controlled trial
Study duration: October 1986 to March 1988
Setting: hospital setting
Country: USA
Number of individuals randomized:820
Number of individuals receiving the intervention:
asymptomatic: 220
symptomatic: 163 (data not extracted)
Number of individuals receiving the control:
asymptomatic: 231
symptomatic: 194 (data not extracted)
Number of individuals lost to follow-up: 5
Sample size calculated: no information
Participants Sex: no significant difference in male/female ratio between AC and control group
Age: no significant difference in age between AC and control group
Country (if different from study authors’): NA
Type, dose and timing of poisoning: self-reported poisoning with substances other than
described in exclusion criteria
Selection criteria: excluded if their presenting history included ingestion of any of the
following: acetaminophen > 140 mg/kg, lithium, monoamine oxidase inhibitors, heavy
metals, formaldehyde,mushrooms, digitalis,methanol, ethylene glycol, iron, or sustained
release products. Diagnostic criteria: AMSE score ≥ 7, GCS of 15 and vital signs in the
following ranges: systolic blood pressure between 110 mmHg and 160 mmHg, diastolic
blood pressure between 60 mm Hg and 100 mm Hg, pulse rate between 60 beats/min
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and 110 beats/min, temperature between 36.4° C and 37.5°C (oral)
Interventions Intervention arm:
Type: oral activated charcoal
Timing: no information
Dose: 50 g
Frequency: 1×
Integrity: no information
Control arm:
Type: observation only
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Clinical deterioration
Time in ED (min) (see Table 4)
Admission to ICU
Intubation
Duration of intubation (h)
Timing: each patient was observed for 4 h (early)
Funding No information
Notes Data for asymptomatic participants (receiving ipecac or gastric lavage)were not extracted,
because these were analyzed as one group (gastric emptying)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients presenting with asymp-
tomatic overdoses were given 50 grams of
AC orally on even days and were simply
observed without AC on odd days.”
Comment: alternation is not an adequate
randomization method
Allocation concealment (selection bias) High risk Quote: “Patients presenting with asymp-
tomatic overdoses were given 50 grams of
AC orally on even days and were simply
observed without AC on odd days.”
Comment: does not allow for allocation
concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Incomplete outcome data (attrition bias)
All outcomes
Low risk No unexplained loss to follow-up. Only
small number of participants (5/451 = 1.
1%) excluded from analysis due to receiv-
ing incorrect treatment
Selective reporting (reporting bias) Low risk No reason to believe there is reporting bias
Other bias High risk Study only observes the effects of AC in
asymptomatic participants, which aremore
likely not to experience a benefit from a
treatment
Merigian 2002
Methods Study design: randomized controlled trial
Study duration: inclusion period was 24 months, 1992-1994, no follow-up after hospital
discharge
Setting: hospital setting: emergency department of a regional medical center
Country: USA
Number of individuals randomized: 1479
Number of individuals receiving the intervention: 404
Number of individuals receiving the control: 1075
Number of individuals lost to follow-up: 1
Sample size calculated: no information
Participants Sex: 688 males and 791 females
Age: 30 (SD 10.4) years (range 22-82 years)
Country (if different from study authors’): USA (61% African-American, 38% white, <
1% other)
Type, dose and timing of poisoning:
Participants with a history of recent oral drug overdose. Not specified further. 48%
reported ingesting a single agent, 52% ingested 2 or more drugs
Exclusion criteria: more than 140 mg/kg paracetamol ingested; inhalation/ingestion of
crack; ingestion of mushrooms, volatiles, caustic agents, heavy metals, lithium, iron
preparations; participants did not receive a gastric emptying or lavage procedure
Interventions Intervention arm:
Type: oral activated charcoal + supportive therapy when necessary (including but not
limited to: maintenance of airway, pulmonary hygiene, intubation, circulatory support,
assurance of adequate urine output and renal function)
Timing: no information
Dose: 50 g
Frequency: 1×
Integrity: 1 patient was excluded from the analysis due to receiving lavage at the emer-
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gency department. 4 others received lavage but stayed in the study, 3 in the ICU and
one before being transferred to the hospital
Control arm:
Type: supportive therapy (including but not limited to: maintenance of airway, pul-
monary hygiene, intubation, circulatory support, assurance of adequate urine output
and renal function)
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Length of stay in the emergency department (ED) (h) (see Table 4)
Length of stay in the intensive care unit (ICU) (h) (see Table 4)
Clinical deteriorationof symptoms (definedby presence of one of pre-definedparameters:
table 1)
Proportion of intubation
Duration of intubation (h)
Adverse events/complications
Incidence of vomiting
Timing: on occurrence or at discharge (intermediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Our protocol required that pa-
tients given OAC be observed in the ED
for a minimum of 4 hours on even days.
On odd days, patients received supportive
observation only, with no OAC adminis-
tration, for a minimum of 4 hours.”
Comment: alternation is not an adequate
randomization method
Allocation concealment (selection bias) High risk Quote: “Our protocol required that pa-
tients given OAC be observed in the ED
for a minimum of 4 hours on even days.
On odd days, patients received supportive
observation only, with no OAC adminis-
tration, for a minimum of 4 hours.”
Comment: randomization process does not
allow for allocation concealment
89First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Merigian 2002 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither participants nor personnel were
blinded, which may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding of outcome
assessors; could influence subjective out-
comes studied
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 patient was excluded from the analysis
due to receiving lavage at the emergency
department. 4 others received lavage but
stayed in the study, 3 in the ICU and one
before being transferred to the hospital. All
received activated charcoal. Low attrition
rate: 1/404 (0.25%)
Selective reporting (reporting bias) High risk No reporting of the amount of intubations
in the ED or hospital groups, no reporting
of the time of intubation in the ICU group,
selectively grouping of the ED and hospital
groups for the outcome time of intubation
Other bias High risk Post hoc analyses according to clinical
severity
No follow-up after discharge from the hos-
pital
Montoya-Cabrera 1999
Methods Study design: randomized controlled trial
Study duration: blood sampling was done up to 48 h, mean duration between final and
initial dose of treatment was 21 h (range 6-36 h)
Setting: hospital setting: toxicology department of a children’s hospital
Country: Mexico
Number of individuals randomized: 14
Number of individuals receiving the intervention: 7
Number of individuals receiving the control: 7
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: no information, but from both sexes.
Age: mean: 2 years and 5 months (range 8 months to 8 years and 2 months)
Country (if different from study authors’): NA
Type, dose and timing of poisoning: children admitted to the toxicology department with
suspected overdose of paracetamol of 122 (SD 81) mg/kg (54-247 mg/kg), with a delay
of 60 h (10-168 h)
Inclusion criteria: overdose was defined as an administered dose that was higher than
therapeutic (10-15 mg/kg) and plasma levels of paracetamol were over 20 mg/mL for
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over 4 h
Interventions Intervention arm:
Type: N-acetylcysteine, as in the control group, followed by AC (with magnesium sul-
phate), also delivered via the nasogastric tube
Timing:
AC: every 4 h for 24 h
MgSO4: every 12 h
Dose:
1 g/kg AC, suspended in 120-200 mL saline
1 g/kg MgSO4, added to the AC
Frequency: 6× AC
Integrity: no information
Control arm:
Type: N-acetylcysteine, administered via a nasogastric tube
Timing: upon admission and every 4 h
Dose: initial dose of 140 mg/kg, followed by repeat doses of 70 mg/kg
Frequency: 18×
Integrity: no information
Outcomes Type (unit):
Elimination half-life: T1/2 (h)
Total body clearance ClB (mL × kg × min)
Prothrombin time
Aminotransferases ASAT & ALAT (U/dL) (data not extracted)
Timing: blood was sampled at 0 h, 24 h and 48 h (intermediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No informationonhow randomizationwas
achieved
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information on blinding, but should
not affect outcome assessment
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Montoya-Cabrera 1999 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No indication of incomplete outcomes.
Selective reporting (reporting bias) High risk No standard deviations for main outcomes
of interest, no information about clinical
course of the overdose, especially with re-
gard to the obvious and not further investi-
gated difference in hepatic toxicity between
groups
Other bias High risk Hepatic toxicity marker values suggest a
clinically meaningful difference between
the 2 treatment groups
Passeron 1989
Methods Study design: randomized controlled trial
Study duration: no information on recruitment period, delay before presentation to the
hospital was comparable between groups mean:
intervention: 6.2 (SD 4.6); control: 7 (SD 4.6). Clinical follow-up was done up to 48 h
after administration/no administration of AC
Setting: hospital setting: emergency department of a university hospital
Country: France
Number of individuals randomized: 32
Number of individuals receiving the intervention: 16
Number of individuals receiving the control: 16
Number of individuals lost to follow-up: 7 (44%) and 2 (13%) participants in control and
intervention group did not have a blood sample at 9 h
Sample size calculated: no information
Participants Sex: no information on proportion of males and females
Age:
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants presenting at the emergency department with an overdose (confirmed by
positive blood test) of benzodiazepines, barbiturates or imipramine. Participants in the
intervention and control groups did not differ with regard to: their initial mean Glasgow
Coma Scale score: intervention: 9 (SD 4.5); control: 10 (SD 4.5); drugs taken: interven-
tion: 12 benzodiazepines, 2 barbiturates and 3 imipramine; control: 13 benzodiazepines,
1 barbiturates and 5 imipramine
Inclusion criteria: overdose of benzodiazepines, barbiturates or imipramine. Confirmed
blood toxicology test
Interventions Intervention arm:
Type: AC-sorbitol, in addition to usual care (gastric lavage), delivered via nasogastric
tube
Timing: immediately after gastric lavage
Dose: 1 g/kg AC in a 70% sorbitol solution
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Passeron 1989 (Continued)
Frequency: 1×
Integrity: no information
Control arm:
Type: usual care, consisting of gastric lavage, forced diuresis and supportive treatment of
symptoms
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Glasgow Coma Scale
Blood pressure
Heart rhythm
Serum levels of benzodiazepines, barbiturates and imipramine (µg/mL): evolution &
proportion with increasing levels) (data not extracted)
Side effects of the intervention: gastrointestinal issues, pulmonary complications, elec-
trolyte balance (measured via ionogram, glycemia and acidosis)
Timing:
Glasgow Coma Scale: at 0 h, 3 h, 9 h, 24 h and 48 h after treatment (intermediate)
Serum drug levels, blood pressure, heart rhythm, and side effects at 0 h, 3 h and 9 h after
treatment (early)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on randomization process
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information on blinding, but blind-
ing not possible due to differences in treat-
ments. May affect outcomes studied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding, might influ-
ence assessment of outcomes, such as Glas-
gow Coma Scale
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Certain patients did not have a
blood sample taken at 9 h.”
Comment: 7 (44%) and 2 (13%) patients
in control and intervention group did not
have a blood sample at 9 h
93First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Passeron 1989 (Continued)
Selective reporting (reporting bias) High risk Not reporting the normal pharmacokinetic
outcomes, incomplete reporting of basi-
cally every outcome reported, no further re-
porting of the pre-specified outcomes heart
rhythm and pulse pressure
Other bias Low risk No other risk of bias detected
Pond 1995
Methods Study design: randomized controlled trial
Study duration: recruitment period from 4 January 1988 to 11 June 1990 (29 months)
Setting: hospital setting: emergency department of a tertiary referral hospital (Princess
Alexandra Hospital, Brisbane)
Country: Australia
Number of individuals randomized: 876
Number of individuals receiving the intervention: 459 (ipecac or lavage)
Ipecac: 220
Gastric lavage: 209
Number of individuals receiving the control: 417 (charcoal, oral or nasogastrically)
AC: 274
Nasogastric tube: 133
Number of individuals lost to follow-up: 82
Sample size calculated: post hoc power calculation
Participants Sex: 377 males and 499 females
Age: male: 30 (SD 11; range 14-82 years); female: 30 (SD 1; range 13-81 years)
Intervention: 30 (SD 12 years (range 13-76 years)
Control: 31 (SD 13 years; range 13-82 years)
Country (if different from study authors’): NA
Type, dose and timing of poisoning:
Participants presenting within 12 h of drug overdose (adsorbing to AC) whether acciden-
tal, intended or during recreational use, at the emergency department. Most presented
earlier (140 < 1 h). 59% ingested more than 1 drug
Ingestion of paracetamol, salicylate, phenothiazines or ethanol, or other drugs
Inclusion criteria: history of drug overdose, whether accidental, intended or recreational,
> 13 years old
Exclusion criteria: ingestion > 12 h before presentation, treated in a way breaching the
protocol, gastric emptying contraindicated, gastric emptying indicated for diagnostic
purposes, substance not adsorbed by AC. Confirmation of intoxication by measuring in
serum/blood
Interventions Intervention arm:
Type: gastric emptying, being via ipecac in conscious and gastric lavage in obtunted
participants. All participants received activated charcoal (Norit “C” Extra) in a slurry
with 200 mL sorbitol. AC was given after ipecac-induced vomiting had ceased or after
gastric lavage
Timing: before receiving AC-sorbitol
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Pond 1995 (Continued)
Dose: 30-50 mL ipecac followed by 200 mL water; at least 2 L tap water for gastric
lavage, via nasogastric tube
Frequency: 1×, repeated if no vomiting within 30 min
Integrity: no information
Control arm:
Type: activated charcoal-sorbitol + supportive and drug-specific treatment, orally in
conscious and via nasogastric tube in obtunted participants
Timing: after diagnosis and allocation to treatment group
Dose: 50 g AC in 200 mL 70% sorbitol slurry
Frequency: 1×
Integrity: no information
Outcomes Type (unit):
Proportion with clinical deterioration in the first 6 h after treatment
Number of days hospitalized (for medical indication related to overdose or its treatment
and complications)
Number of complications
Admission to ward/ICU
Timing: clinical course was assessed over the first 6 h at 1-2 h intervals (early)
Funding No information
Notes Data for gastric lavage was not extracted, because not within scope of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “Patients were allocated to one of
two groups: those who presented on odd-
numbered dates to the emptied (E) group;
those on even-numbered days to the not-
emptied (NE) group.”
Comment: no adequate randomization
Allocation concealment (selection bias) High risk Quote: “Patients were allocated to one of
two groups: those who presented on odd-
numbered dates to the emptied (E) group;
those on even-numbered days to the not-
emptied (NE) group.”
Comment: allocation was not concealed, as
randomisation scheme is predictable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded (not possible
due to difference in interventions); might
influence outcomes
95First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pond 1995 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding, but might
affect assessment of subjective outcomes
(clinical deterioration)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not all participants allocated were treated,
but the number remains small (9%) and
reasons are thoroughly justified
Selective reporting (reporting bias) High risk Certain outcomes (no. referred to wards/
ICU, type of complication) only reported
for gastric emptying group as a whole, not
stratified per treatment
Other bias Low risk No other risk of bias detected
Roberts 2006
Methods Study design: randomized controlled trial
Study duration: recruitment period: 31 March 2002 to October 2004
Participants were followed up until death/discharge
Setting: hospital setting: medical wards of 2 Sri Lankan secondary hospitals
Country: Australia
Number of individuals randomized: 104
Number of individuals receiving the intervention: 64
SDAC: 28
MDAC: 36
Number of individuals receiving the control: 40
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex:
Usual care group: 20 male and 20 female
SDAC: 8 male and 20 female
MDAC: 22 male and 14 female
Age: median (IQR)
Usual care group:
21.5 (17.5 to 28.5)
SDAC: 22 (18.0 to 33.0)
MDAC: 22.5 (17.5 to 28.0)
Country (if different from study authors’): Sri Lanka
Type, dose and timing of poisoning: participants with acute yellow oleander poisoning,
admitted to the medical ward of 3 secondary referral hospitals in Sri Lanka
Exclusion criteria: < 14 years, pregnant, ingestion of hydrocarbons alone or corrosives,
requirement for oral medication, inability to intubate participants with Glasgow coma
score < 13, presentation > 72 h postingestion, previous recruitment in the study, previous
AC administration for the poisoning episode, < 16 years or unconscious without relatives
present to give consent
96First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Roberts 2006 (Continued)
Interventions Intervention arm:
Type: SDAC or MDAC in water suspension, in addition to usual care
Timing: “soon” after admission, for MDAC repeated at 4 h intervals
Dose: 50 g superactivated charcoal (Carbomix) in 300mLwater (per dose), administered
orally or via nasogastric tube if unconscious
Frequency:
SDAC: 1×
MDAC: 6×
Integrity: first protocol intended to deliver 18 doses of AC in the multi-dose group, this
however was not feasible, so protocol was adapted to 6 doses
Compliance was not anticipated a problem as was given while patient was under super-
vision, however participants was not forced. Analyses were performed intention-to-treat
Control arm:
Type: usual care, consisting of atropine and intravenous fluids, where needed tomaintain
heart rate > 70 bpm and systolic blood pressure > 80 mmHg. Gastric lavage was initially
not planned but upon request of treating physicians was included in standard treatment
if participants presented within 2 h of a potentially serious poisoning (3 × 300 mL of
water). Furthermore, forced emesis (ipecac) and lavage were mostly performed (54% and
7.5%, respectively) at primary hospitals before transfer to the secondary study hospitals
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit):
Primary outcome:
All-cause hospital mortality
Secondary outcome:
Proportion cardiac dysrhythmias requiring anti-digoxin Fab or transfer to tertiary care
(3° heart block, Mobitz type II 2° block, sinus bradycardia with heart rate < 35 bpm and
sinus arrest or block with sinus pauses > 3 s)
Cmax (µg/L)
Tmax (µg/L)
AUC0−24 (µg/L × h)
Gradient of the linear regression time of the concentration/AUC0−24 curve (representing
elimination) (data not extracted)
Mean residence time0−24 (h) (data not extracted)
Timing: blood samples were taken at 0 h, 1 h, 4 h, 12 h, 24 h after administration of the
first charcoal dose and from then on every 24 h until discharge or death (intermediate)
Funding National Health and Medical Research Council (Australia), The Welcome trust: grants
GR063560MA and GR071669MA
Notes This study is part of the Eddleston study, part of the info here comes from the protocol
of Eddleston 2008.
Risk of bias
Bias Authors’ judgement Support for judgement
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Roberts 2006 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “Participants were recruited and
randomised by a study doctor at the bed-
side using a dedicated handheld computer
at each study hospital. Randomisation oc-
curred after the patient’s baseline data had
been entered and receipt of consent noted,
and could not be manipulated by study
doctors. The recruiting doctor was unable
to predict allocation before randomisation.
”
Comment: adequate randomization
Allocation concealment (selection bias) Low risk Quote: “The recruiting doctor was unable
to predict allocation before randomisation.
”
Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “the primary outcome, vital status
at discharge, was unambiguous, and the
secondary outcomeswere objective; all out-
comes were recorded systematically by the
study team, not other hospital physicians”
Comment: lack of blinding may affect out-
comes studied
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “the primary outcome, vital status
at discharge, was unambiguous, and the
secondary outcomeswere objective; all out-
comes were recorded systematically by the
study team, not other hospital physicians”
Comment: outcome assessors were kept
blinded from data analysis. They were not
kept blinded from treatment, but objective
outcomes are used
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: data from all eligible partic-
ipants are reported. Non-eligibility from
other participants is thoroughly justified
Quote: “patient follow-up was expected to
be near 100% complete; and the analysis
will be performed on an intention-to-treat
basis.”
Selective reporting (reporting bias) Low risk All pre-defined outcomes are reported
Other bias High risk It is not entirely clear, even to the authors,
what exactly is measured with the digoxin
assay. The fact that both active cardenolides
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Roberts 2006 (Continued)
and (inactive?) metabolites might bind the
assay compromise the results of these anal-
yses, as they might explain the wide vari-
ability observed
Only participants with ’mild’ intoxication
were included in this analysis, as the severe
cases were treated with Fab or transferred
to a tertiary hospital, but these might have
shown the biggest effect
Sue 1994
Methods Study design: randomized controlled trial
Study duration: recruitment period from October 1990 to April 1992
Setting: hospital setting: emergency department of a children’s hospital
Country: USA
Number of individuals randomized: 64
Number of individuals receiving the intervention:
4 mL/kg group: 16
6 mL/kg group: 16
8 mL/kg group: 18
Number of individuals receiving the control: 14
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: no information
Age: median age: 25 months (range 3-53 months)
Country (if different from study authors’): NA
Type, dose and timing of poisoning: children presenting to the emergency department,
following a toxic ingestion requiring SDAC
Exclusion criteria: dehydrated or renal dysfunction and those whose ingestions required
MDAC
Interventions Intervention arm:
Type: activated charcoal + MgCitrate (6%)
Timing: after appropriate initial care (supportive care, gastric emptying if indicated and
diagnostic laboratory evaluation)
Dose:
50 g AC in 240 mL, combined with:
4 mL/kg of MgCitrate (6%) and 2 mL/kg water
6 mL/kg of MgCitrate (6%)
8 mL/kg of MgCitrate (6%)
Frequency: 1×
Integrity: no attempts were made to control the oral intake of the children following
administration of the charcoal slurry
Control arm:
Type: activated charcoal
Timing: after appropriate initial care (supportive care, gastric emptying if indicated and
diagnostic laboratory evaluation)
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Sue 1994 (Continued)
Dose: 1 g/kg: 50 g AC in 240 mL, combined with 6 mL/kg water
Frequency: 1×
Integrity: no attempts were made to control the oral intake of the children following
administration of the charcoal slurry
Outcomes Type (unit):
Time to first stool (h) (data not extracted)
Number requiring hospitalization
Number of black-colored stools (data not extracted)
Potential adverse events (vomiting, diarrhoea, abdominal pain, lethargy)
Timing: outcomes were measured during the subsequent 48 h after treatment, either by
review of the hospital chart or telephone follow-up (intermediate)
Funding No information
Notes Only clinically relevant outcome is requirement of hospitalization
Not clear when outcome hospitalization was measured: after 48 h or initially
Study reports “no difference” in diarrhoea, abdominal pain, but no numbers reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on randomization process
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information to support judgment, but
lack of blinding may affect outcomes stud-
ied
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information on blinding, but could af-
fect outcomes studies (e.g. hospitalization)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “No enrolled patient withdrew
from the study, and follow-up information
was obtained for all children.”
Comment: adequate
Selective reporting (reporting bias) High risk Clinical outcome data are lacking. Adverse
events incompletely reported
Other bias Low risk No other risk of bias detected
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Underhill 1990
Methods Study design: randomized controlled trial
Study duration: recruitment period between April and October 1988
Setting: hospital setting: accident and emergency departments of two teaching hospitals
Country: UK
Number of individuals randomized: 60
Number of individuals receiving the intervention:
Gastric lavage: 14
Acitvated charcoal: 20
Ipecac: 21
Number of individuals receiving the control: 5
Number of individuals lost to follow-up: 0
Sample size calculated:
Participants Sex: 16 male and 44 female
Age: mean (range): 25.7 (16-62) years
Country (if different from study authors’): NA
Type, dose and timing of poisoning: participants presenting within 4 h after an overdose
(meandelay: 123min, range 30-240min) of at least 5 g paracetamol. 48 took paracetamol
without another drug; 21 took paracetamol with alcohol
Inclusion criteria: > 16 years, presenting < 4 h after intake, ingested > 5 g paracetamol
Exclusion criteria: depressed conscious level, conditions that might preclude use of any
one of the treatment methods
Interventions Intervention arm 1:
Type: gastric lavage
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Intervention arm 2:
Type: activated charcoal (Carbomix)
Timing: no information
Dose: AC:Drug ratio of 10:1
Frequency: 1×
Integrity: 16participantsmanaged to take the recommendeddose. 4 participants vomited
and 1 refused to take more than one mouthful
Intervention arm 3:
Type: ipecac
Timing: no information
Dose: 30 mL
Frequency: 1×, repeated if no vomiting after 30 min
Integrity: mean time to emesis was 20 min (range 5-50), 2 participants did not vomit
until 50 min and 2 did not vomit at all
Control arm:
Type: no intervention
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
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Underhill 1990 (Continued)
Outcomes Type (unit):
Plasma paracetamol levels
Adverse events
Timing: prior to treatment and 60 min, 90 min and 150 min after the first sample (early)
Funding No information
Notes No treatment group was stopped for ethical reasons when the serum paracetamol levels
increased between the first and last samples in 4 out of 5 participants
Data for gastric lavage was not extracted, because not within scope of this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on randomization process
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants were not blinded (not possible
due to difference in interventions); might
influence outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information on blinding, but should
not affect outcome measurements
Incomplete outcome data (attrition bias)
All outcomes
Low risk No indication of incomplete outcomes
Selective reporting (reporting bias) High risk No clinical outcomes reported, adverse
events incompletely reported
Other bias Low risk No other risk of bias detected
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Wax 1999
Methods Study design: randomized controlled trial
Study duration: 27-month recruitment period
Setting: home setting, with telephone support from a poison centre
Country: USA
Number of individuals randomized: 103
Number of individuals receiving the intervention: 51
Number of individuals receiving the control: 52
Number of individuals lost to follow-up: 0
Sample size calculated: no information
Participants Sex: 57 male and 46 female
Age: median (range): 2 years (9 months-5 years)
Country (if different from study authors’): NA
Type, dose and timing of poisoning: asymptomatic participants with suspected ingestion of
a small number (< 6) of potentially toxic berries, including Taxus species (yew), Solanum
americanus (nightshade), Ilex species (holly) or unknown berries
Exclusion criteria: ingestion of a known other type of berry, > 5 berries ingested, symp-
tomatic when calling poison centre, parents planning transport to healthcare facility re-
gardless of the advice of the poison centre, ingestion of more than 1 type of berry/plant
parts, contraindication for syrup of ipecac
Interventions Intervention arm:
Type: syrup of ipecac (+ home observation)
Timing: no information
Dose: no information
Frequency: no information
Integrity: no information
Control arm:
Type: home observation
Timing: NA
Dose: NA
Frequency: NA
Integrity: NA
Outcomes Type (unit): symptom assessment (vomiting, diarrhoea, abdominal pain, drowsiness,
agitation) and disposition assessment (ED referral, hospital admission)
Timing: 24 h after telephone call to poison centre (intermediate)
Funding No information
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “The group who called the poi-
son centre on even days of the month
received ipecac followed by parenteral/
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Wax 1999 (Continued)
guardian HO. The group that called the
poison centre on odd days of the month
were assigned to the HO only group”
Comment: not an adequate method of ran-
domization
Allocation concealment (selection bias) High risk Randomization method does not allow for
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind, but might affect sub-
jective symptom outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessorswere not blinded,which
might influence assessment of subjective
symptom outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk No indication of missing data
Selective reporting (reporting bias) Low risk Specified outcomes are reported
Other bias High risk Only asymptomatic participants included,
no confirmation of actual ingestion and
uptake, reporting dichotomous outcomes
while measuring using an ordinal scale
AC: activated charcoal; APACHE: acute physiology and chronic health evaluation; AUC: area under the receiver operating curve;
bpm: beats per minute; CBZ: carbamazepine; ECG: electrocardiogram;ED: emergency department; ICU: intensive care unit;
IQR: interquartile range; MDAC: multi-dose activated charcoal; NA: not applicable; SAPS: simplified acute physiology score; SD:
standard deviation; SDAC: single-dose activated charcoal; SEM: standard error of the mean; SOI: syrup of ipecac; TCA: tricyclic
antidepressant; UC: University of California.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Afshari 2010a Ineligible intervention: IV administration of intervention
Afshari 2010b Ineligible intervention: IV administration of intervention
Auerbach 1986 Ineligible intervention: comparison between gastric lavage and ipecac
Belon 2007 Ineligible intervention: homeopathic remedy
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Berg 1982 Ineligible study population: not oral poisoning
Berlinger 1983 Ineligible population: not oral poisoning
Bhalla 2014 Ineligible intervention: IV administration of intervention
Bosse 1995 Ineligible intervention: not possible to determine the additional effect of activated charcoal on top
of hospital treatment
Boxer 1969 Ineligible comparison: hospital treatment vs ipecac
Boyd 1999 Ineligible comparison: 2 types of charcoal compared, no control group without charcoal
Campbell 1992 Ineligible intervention: repeat dose of activated charcoal, no control groupwithout activated charcoal
Chamberlain 1993 Ineligible intervention: different groups received different doses of N-acetylcysteine. Impossible to
distinguish the effect of AC from this
Corby 1968 Ineligible intervention: control is apomorphine
Crome 1976 Ineligible intervention: methionine
Eddleston 2009 Ineligible intervention: pralidoxime
Ekins 1987 Ineligible study population: not poisoned patients
Escalante 2016 Recent trial that was not prospectively registered in a trials register
Espinosa 1987 Ineligible intervention: feasibility of administration
Filippone 1987 Ineligible intervention: pre-absorbed durg-charcoal mixture
Fischer 1999 Ineligible comparison: 2 types of charcoal compared, no control group without charcoal
Frenia 1996 Ineligible study population: not oral poisoning
Gomez 1997 Ineligible intervention: pre-absorbed durg-charcoal mixture
Grierson 2000 Ineligible intervention: gastric lavage
Hoegberg 2005 Ineligible intervention: yoghourt
Hoegberg 2012 Ineligible intervention: alcohol
Ilkhanipour 1992 Ineligible study population: not oral poisoning
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Ilkhanipour 1993 Ineligible study population: not oral poisoning
IRCT138811142717N1 2010 Ineligible intervention: IV administration of intervention
Isbister 2011 Ineligible study population: not oral poisoning
ISRCTN50739829 2006 Ineligible intervention: IV administration of treatment
Karim 2001 Ineligible intervention: feasibility of administration
Krenzelok 1985a Ineligible study population: not poisoning patients
Ly 2004 Ineligible intervention: whole bowel irrigation
MacLean 1973 Ineligible intervention: apomorphine
Mahutte 1983 Ineligible study population: not oral poisoning
Merigian 1988 Ineligible intervention: gastric emptying not specified
Nogue 1987 Ineligible intervention: two formulations of ipecac compared
Olsen 1993 Ineligible intervention: whole bowel irrigation
Olsen 1995 Ineligible intervention: whole bowel irrigation
Pond 1984 Ineligible comparison: no suitable comparison
Roberts 1997 Ineligible intervention: comparison of 2 brands of activated charcoal
Schofferman 1976 Ineligible intervention: apomorphine
Skinner 2012 Ineligible population: chronic poisoning patients
Smith 1967 Ineligible intervention: montmorillonite
Varipapa 1977 Ineligible study population: not oral poisoning
Vijayakumar 2017 Ineligible intervention: IV administration of intervention
Young 1993 Inelgible comparison: hospital treatment vs ipecac
IV: intravenous.
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D A T A A N D A N A L Y S E S
Comparison 1. SDAC vs no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of adverse events 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
1.1 Incidence of adverse
events
1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Incidence of vomiting 1 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. SDAC + hospital intervention vs hospital intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of mortality 2 3425 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.04 [0.79, 1.37]
2 Incidence of adverse events 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Incidence of vomiting 2 1806 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.88, 2.37]
2.2 Incidence of absent bowel
sounds
1 3098 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.17, 1.00]
3 Incidence of need for intubation 4 3562 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.76, 2.47]
3.1 Gastric lavage prior to
SDAC
2 3175 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.27]
3.2 No gastric lavage prior to
SDAC
2 387 Risk Ratio (M-H, Random, 95% CI) 2.61 [1.38, 4.93]
4 Incidence of convulsions 2 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Duration of intubation (h) Other data No numeric data
6 AUC ((µg/L) × h) Other data No numeric data
7 Cmax (µg/L) Other data No numeric data
8 Tmax (h) Other data No numeric data
9 Incidence of hospitalization 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
10 Incidence of ICU admission 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. SDAC vs syrup of ipecac
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of adverse events 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
2 Glasgow Coma Scale score 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Mean arterial blood pressure
(mmHg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Heart rate (bpm) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
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5 Respiratory rate (breaths/min) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 4. MDAC + hospital intervention vs SDAC + hospital intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of mortality 2 3476 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.21, 1.63]
2 Incidence of adverse events 2 3476 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.55 [1.85, 6.79]
3 Incidence of need for cardiac
pacing/antitoxin treatment
2 1490 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.02, 4.18]
4 Incidence of life-threatening
arrhythmias
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Amount of atropine administered
(mg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Number of atropine boluses
administered
Other data No numeric data
7 Incidence of need for intubation 2 3097 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.75, 1.38]
8 Incidence of convulsions 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Duration of coma (h) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
10 Duration of intubation (h) Other data No numeric data
11 Cmax (µg/L) Other data No numeric data
12 Tmax (h) Other data No numeric data
13 T1/2 (h) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
14 AUC ((µg/L) × h) Other data No numeric data
15 Incidence of ICU admission 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 5. MDAC + hospital intervention vs hospital intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Incidence of adverse events 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Incidence of need for intubation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Incidence of seizures 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Incidence of need for cardiac
pacing/antitoxin treatment
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Length of intubation (h) Other data No numeric data
7 AUC Other data No numeric data
8 Cmax Other data No numeric data
9 Tmax Other data No numeric data
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Comparison 6. Syrup of ipecac vs no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of diarrhoea 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Incidence of abdominal pain 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Incidence of sedation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Incidence of agitation 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 7. Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of mortality 2 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
2 Incidence of adverse events 3 764 Risk Ratio (M-H, Random, 95% CI) 2.59 [1.37, 4.91]
3 Incidence of clinical
improvement
3 989 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.83, 1.21]
4 Incidence of clinical
deterioration
2 970 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.46, 1.69]
5 Incidence of hospitalization 3 746 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.69, 1.98]
6 Incidence of ICU admission 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 8. SDAC + cathartic vs SDAC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Lethargy during follow-up 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Incidence of hospitalization 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Comparison 9. SDAC + cathartic vs SDAC + cathartic (higher dose)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of hospitalization (8
mL vs 6 mL)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 10. SDAC + cathartic vs SDAC + cathartic (different type)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of vomiting (sorbitol
vs magnesium sulphate
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Incidence of vomiting (sorbitol
vs magnesium citrate)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Incidence of vomiting
(magnesium sulphate vs
magnesium citrate)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 11. SDAC + cathartic + hospital intervention vs hospital intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of adverse events 1 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 SDAC vs no intervention, Outcome 1 Incidence of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 1 SDAC vs no intervention
Outcome: 1 Incidence of adverse events
Study or subgroup SDAC No SDAC
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Incidence of adverse events
Merigian 1990 0/220 0/231 Not estimable
2 Incidence of vomiting
Underhill 1990 4/20 0/5 4.17 [ 0.30, 57.26 ]
0.01 0.1 1 10 100
Favours SDAC Favours no SDAC
Analysis 2.1. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 1 Incidence of
mortality.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 1 Incidence of mortality
Study or subgroup SDAC No SDAC
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Cooper 2005 0/166 1/161 0.5 % 0.13 [ 0.00, 6.61 ]
Eddleston 2008 109/1544 105/1554 99.5 % 1.05 [ 0.79, 1.38 ]
Total (95% CI) 1710 1715 100.0 % 1.04 [ 0.79, 1.37 ]
Total events: 109 (SDAC), 106 (No SDAC)
Heterogeneity: Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours SDAC Favours no SDAC
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Analysis 2.2. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 2 Incidence of
adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 2 Incidence of adverse events
Study or subgroup SDAC No SDAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Incidence of vomiting
Cooper 2005 25/166 23/161 39.4 % 1.05 [ 0.62, 1.78 ]
Merigian 2002 93/404 140/1075 60.6 % 1.77 [ 1.40, 2.24 ]
Subtotal (95% CI) 570 1236 100.0 % 1.44 [ 0.88, 2.37 ]
Total events: 118 (SDAC), 163 (No SDAC)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Incidence of absent bowel sounds
Eddleston 2008 7/1544 17/1554 100.0 % 0.41 [ 0.17, 1.00 ]
Subtotal (95% CI) 1544 1554 100.0 % 0.41 [ 0.17, 1.00 ]
Total events: 7 (SDAC), 17 (No SDAC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 5.88, df = 1 (P = 0.02), I2 =83%
0.1 0.2 0.5 1 2 5 10
Favours SDAC Favours no SDAC
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Analysis 2.3. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 3 Incidence of
need for intubation.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 3 Incidence of need for intubation
Study or subgroup Favours SDAC No SDAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Gastric lavage prior to SDAC
Eddleston 2008 73/1544 76/1554 37.7 % 0.97 [ 0.71, 1.32 ]
Hult n 1988 7/34 11/43 22.9 % 0.80 [ 0.35, 1.85 ]
Subtotal (95% CI) 1578 1597 60.6 % 0.95 [ 0.70, 1.27 ]
Total events: 80 (Favours SDAC), 87 (No SDAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
2 No gastric lavage prior to SDAC
Cooper 2005 8/166 3/161 13.7 % 2.59 [ 0.70, 9.58 ]
Merigian 2002 16/28 7/32 25.7 % 2.61 [ 1.26, 5.42 ]
Subtotal (95% CI) 194 193 39.4 % 2.61 [ 1.38, 4.93 ]
Total events: 24 (Favours SDAC), 10 (No SDAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 1772 1790 100.0 % 1.37 [ 0.76, 2.47 ]
Total events: 104 (Favours SDAC), 97 (No SDAC)
Heterogeneity: Tau2 = 0.22; Chi2 = 8.21, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 8.04, df = 1 (P = 0.00), I2 =88%
0.1 0.2 0.5 1 2 5 10
Favours SDAC Favours no SDAC
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Analysis 2.4. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 4 Incidence of
convulsions.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 4 Incidence of convulsions
Study or subgroup SDAC No SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 13/1544 7/1554 1.87 [ 0.75, 4.67 ]
Hult n 1988 2/34 9/43 0.28 [ 0.06, 1.22 ]
0.01 0.1 1 10 100
Favours SDAC Favours no SDAC
Analysis 2.5. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 5 Duration of
intubation (h).
Duration of intubation (h)
Study SDAC No SDAC Summary estimate (P
value)
# participants
Eddleston 2008 median (IQR): 112.0 (36.
6-234.9)
median (IQR): 88.5 (38.5-
203.1)
median difference: 23.5 (P
> 0.05)
No information
Merigian 2002 mean: 54.6 mean: 39.9 mean difference: 14.7 (P =
0.70)
No information
Analysis 2.6. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 6 AUC ((µg/L)
× h).
AUC ((µg/L) × h)
Study SDAC (median (IQR)) no SDAC (median (IQR)) Summary estimate (P
value)
# participants
Roberts 2006 17.7 (11.1;21.8) 19.0 (13.7;24.3) -1.3 (P > 0.05) 28 vs 40
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Analysis 2.7. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 7 Cmax (µg/L).
Cmax (µg/L)
Study SDAC (median (IQR)) no SDAC (median (IQR)) Summary estimate (P
value)
# participants
Roberts 2006 0.98 (0.72;1.50) 1.05 (0.75;1.40) -0.07 (P > 0.05) 28 vs 40
Analysis 2.8. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 8 Tmax (h).
Tmax (h)
Study SDAC (median (IQR)) no SDAC (median (IQR)) summary estimate (P
value)
# participants
Roberts 2006 7.2 (5.7;13.8) 12.1 (5.4;17.4) -4.9 (P > 0.05) 28 vs 40
Analysis 2.9. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 9 Incidence of
hospitalization.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 9 Incidence of hospitalization
Study or subgroup SDAC No SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Merigian 2002 79/404 134/1075 1.57 [ 1.22, 2.02 ]
0.2 0.5 1 2 5
Favours SDAC Favours no SDAC
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Analysis 2.10. Comparison 2 SDAC + hospital intervention vs hospital intervention, Outcome 10 Incidence
of ICU admission.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 2 SDAC + hospital intervention vs hospital intervention
Outcome: 10 Incidence of ICU admission
Study or subgroup SDAC No SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Merigian 2002 28/404 32/1075 2.33 [ 1.42, 3.82 ]
0.2 0.5 1 2 5
Favours SDAC Favours no SDAC
Analysis 3.1. Comparison 3 SDAC vs syrup of ipecac, Outcome 1 Incidence of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 3 SDAC vs syrup of ipecac
Outcome: 1 Incidence of adverse events
Study or subgroup Syrup of ipecac SDAC
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Amig Tad n 2002 4/21 2/13 0.04 [ -0.22, 0.29 ]
-1 -0.5 0 0.5 1
Favours SDAC Favours Syrup of ipecac
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Analysis 3.2. Comparison 3 SDAC vs syrup of ipecac, Outcome 2 Glasgow Coma Scale score.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 3 SDAC vs syrup of ipecac
Outcome: 2 Glasgow Coma Scale score
Study or subgroup Syrup of ipecac SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amig Tad n 2002 21 14.76 (0.56) 13 14.91 (0.25) -0.15 [ -0.43, 0.13 ]
-2 -1 0 1 2
Favours SDAC Favours Syrup of ipecac
Analysis 3.3. Comparison 3 SDAC vs syrup of ipecac, Outcome 3 Mean arterial blood pressure (mmHg).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 3 SDAC vs syrup of ipecac
Outcome: 3 Mean arterial blood pressure (mmHg)
Study or subgroup Syrup of ipecac SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amig Tad n 2002 21 87 (14) 13 80 (16) 7.00 [ -3.56, 17.56 ]
-100 -50 0 50 100
Favours SDAC Favours Syrup of ipecac
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Analysis 3.4. Comparison 3 SDAC vs syrup of ipecac, Outcome 4 Heart rate (bpm).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 3 SDAC vs syrup of ipecac
Outcome: 4 Heart rate (bpm)
Study or subgroup Syrup of ipecac SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amig Tad n 2002 21 87.11 (15.93) 13 89.5 (20.77) -2.39 [ -15.58, 10.80 ]
-100 -50 0 50 100
Favours Syrup of ipecac Favours SDAC
Analysis 3.5. Comparison 3 SDAC vs syrup of ipecac, Outcome 5 Respiratory rate (breaths/min).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 3 SDAC vs syrup of ipecac
Outcome: 5 Respiratory rate (breaths/min)
Study or subgroup Syrup of ipecac SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amig Tad n 2002 21 19.79 (4.26) 13 18.67 (3.94) 1.12 [ -1.69, 3.93 ]
-20 -10 0 10 20
Favours Syrup of ipecac Favours SDAC
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Analysis 4.1. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 1
Incidence of mortality.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 1 Incidence of mortality
Study or subgroup MDAC SDAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Silva 2003 5/201 16/200 39.6 % 0.31 [ 0.12, 0.83 ]
Eddleston 2008 97/1531 109/1544 60.4 % 0.90 [ 0.69, 1.17 ]
Total (95% CI) 1732 1744 100.0 % 0.59 [ 0.21, 1.63 ]
Total events: 102 (MDAC), 125 (SDAC)
Heterogeneity: Tau2 = 0.43; Chi2 = 4.17, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours SDAC
Analysis 4.2. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 2
Incidence of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 2 Incidence of adverse events
Study or subgroup MDAC SDAC
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
De Silva 2003 13/201 0/200 34.6 % 7.82 [ 2.59, 23.58 ]
Eddleston 2008 17/1531 7/1544 65.4 % 2.34 [ 1.05, 5.21 ]
Total (95% CI) 1732 1744 100.0 % 3.55 [ 1.85, 6.79 ]
Total events: 30 (MDAC), 7 (SDAC)
Heterogeneity: Chi2 = 3.01, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 3.82 (P = 0.00013)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours MDAC Favours SDAC
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Analysis 4.3. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 3
Incidence of need for cardiac pacing/antitoxin treatment.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 3 Incidence of need for cardiac pacing/antitoxin treatment
Study or subgroup MDAC SDAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Silva 2003 1/201 18/200 43.7 % 0.06 [ 0.01, 0.41 ]
Eddleston 2008 85/540 101/549 56.3 % 0.86 [ 0.66, 1.11 ]
Total (95% CI) 741 749 100.0 % 0.26 [ 0.02, 4.18 ]
Total events: 86 (MDAC), 119 (SDAC)
Heterogeneity: Tau2 = 3.57; Chi2 = 7.71, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours MDAC Favours SDAC
Analysis 4.4. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 4
Incidence of life-threatening arrhythmias.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 4 Incidence of life-threatening arrhythmias
Study or subgroup MDAC SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Silva 2003 3/195 14/190 0.21 [ 0.06, 0.71 ]
0.01 0.1 1 10 100
Favours MDAC Favours SDAC
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Analysis 4.5. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 5
Amount of atropine administered (mg).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 5 Amount of atropine administered (mg)
Study or subgroup MDAC SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
De Silva 2003 201 3.6 (2.7) 200 5.2 (3.8) -1.60 [ -2.25, -0.95 ]
-4 -2 0 2 4
Favours MDAC Favours SDAC
Analysis 4.6. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 6
Number of atropine boluses administered.
Number of atropine boluses administered
Study MDAC (median
(range))
SDAC (median
(range))
Median difference
[95% CI]
P value # participants
De Silva 2003 1 (1-6) 2 (1-12) 0.0 (0.0-1.0) P < 0.0001 201 vs 200
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Analysis 4.7. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 7
Incidence of need for intubation.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 7 Incidence of need for intubation
Study or subgroup MDAC SDAC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brahmi 2006 3/6 3/6 7.3 % 1.00 [ 0.32, 3.10 ]
Eddleston 2008 73/1531 73/1554 92.7 % 1.02 [ 0.74, 1.39 ]
Total (95% CI) 1537 1560 100.0 % 1.01 [ 0.75, 1.38 ]
Total events: 76 (MDAC), 76 (SDAC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours SDAC
Analysis 4.8. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 8
Incidence of convulsions.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 8 Incidence of convulsions
Study or subgroup MDAC SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 14/1531 13/1554 1.09 [ 0.52, 2.32 ]
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours SDAC
122First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.9. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 9
Duration of coma (h).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 9 Duration of coma (h)
Study or subgroup MDAC SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brahmi 2006 3 20.33 (3.05) 3 29.33 (4.11) -9.00 [ -14.79, -3.21 ]
-50 -25 0 25 50
Favours MDAC Favours SDAC
Analysis 4.10. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 10
Duration of intubation (h).
Duration of intubation (h)
Study MDAC SDAC Summary estimate P value # participants
Brahmi 2006 mean±SD: 24.1±4.2 mean±SD: 36.4±3.6 MD: -12.30, 95%CI
[-18.56;-6.04]
P = 0.0001 3 vs 3
Eddleston 2008 median [IQR]: 83.8
(35.0-173.0)
median [IQR]: 112.
0 (36.6-234.9)
median difference: -
28.2
No information No information
Analysis 4.11. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 11
Cmax (µg/L).
Cmax (µg/L)
Study MDAC SDAC Summary estimate P value # participants
Brahmi 2006 mean±SD: 33±3.46 mean±SD: 32.6±5.
63
MD: 0.40, 95%CI [-
4.89;5.69]
P = 0.88 6 vs 6
Roberts 2006 median (IQR): 1.13
(0.86;1.47)
median (IQR): 0.98
(0.72;1.50)
median difference: 0.
15
P > 0.05 36 vs 28
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Analysis 4.12. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 12
Tmax (h).
Tmax (h)
Study MDAC SDAC Summary estimate P value # participants
Roberts 2006 median (IQR): 8.3
(4.8;15.0)
median (IQR): 7.2
(5.7;13.8)
median difference: 1.
1
P > 0.05 36 vs 28
Analysis 4.13. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 13
T1/2 (h).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 13 T1/2 (h)
Study or subgroup MDAC SDAC
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brahmi 2006 6 12.56 (3.5) 6 27.88 (7.36) -15.32 [ -21.84, -8.80 ]
-50 -25 0 25 50
Favours MDAC Favours SDAC
Analysis 4.14. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 14
AUC ((µg/L) × h).
AUC ((µg/L) × h)
Study MDAC SDAC Summary estimate P value # participants
Roberts 2006 median (IQR): 17.3
(12.8;21.7)
median (IQR): 17.7
(11.1;21.8)
median difference: -
0.4
P > 0.05 36 vs 28
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Analysis 4.15. Comparison 4 MDAC + hospital intervention vs SDAC + hospital intervention, Outcome 15
Incidence of ICU admission.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 4 MDAC + hospital intervention vs SDAC + hospital intervention
Outcome: 15 Incidence of ICU admission
Study or subgroup MDAC SDAC Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
De Silva 2003 5/201 16/200 0.31 [ 0.12, 0.83 ]
0.01 0.1 1 10 100
Favours MDAC Favours SDAC
Analysis 5.1. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 1 Incidence of
mortality.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 5 MDAC + hospital intervention vs hospital intervention
Outcome: 1 Incidence of mortality
Study or subgroup MDAC No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 97/1531 105/1554 0.94 [ 0.72, 1.22 ]
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours no intervention
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Analysis 5.2. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 2 Incidence of
adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 5 MDAC + hospital intervention vs hospital intervention
Outcome: 2 Incidence of adverse events
Study or subgroup MDAC No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 17/1531 17/1554 1.02 [ 0.52, 1.98 ]
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours no intervention
Analysis 5.3. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 3 Incidence of
need for intubation.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 5 MDAC + hospital intervention vs hospital intervention
Outcome: 3 Incidence of need for intubation
Study or subgroup MDAC No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 73/1531 76/1554 0.97 [ 0.71, 1.33 ]
0.1 0.2 0.5 1 2 5 10
Favours MDAC Favours no intervention
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Analysis 5.4. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 4 Incidence of
seizures.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 5 MDAC + hospital intervention vs hospital intervention
Outcome: 4 Incidence of seizures
Study or subgroup MDAC No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 14/1531 7/1554 2.03 [ 0.82, 5.02 ]
0.01 0.1 1 10 100
Favours MDAC Favours no intervention
Analysis 5.5. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 5 Incidence of
need for cardiac pacing/antitoxin treatment.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 5 MDAC + hospital intervention vs hospital intervention
Outcome: 5 Incidence of need for cardiac pacing/antitoxin treatment
Study or subgroup MDAC No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eddleston 2008 85/540 101/555 0.86 [ 0.66, 1.13 ]
0.2 0.5 1 2 5
Favours MDAC Favours no intervention
Analysis 5.6. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 6 Length of
intubation (h).
Length of intubation (h)
Study MDAC (median
IQR)
no intervention
(median IQR)
Summary estimate P value # participants
127First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Length of intubation (h) (Continued)
Eddleston 2008 83.8 (35.0-173.0) 88.5 (38.5-203.1) median difference: -
4.7
P > 0.05 No information
Analysis 5.7. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 7 AUC.
AUC
Study MDAC (median
IQR)
no intervention
(median IQR)
Summary estimate P value # participants
Roberts 2006 17.3 (12.8;21.7) 19.0 (13.7;24.3) median difference: -
1.7
P > 0.05 36 vs 40
Analysis 5.8. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 8 Cmax .
Cmax
Study MDAC (median
IQR)
no intervention
(median IQR)
Summary estimate P value # participants
Roberts 2006 1.13 (0.86;1.47) 1.05 (0.75;1.40) median difference: 0.
08
P > 0.05 36 vs 40
Analysis 5.9. Comparison 5 MDAC + hospital intervention vs hospital intervention, Outcome 9 Tmax .
Tmax
Study MDAC (median
IQR)
no intervention
(median IQR)
Summary estimate P value # participants
Roberts 2006 8.3 (4.8;15.0) 12.1 (5.4;17.4) median difference: -
3.8
P > 0.05 36 vs 40
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Analysis 6.1. Comparison 6 Syrup of ipecac vs no intervention, Outcome 1 Incidence of diarrhoea.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 6 Syrup of ipecac vs no intervention
Outcome: 1 Incidence of diarrhoea
Study or subgroup Syrup of ipecac No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wax 1999 20/51 5/52 4.08 [ 1.66, 10.04 ]
0.01 0.1 1 10 100
Favours Syrup of ipecac Favours no intervention
Analysis 6.2. Comparison 6 Syrup of ipecac vs no intervention, Outcome 2 Incidence of abdominal pain.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 6 Syrup of ipecac vs no intervention
Outcome: 2 Incidence of abdominal pain
Study or subgroup Syrup of ipecac No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wax 1999 1/51 1/52 1.02 [ 0.07, 15.87 ]
0.01 0.1 1 10 100
Favours Syrup of ipecac Favours no intervention
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Analysis 6.3. Comparison 6 Syrup of ipecac vs no intervention, Outcome 3 Incidence of sedation.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 6 Syrup of ipecac vs no intervention
Outcome: 3 Incidence of sedation
Study or subgroup Syrup of ipecac No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wax 1999 10/51 2/52 5.10 [ 1.17, 22.13 ]
0.01 0.1 1 10 100
Favours Syrup of ipecac Favours no intervention
Analysis 6.4. Comparison 6 Syrup of ipecac vs no intervention, Outcome 4 Incidence of agitation.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 6 Syrup of ipecac vs no intervention
Outcome: 4 Incidence of agitation
Study or subgroup Syrup of ipecac No intervention Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wax 1999 3/51 2/52 1.53 [ 0.27, 8.77 ]
0.01 0.1 1 10 100
Favours Syrup of ipecac Favours no intervention
130First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.1. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 1 Incidence
of mortality.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 1 Incidence of mortality
Study or subgroup Syrup of ipecac No Syrup of ipecac
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Kornberg 1991 0/32 0/38 Not estimable
Kulig 1985 0/241 0/262 Not estimable
0.01 0.1 1 10 100
Favours SOI Favours no SOI
Analysis 7.2. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 2 Incidence
of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 2 Incidence of adverse events
Study or subgroup Syrup of ipecac no Syrup of ipecac Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albertson 1989 5/93 1/107 8.5 % 5.75 [ 0.68, 48.36 ]
Kornberg 1991 18/32 6/38 46.2 % 3.56 [ 1.61, 7.89 ]
Pond 1995 13/220 10/274 45.3 % 1.62 [ 0.72, 3.62 ]
Total (95% CI) 345 419 100.0 % 2.59 [ 1.37, 4.91 ]
Total events: 36 (Syrup of ipecac), 17 (no Syrup of ipecac)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours SOI Favours no SOI
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Analysis 7.3. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 3 Incidence
of clinical improvement.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 3 Incidence of clinical improvement
Study or subgroup Syrup of ipecac no Syrup of ipecac Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kornberg 1991 9/11 7/8 17.7 % 0.94 [ 0.64, 1.37 ]
Kulig 1985 211/214 260/262 69.7 % 0.99 [ 0.97, 1.01 ]
Pond 1995 29/220 31/274 12.6 % 1.17 [ 0.73, 1.87 ]
Total (95% CI) 445 544 100.0 % 1.00 [ 0.83, 1.21 ]
Total events: 249 (Syrup of ipecac), 298 (no Syrup of ipecac)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.11, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours SOI Favours no SOI
Analysis 7.4. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 4 Incidence
of clinical deterioration.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 4 Incidence of clinical deterioration
Study or subgroup Syrup of ipecac no Syrup of ipecac Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kulig 1985 3/214 2/262 13.4 % 1.84 [ 0.31, 10.89 ]
Pond 1995 12/220 19/274 86.6 % 0.79 [ 0.39, 1.58 ]
Total (95% CI) 434 536 100.0 % 0.88 [ 0.46, 1.69 ]
Total events: 15 (Syrup of ipecac), 21 (no Syrup of ipecac)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours SOI Favours no SOI
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Analysis 7.5. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 5 Incidence
of hospitalization.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 5 Incidence of hospitalization
Study or subgroup Syrup of ipecac No Syrup of ipecac
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Albertson 1989 13/93 12/107 39.6 % 1.29 [ 0.56, 2.97 ]
Kornberg 1991 3/32 0/38 5.2 % 9.51 [ 0.95, 95.39 ]
Kulig 1985 14/214 19/262 55.2 % 0.90 [ 0.44, 1.82 ]
Total (95% CI) 339 407 100.0 % 1.17 [ 0.69, 1.98 ]
Total events: 30 (Syrup of ipecac), 31 (No Syrup of ipecac)
Heterogeneity: Chi2 = 3.77, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours SOI Favours no SOI
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Analysis 7.6. Comparison 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic, Outcome 6 Incidence
of ICU admission.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 7 Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Outcome: 6 Incidence of ICU admission
Study or subgroup Syrup of ipecac No Syrup of ipecac Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Albertson 1989 6/93 5/107 1.38 [ 0.44, 4.38 ]
0.1 0.2 0.5 1 2 5 10
Favours SOI Favours no SOI
Analysis 8.1. Comparison 8 SDAC + cathartic vs SDAC, Outcome 1 Incidence of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 8 SDAC + cathartic vs SDAC
Outcome: 1 Incidence of adverse events
Study or subgroup Cathartics No cathartics Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Vomiting
James 1995 23/88 5/28 1.46 [ 0.61, 3.49 ]
2 Lethargy during follow-up
Sue 1994 0/50 0/14 Not estimable
0.01 0.1 1 10 100
Favours Cathartics Favours no cathartics
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Analysis 8.2. Comparison 8 SDAC + cathartic vs SDAC, Outcome 2 Incidence of hospitalization.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 8 SDAC + cathartic vs SDAC
Outcome: 2 Incidence of hospitalization
Study or subgroup Cathartic No cathartics Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sue 1994 3/50 1/14 0.84 [ 0.09, 7.46 ]
0.01 0.1 1 10 100
Favours Cathartics Favours no cathartics
Analysis 9.1. Comparison 9 SDAC + cathartic vs SDAC + cathartic (higher dose), Outcome 1 Incidence of
hospitalization (8 mL vs 6 mL).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 9 SDAC + cathartic vs SDAC + cathartic (higher dose)
Outcome: 1 Incidence of hospitalization (8 mL vs 6 mL)
Study or subgroup 8 ml cathartic 6 ml cathartic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sue 1994 2/18 1/16 1.78 [ 0.18, 17.80 ]
0.01 0.1 1 10 100
Favours 8 ml cathartic Favours 6 ml cathartic
135First aid interventions by laypeople for acute oral poisoning (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.1. Comparison 10 SDAC + cathartic vs SDAC + cathartic (different type), Outcome 1 Incidence
of vomiting (sorbitol vs magnesium sulphate.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 10 SDAC + cathartic vs SDAC + cathartic (different type)
Outcome: 1 Incidence of vomiting (sorbitol vs magnesium sulphate
Study or subgroup Sorbitol Magnesium sulphate Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
James 1995 13/32 4/23 2.34 [ 0.87, 6.25 ]
0.01 0.1 1 10 100
Favours Sorbitol Favours MgSO4
Analysis 10.2. Comparison 10 SDAC + cathartic vs SDAC + cathartic (different type), Outcome 2 Incidence
of vomiting (sorbitol vs magnesium citrate).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 10 SDAC + cathartic vs SDAC + cathartic (different type)
Outcome: 2 Incidence of vomiting (sorbitol vs magnesium citrate)
Study or subgroup Sorbitol Magnesium citrate Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
James 1995 13/32 6/33 2.23 [ 0.97, 5.16 ]
0.01 0.1 1 10 100
Favours Sorbitol Favours Mg Citrate
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Analysis 10.3. Comparison 10 SDAC + cathartic vs SDAC + cathartic (different type), Outcome 3 Incidence
of vomiting (magnesium sulphate vs magnesium citrate).
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 10 SDAC + cathartic vs SDAC + cathartic (different type)
Outcome: 3 Incidence of vomiting (magnesium sulphate vs magnesium citrate)
Study or subgroup Magnesium Sulphate Magnesium Citrate Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
James 1995 4/23 6/33 0.96 [ 0.30, 3.01 ]
0.01 0.1 1 10 100
Favours MgSO4 Favours Mg Citrate
Analysis 11.1. Comparison 11 SDAC + cathartic + hospital intervention vs hospital intervention, Outcome 1
Incidence of adverse events.
Review: First aid interventions by laypeople for acute oral poisoning
Comparison: 11 SDAC + cathartic + hospital intervention vs hospital intervention
Outcome: 1 Incidence of adverse events
Study or subgroup SDAC+Cathartic No intervention
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Passeron 1989 5/16 0/16 9.94 [ 1.52, 65.02 ]
0.01 0.1 1 10 100
Favours SDAC+Cathartic Favours no intervention
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A D D I T I O N A L T A B L E S
Table 1. Sources of individual studies
Author and year of publication Title
Abrass 2012 The evidence for activated charcoal in resource poor settings: a systematic review
American Academy of Clinical Toxicology 1999 Position statement and practice guidelines on the use of multi-dose activated
charcoal in the treatment of acute poisoning
American Academy of Clinical Toxicology 2004 Position paper: cathartics
Brok 2006 Interventions for paracetamol (acetaminophen) overdoses
Chyka 2005 Position paper: single-dose activated charcoal
Eddleston 2003 Does gastric lavage really push poisons beyond the pylorus? A systematic review
of the evidence
Blain 2011 Organophosphorus poisoning (acute)
Höjer 2013 Position paper update: ipecac syrup for gastrointestinal decontamination
Jones 2002 Towards evidence based emergency medicine: best BETs from the Manchester
Royal Infirmary. Activated charcoal and gastric absorption of iron compounds
Manoguerra 2005 Guideline on the use of ipecac syrup in the out-of-hospitalmanagement of ingested
poisons
Qureshi 2011 Adverse effects of activated charcoal used for the treatment of poisoning
Roberts 2011 Enhanced elimination in acute barbiturate poisoning - a systematic review
Table 2. Overview of comparisons
Comparison Type of poisoning Study
A. First aid interventions that limit or delay the absorption of the poison in the body
SDAC
vs no intervention
Not specified Merigian 1990
Paracetamol Underhill 1990
SDAC + hospital intervention vs
hospital intervention
Not specified Comstock 1982
Benzodiazepines + paracetamol or other
drug combinations
Cooper 2005
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Table 2. Overview of comparisons (Continued)
Tricyclic antidepressants Crome 1983
Yellow oleander, organophosphorus/carba-
mate pesticide, organochlorine, other/un-
known pesticide or paraquat, medicine or
unknown
Eddleston 2008
Amitriptyline, clomipramine, mianserin,
imipramine, dothiepin, doxepin, nor-
triptyline,mixed overdoses withmost com-
monly benzodiazepines or alcohol
Hultén 1988
Not specified Merigian 2002
Yellow oleander Roberts 2006
MDAC + hospital intervention
vs SDAC + hospital intervention
Carbamazepine Behnoush 2009
Carbamazepine Brahmi 2006
Yellow oleander De Silva 2003
Yellow oleander, organophosphorus/carba-
mate pesticide, organochlorine, other/un-
known pesticide or paraquat, medicine or
unknown
Eddleston 2008
Yellow oleander Roberts 2006
SDAC
vs syrup of ipecac
Anti-inflammatory drugs, analgesics or
psychotropic drugs
Amigó Tadín 2002
MDAC + hospital intervention
vs hospital intervention
Benzodiazepine Bouget 1989
Yellow oleander, organophosphorus/carba-
mate pesticide, organochlorine, other/un-
known pesticide or paraquat, medicine or
unknown
Eddleston 2008
Yellow oleander Roberts 2006
B. First aid interventions that evacuate the poison from the gastrointestinal tract
Emetics
Syrup of ipecac vs no intervention Toxic berries Wax 1999
Syrup of ipecac + SDAC + cathartic
vs SDAC + cathartic
Not specified Albertson 1989
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Table 2. Overview of comparisons (Continued)
Wide variety, most commonly paracetamol Kornberg 1991
Not specified Kulig 1985
Paracetamol, salicylate, phenothiazines or
ethanol, or other drugs
Pond 1995
Syrup of ipecac APF vs syrup of ipecac USP
(dose)
Benzodiazepine tranquillizers or hypnotics,
other tranquillizers, other hypnotics, an-
tidepressants, analgesics, antihistamines,
miscellaneous drugs and chemicals
Ilett 1977
Cathartics
SDAC + cathartic
vs SDAC
Not specified Sue 1994
SDAC + cathartic
vs
SDAC
Analgesics, anticonvulsants, antihistamines
and decongestants, asthma therapies, au-
tomotive products, cardiovascular drugs,
gastrointestinal preparations, insecticides,
mushrooms, psychotropic drugs, rodenti-
cides, topicals, miscellaneous drugs
James 1995
SDAC + cathartic
vs SDAC + cathartic (dose)
Not specified Sue 1994
SDAC + cathartic
vs
SDAC + cathartic (type)
Analgesics, anticonvulsants, antihistamines
and decongestants, asthma therapies, au-
tomotive products, cardiovascular drugs,
gastrointestinal preparations, insecticides,
mushrooms, psychotropic drugs, rodenti-
cides, topicals, miscellaneous drugs
James 1995
C. Combined first aid interventions that limit uptake and promote evacuation of the poison from the gastrointestinal tract
SDAC + cathartic + hospital intervention
vs hospital intervention
Benzodiazepines, barbiturates or
imipramine
Passeron 1989
MDAC + cathartic + hospital intervention
vs hospital intervention
Paracetamol Montoya-Cabrera 1999
D. First aid interventions that neutralize or dilute the poison
No studies were identified
APF: Australian Pharmaceutical Formulary;MDAC: multi-dose activated charcoal; SDAC: single-dose activated charcoal;USP: United
States Pharmacopeia.
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Table 3. Additional pre-defined outcomes reported in the included studies
A. First aid interventions that limit or delay the absorption of the poison in the body
SDAC vs no intervention
Incidence of clinical deterioration
SDAC No intervention
Study Events Total Events Total Peto OR (95% CI)
Merigian 1990 0 220 0 231 Not estimable
Incidence of ICU admission
SDAC No intervention
Study Events Total Events Total Peto OR (95% CI)
Merigian 1990 0 220 0 231 7.77 (0.15 to 391.93)
SDAC + hospitalintervention vs hospitalintervention
Incidence of clinical deterioration
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total Peto OR (95% CI)
Merigian 2002 0 455 0 1075 Not estimable
Grade of coma (4 h after admission)
SDAC + hospital
treatment (N = 9)
Hospital treatment (N = 7)
Study Median IQR Median IQR Median difference (P value)
Crome 1983 2 (1 to 3) 2 (1 to 2.5) 0 (P = 0.55)
Grade of coma (8 h after admission)
SDAC + hospital
treatment (N = 9)
Hospital treatment (N = 7)
Study Median IQR Median IQR Median difference (P value)
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
Crome 1983 2 (1 to 3) 1 (0.5 to 2) 1 (P = 0.38)
Grade of coma (24 h after admission)
SDAC + hospital
treatment (N = 9)
Hospital treatment (N = 7)
Study Median IQR Median IQR Median difference (P value)
Crome 1983 1 (0 to 2) 0 (0 to 0.5) 1 (P = 0.27)
Incidence of coma grade III (4 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 7 34 6 43 1.48 (0.55 to 3.98)
Incidence of coma grade IV (4 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 7 43 0.18 (0.02 to 1.40)
Incidence of coma grade III (8 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 2 34 2 43 1.26 (0.19 to 8.52)
Incidence of coma grade IV (8 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 0 34 2 43 0.16 (0.01 to 2.70)
Incidence of coma grade III (24 h after admission)
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total Peto OR (95% CI)
Hultén 1988 0 34 0 43 Not estimable
Incidence of coma grade IV (24 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total Peto OR (95% CI)
Hultén 1988 0 34 0 43 Not estimable
Incidence of need for cardiac pacing/antitoxin
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Eddleston 2008 101 549 101 555 1.01 (0.79 to 1.30)
Incidence of need for respirator
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 2 34 9 43 0.28 (0.06 to 1.22)
Incidence of systolic blood pressure < 100 mmHg (4 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 4 34 8 43 0.63 (0.21 to 1.92)
Incidence of systolic blood pressure < 100 mmHg (8 h after admission)
SDAC + hospital
treatment
Hospital treatment
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 5 43 0.25 (0.03 to 2.06)
Incidence of systolic blood pressure < 100 mmHg (24 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 0 34 2 43 0.16 (0.01 to 2.70)
Incidence of heart rate > 100 bpm (4 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 10 34 15 43 0.84 (0.44 to 1.63)
Incidence of heart rate > 100 bpm (8 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 8 34 10 43 1.01 (0.45 to 2.28)
Incidence of heart rate > 100 bpm (24 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 10 34 10 43 1.26 (0.60 to 2.68)
Incidence of cardiac arrhythmias (4 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 4 43 0.32 (0.04 to 2.70)
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
Incidence of cardiac arrhythmias (8 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 3 43 0.42 (0.05 to 3.87)
Incidence of cardiac arrhythmias (24 h after admission)
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 2 43 0.63 (0.06 to 6.68)
Incidence of intubation > 8 h
SDAC + hospital
treatment
Hospital treatment
Study Events Total Events Total RR (95% CI)
Hultén 1988 4 34 9 43 0.56 (0.19 to 1.67)
B. First aid interventions that evacuate the poison from the gastrointestinal tract
Syrup of ipecac vs no intervention
Incidence of referrals to the emergency department
Syrup of ipecac No intervention
Study Events Total Events Total Peto OR (95% CI)
Wax 1999 1 51 0 52 7.54 (0.15 to 378.83)
Incidence of hospitalizations
Syrup of ipecac No intervention
Study Events Total Events Total Peto OR (95% CI)
Wax 1999 0 51 0 52 Not estimable
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
SDAC + cathartic vs SDAC (higher dose)
Incidence of adverse events (6 mL vs 4 mL)
SDAC + 6 mL
cathartic
SDAC + 4 mL cathartic
Study Events Total Events Total Peto OR (95% CI)
Sue 1994 0 16 0 16 Not estimable
Incidence of adverse events (8 mL vs 4 mL)
SDAC + 8 mL
cathartic
SDAC + 4 mL cathartic
Study Events Total Events Total Peto OR (95% CI)
Sue 1994 0 18 0 16 Not estimable
Incidence of adverse events (8 mL vs 6 mL)
SDAC + 8 mL
cathartic
SDAC + 6 mL cathartic
Study Events Total Events Total Peto OR (95% CI)
Sue 1994 0 18 0 16 Not estimable
Incidence of hospitalization (6 mL vs 4 mL)
SDAC + 6 mL
cathartic
SDAC + 4 mL cathartic
Study Events Total Events Total Peto OR (95% CI)
Sue 1994 1 16 0 16 7.39 (0.15 to 372.38)
Incidence of hospitalization (8 mL vs 4 mL)
SDAC + 8 mL
cathartic
SDAC + 4 mL cathartic
Study Events Total Events Total Peto OR (95% CI)
Sue 1994 2 18 0 16 7.01 (0.42 to 117.63)
C. Combined first aid interventions that limit uptake and promote removal of the poison
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Table 3. Additional pre-defined outcomes reported in the included studies (Continued)
MDAC + cathartic + hospitalintervention vs hospitalintervention
Incidence of adverse events
MDAC + cathar-
tic + hospital inter-
vention
Hospital intervention
Study Events Total Events Total Peto OR (95% CI)
Montoya-Cabrera
1999
0 7 0 7 Not estimable
T1/2 (h)
MDAC + cathar-
tic + hospital inter-
vention (N = 7)
Hospital intervention (N = 7)
Study Mean SD Mean SD MD (95% CI)
Montoya-Cabrera
1999
10 N/A 17 N/A −7 (not estimable)
bpm: beats per minute; CI: confidence interval; IQR: interquartile range;OR: odds ratio; RR: risk ratio;MDAC; multi-dose activated
charcoal; SDAC: single-dose activated charcoal.
Table 4. Pre-defined outcomes that were extracted but not included in the review
A. First aid interventions that limit or delay the absorption of the poison in the body
SDAC vs no intervention
Length of stay in the emergency department (min)
SDAC No intervention
Study Mean SD N Mean SD N MD (95% CI)
Merigian
1990
252 279 220 230 166 231 22.00 (−20.63 to 64.63)
SDAC + hospitalintervention vs hospitalintervention
Length of ICU stay (h)
SDAC + hospital intervention Hospital intervention
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Table 4. Pre-defined outcomes that were extracted but not included in the review (Continued)
Study Mean SD N Mean SD N MD (95% CI)
Merigian
2002
54.4 93.15 28 45.5 36.3 32 8.90 (−27.82 to 45.62)
Incidence of ICU stay > 3 days
SDAC + hospital intervention Hospital intervention
Study Events Total Events Total RR (95% CI)
Hultén 1988 0 34 5 43 0.11 (0.01 to 2.00)
Length of hospital stay (h)
SDAC + hospital intervention Hospital intervention
Study Mean SD N Mean SD N MD (95% CI)
Merigian
2002
63.8 79.8 51 91.7 103.97 102 −27.90 (−57.68 to 1.88)
Study Median IQR N Median IQR N Median difference (P value)
Cooper 2005 6.8 (4.0 to 14.0) 166 5.5 (3.0 to 12.0) 161 1.3 (P = 0.11)
Incidence of hospital stay > 3 days
SDAC + hospital intervention Hospital intervention
Study Events Total Events Total RR (95% CI)
Hultén 1988 1 34 4 43 0.32 (0.04 to 2.70)
Length of stay in the emergency department (h)
SDAC + hospital intervention Hospital intervention
Study Mean SD N Mean SD N MD (95% CI)
Merigian
2002
6.2 3.9 325 5.3 3.9 941 0.90 (0.41 to 1.39)
MDAC + hospitalintervention vs hospitalintervention
Length of hospital stay (h)
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Table 4. Pre-defined outcomes that were extracted but not included in the review (Continued)
MDAC + hospital intervention Hospital intervention
Study Mean SD N Mean SD N MD (95% CI)
Behnoush
2009
31.0 8.9 30 55.0 8.5 30 −24.00 (−28.40 to −19.60)
Brahmi 2006 30.3 3.4 6 39.7 7.3 6 −9.40 (−15.84 to −2.96)
Median IQR N Median IQR N Median difference (P value)
De Silva 2003 3 (0.25 to 24) 201 3 (0.5 to 10) 200 0 (P = 0.90)
SDAC vs syrup of ipecac
Length of stay in the emergency department (min)
Syrup of ipecac SDAC
Study Mean SD N Mean SD N MD (95% CI)
Amigó Tadín
2002
113.21 66.0 21 81.46 27.92 13 31.75 (−0.30 to 63.80)
B. First aid interventions that evacuate the poison from the gastrointestinal tract
Syrup of ipecac + SDAC + cathartic vs SDAC + cathartic
Length of hospital stay (days)
Syrup of ipecac + SDAC +
cathartic
SDAC + cathartic
Study Mean SD N Mean SD N MD (95% CI)
Albertson
1989
2.4 5.8 13 1.7 5.2 12 0.70 (−3.61 to 5.01)
Length of stay in the emergency department (h)
Syrup of ipecac + SDAC +
cathartic
SDAC + cathartic
Study Mean SD N Mean SD N MD (95% CI)
Albertson
1989
6.8 2.9 93 6.0 2.1 107 0.80 (0.09 to 1.51)
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Table 4. Pre-defined outcomes that were extracted but not included in the review (Continued)
Kornberg
1991
4.1 1.1 29 3.4 1.2 38 0.70 (0.15 to 1.25)
Length of ICU stay (h)
Syrup of ipecac + SDAC +
cathartic
SDAC + cathartic
Study Mean SD N Mean SD N MD (95% CI)
Albertson
1989
1.8 3.9 6 1.0 0.0 5 Not estimable
CI: confidence interval; ICU: intensive care unit; IQR: interquartile range; MD: mean difference; SD: standard deviation; SDAC:
single-dose activated charcoal.
A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library
1. [mh “poisoning”] OR [mh “poisons”] OR poison*:ti,ab,kw OR (toxic NEXT/1 ingestion*):ti,ab,kw OR intoxica*:ti,ab,kw OR
overdos*:ti,ab,kw OR [mh “drug overdose”]
2. (active NEXT/1 charcoal):ti,ab,kw OR (activated NEXT/1 charcoal):ti,ab,kw OR (active NEXT/1 carbon):ti,ab,kw OR (activated
NEXT/1 carbon):ti,ab,kw OR [mh “charcoal”]
3. [mh “vomiting”] OR vomit*:ti,ab,kw OR emesis:ti,ab,kw OR (gastric NEXT/1 evacuation*):ti,ab,kw OR (gastrointestinal NEXT/1
decontamination*):ti,ab,kw OR [mh “ipecac”] OR ipecac*:ti,ab,kwOR emetic*:ti,ab,kwOR [mh “emetics”] OR [mh “cathartics”] OR
cathartic*:ti,ab,kwORpurgative*:ti,ab,kwORbowel evacuant*:ti,ab,kwOR [mh “sorbitol”]OR sorbitol:ti,ab,kwOR [mh “mannitol”]
ORmannitol:ti,ab,kw OR [mh “lactulose”] OR lactulose:ti,ab,kw OR [mh “magnesium sulfate”] OR (magnesium NEXT/1 sulphate):
ti,ab,kw OR (magnesium NEXT/1 sulfate):ti,ab,kw OR (magnesium NEXT/1 citrate):ti,ab,kw OR (sodium NEXT/1 sulphate):
ti,ab,kw OR (sodium NEXT/1 sulfate):ti,ab,kw
4. ([mh “Drinking”] OR drink*:ti,ab,kw OR intake:ti,ab,kw OR consum*:ti,ab,kw OR ingest*:ti,ab,kw) AND ([mh “drinking water”]
OR [mh “water”] OR water:ti,ab,kw)
5. (left NEXT/1 side):ti,ab,kw OR (body NEXT/1 position*):ti,ab,kw OR [mh “posture”] OR posture:ti,ab,kw OR (lateral NEXT/1
decubitus):ti,ab,kw
6. [mh “Milk”] OR milk:ti,ab,kw OR [mh “acetic acid”] OR vinegar:ti,ab,kw OR (acetic NEXT/1 acid):ti,ab,kw OR [mh “citrus”]
OR citr*:ti,ab,kw OR orange*:ti,ab,kw OR grapefruit*:ti,ab,kw OR lemon*:ti,ab,kw
7. 2-6 OR
8. 1 AND 7
MEDLINE, using the PubMed interface
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1. “poisoning”[MeSH]OR“poisons”[MeSH]ORpoison*[TIAB]OR toxic ingestion*[TIAB]OR intoxica*[TIAB]ORoverdos*[TIAB]
OR “drug overdose”[MeSH]
2. “active charcoal”[TIAB] OR “activated charcoal”[TIAB] OR “active carbon”[TIAB] OR “activated carbon”[TIAB] OR “char-
coal”[MeSH]
3. “vomiting”[MeSH] OR vomit*[TIAB] OR emesis[TIAB] OR gastric evacuation*[TIAB] OR gastrointestinal decontamina-
tion*[TIAB] OR “ipecac”[MeSH] OR ipecac*[TIAB] OR emetic*[TIAB] OR “emetics”[MeSH] OR “cathartics”[MeSH] OR cathar-
tic*[TIAB] OR purgative*[TIAB] OR bowel evacuant*[TIAB] OR “sorbitol”[MeSH] OR sorbitol[TIAB] OR “mannitol”[MeSH] OR
mannitol[TIAB] OR “lactulose”[MeSH] OR lactulose[TIAB] OR “magnesium sulfate”[MeSH] OR “magnesium sulphate”[TIAB] OR
“magnesium sulfate”[TIAB] OR “magnesium citrate”[TIAB] OR “sodium sulphate”[TIAB] OR “sodium sulfate”[TIAB]
4. (“Drinking”[Mesh] OR drink*[TIAB] OR intake[TIAB] OR consum*[TIAB] OR ingest*[TIAB]) AND (“drinking water”[MeSH]
OR “water”[MeSH] OR water[TIAB])
5. “left side”[TIAB] OR body position*[TIAB] OR “posture”[Mesh] OR posture[TIAB] OR “lateral decubitus”[TIAB]
6. “Milk”[Mesh] OR milk[TIAB] OR “acetic acid”[MeSH] OR vinegar[TIAB] OR “acetic acid”[TIAB] OR “citrus”[MeSH] OR
citric*[TIAB] OR citrus*[TIAB] OR orange*[TIAB] OR grapefruit*[TIAB] OR lemon*[TIAB]
7. 2-6 OR
8. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized[TIAB] OR placebo[TIAB] OR drug therapy[sh]
OR randomly[TIAB] OR trial[TIAB] OR groups[TIAB]) NOT (Animals[MeSH] NOT Humans[MeSH])
9. 1 AND 7 AND 8
Embase, using the Embase.com interface
1. ’intoxication’/exp OR ’poison’/exp OR poison*:ab,ti OR (toxic NEXT/1 ingestion*):ab,ti OR intoxica*:ab,ti OR overdos*:ab,ti OR
’drug overdose’/exp
2. ’active charcoal’:ab,ti OR ’activated charcoal’:ab,ti OR ’active carbon’:ab,ti OR ’activated carbon’:ab,ti OR ’activated carbon’/exp
3. ’vomiting’/exp OR vomit*:ab,ti OR emesis:ab,ti OR (gastric NEXT/1 evacuation*):ab,ti OR (gastrointestinal NEXT/1 decontam-
ination*):ab,ti OR ’ipecac’/exp OR ipecac*:ab,ti OR emetic*:ab,ti OR ’emetic agent’/exp OR ’laxative’/exp OR cathartic*:ab,ti OR
purgative*:ab,ti OR (bowel NEXT/1 evacuant*):ab,ti OR ’sorbitol’/exp OR sorbitol:ab,ti OR ’mannitol’/exp OR mannitol:ab,ti OR
’lactulose’/exp OR lactulose:ab,ti OR ’magnesium sulfate’/exp OR ’magnesium sulphate’:ab,ti OR ’magnesium sulfate’:ab,ti OR ’mag-
nesium citrate’:ab,ti OR ’sodium sulphate’:ab,ti OR ’sodium sulfate’:ab,ti
4. (’Drinking’/exp OR drink*:ab,ti OR intake:ab,ti OR consum*:ab,ti OR ingest*:ab,ti) AND (’drinking water’/exp OR ’water’/exp
OR water:ab,ti)
5. ’left side’:ab,ti OR (body NEXT/1 position*):ab,ti OR ’body position’/exp OR posture:ab,ti OR ’lateral decubitus’:ab,ti
6. ’milk’/exp OR milk:ab,ti OR ’acetic acid’/exp OR vinegar:ab,ti OR ’acetic acid’:ab,ti OR ’citrus’/exp OR citr*:ab,ti OR orange*:
ab,ti OR grapefruit*:ab,ti OR lemon*:ab,ti
7. 2-6 OR
8. (’randomized controlled trial’/exp OR ’controlled clinical trial’/exp OR ’crossover procedure’/exp OR ’double blind procedure’/exp
OR ’single blind procedure’/exp OR random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross-over’:ab,ti OR
’cross over’:ab,ti OR (double NEXT/1 blind*):ab,ti OR (single NEXT/1 blind*):ab,ti OR trial:ab,ti OR groups:ab,ti) NOT (’animal’/
exp NOT ’human’/exp)
9. 1 AND 7 AND 8
CINAHL, using the EBSCO host interface
1. MH “poisoning+” OR MH “poisons+” OR TI “poison*” OR AB “poison*” OR TI “toxic ingestion*” OR AB “toxic ingestion*”
OR TI “intoxica*” OR AB “intoxica*” OR TI “overdos*” OR AB “overdos*” OR MH “overdose”
2. TI “active charcoal” OR AB “active charcoal” OR TI “activated charcoal” OR AB “activated charcoal” OR TI “active carbon” OR
AB “active carbon” OR TI “activated carbon” OR AB “activated carbon” OR MH “charcoal”
3. MH “vomiting+” OR TI “vomit*” OR AB “vomit*” OR TI emesis OR AB emesis OR TI “gastric evacuation*” OR AB “gastric
evacuation*” OR TI “gastrointestinal decontamination*” OR AB “gastrointestinal decontamination*” OR MH “ipecac” OR TI
“ipecac*” OR AB “ipecac*” OR TI “emetic*” OR AB “emetic*” OR MH “emetics+” OR MH “cathartics+” OR TI “cathartic*” OR
AB “cathartic*” OR TI “purgative*” OR AB “purgative*” OR TI “bowel evacuant*” OR AB “bowel evacuant*” OR MH “sorbitol”
OR TI sorbitol OR AB sorbitol OR MH “mannitol” OR TI mannitol OR AB mannitol OR TI lactulose OR AB lactulose OR MH
“magnesium sulfate” OR TI “magnesium sulphate” OR AB “magnesium sulphate” OR TI “magnesium sulfate” OR AB “magnesium
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sulfate” ORTI “magnesium citrate” ORAB “magnesium citrate” ORTI “sodium sulphate” OR AB “sodium sulphate” ORTI “sodium
sulfate” OR AB “sodium sulfate”
4. (TI “drink*” ORAB “drink*” ORTI intake ORAB intake ORTI “consum*” ORAB “consum*” ORTI “ingest*” ORAB “ingest*”)
AND (MH “Water supply” OR MH “water+” OR TI water OR AB water)
5. TI “left side” OR AB “left side” OR TI “body position*” OR AB “body position*” OR MH “posture+” OR TI posture OR AB
posture OR TI “lateral decubitus” OR AB “lateral decubitus”
6. MH “Milk+” OR TI milk OR AB milk OR TI “vinegar” OR AB “vinegar” OR MH “acetic acid” ORMH “citrus+” OR TI “citr*”
OR AB “citr*” OR TI “orange*” OR AB “orange*” OR TI “grapefruit*” OR AB “grapefruit*” OR TI “lemon*” OR AB “lemon*”
7. 2-6 OR
8. ((MH “Random Assignment”) or (MH “Random Sample+”) or (MH “Crossover Design”) or (MH “Clinical Trials+”) or (MH
“Comparative Studies”) or (MH “Control (Research)+”) or (MH “Control Group”) or (MH “Factorial Design”) or (MH “Quasi-
Experimental Studies+”) or (MH “Placebos”) or (MH “Meta Analysis”) or (MH “Sample Size”) or (MH “Research, Nursing”) or
(MH “Research Question”) or (MH “Research Methodology+”) or (MH “Evaluation Research+”) or (MH “Concurrent Prospective
Studies”) or (MH “Prospective Studies”) or (MH “Nursing Practice, Research-Based”) or (MH “Solomon Four-Group Design”) or
(MH “One-Shot Case Study”) or (MH “Pretest-Posttest Design+”) or (MH “Static Group Comparison”) or (MH “Study Design”)
or (MH “Clinical Research+”)) or (clinical nursing research or random* or cross?over or placebo* or control* or factorial or sham* or
meta?analy* or systematic review* or blind* or mask* or trial*)
9. 1 AND 7 AND 8
ISI Web of Science
1. TS=(“poison*”) OR TS=(“toxic ingestion*”) OR TS=(“intoxica*”) OR TS=(“overdos*”)
2. TS=(“active charcoal”) OR TS=(“activated charcoal”) OR TS=(“active carbon”)
3. TS=(“vomit*”) OR TS=(“emesis”) OR TS=(“gastric evacuation*”) OR TS=(“gastrointestinal decontamination*”) OR TS=(“ipecac”)
OR TS=(“emetic*”) OR TS=(“cathartic*”) OR TS=(“purgative*”) OR TS=(“bowel evacuant*”) OR TS=(“sorbitol”) OR TS=(“man-
nitol”) OR TS=(“lactulose”) OR TS=(“magnesium sulphate”) OR TS=(“magnesium sulfate”) OR TS=(“magnesium citrate”) OR TS=
(“sodium sulphate”) OR TS=(“sodium sulfate”)
4. (TS=(“drink*”) OR TS=(“intake”) OR TS=(“consum*”) OR TS=(“ingest*”)) AND (TS=(“water”))
5. TS=(“left side”) OR TS=(“body position”) OR TS=(“posture”) OR TS=(“lateral decubitus”)
6. TS=(“milk”) OR TS=(“acetic acid”) OR TS=(“vinegar”) OR TS=(“citr*”) OR TS=(“orange*”) OR TS=(“grapefruit*”) OR TS=
(“lemon*”)
7. 2-6 OR
8. TS=(clinical trial*) OR TS=(research design) OR TS=(comparative stud*) OR TS=(evaluation stud*) OR TS=(controlled trial*)
OR TS=(follow-up stud*) OR TS=(prospective stud*) OR TS=(random*) OR TS=(placebo*) OR TS=(single blind*) OR TS=(double
blind*)
9. 1 AND 7 AND 8
International Pharmaceutical Abstracts, using the Ovid interface
1. Poisoning.sh. OR poisons.sh. OR poison*.ti,ab. OR toxic ingestion*.ti,ab. OR intoxica*.ti,ab. OR overdos*.ti,ab. OR (drug over-
dose).ti,ab.
2. Charcoal.sh. OR carbon.sh. OR active charcoal.ti,ab. OR activated charcoal.ti,ab. OR active carbon.ti,ab. OR activated carbon.ti,ab.
3. Vomiting.sh. OR vomit*.ti,ab. OR emesis.sh. OR emesis.ti,ab. OR gastric evacuation*.ti,ab. OR gastrointestinal decontamina-
tion*.ti,ab. OR ipecac.sh. OR ipecac*.ti,ab. OR emetic*.ti,ab. OR emetics.sh. OR cathartics.sh. OR cathartic*.ti,ab. OR purga-
tive*.ti,ab. OR bowel evacuant*.ti,ab. OR sorbitol.sh. OR sorbitol.ti,ab. OR mannitol.sh OR mannitol.ti,ab. OR lactulose.sh. OR
lactulose.ti,ab. OR magnesium sulfate.sh. OR magnesium sulphate.ti,ab. OR magnesium sulfate.ti,ab. OR magnesium citrate.sh. OR
magnesium citrate.ti,ab. OR sodium sulfate.sh. OR sodium sulphate.ti,ab. OR sodium sulfate.ti,ab.
4. (drink*.ti,ab. OR intake.ti,ab. OR consum*.ti,ab. OR ingest*.ti,ab.) AND (water.sh. OR water.ti,ab.)
5. left side.ti,ab. OR body position*.ti,ab. OR posture.sh. OR posture.ti,ab. OR lateral decubitus.ti,ab.
6. Milk.sh. OR milk.ti,ab. OR acetic acid.sh. OR vinegar.sh. OR vinegar.ti,ab. OR acetic acid.ti,ab. OR citrus.sh. OR citr*.ti,ab. OR
orange*.ti,ab. OR grapefruit*.ti,ab. OR lemon*.ti,ab.
7. 2-6 OR
8. 1 AND 7
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Clinicaltrials.gov
poisoning OR poison OR poisons OR “toxic ingestion” OR intoxication OR overdose OR overdoses OR overdosing
EU Clinical Trials Register
(poisoning OR poison OR poisons OR “toxic ingestion” OR intoxication OR overdose OR overdoses OR overdosing) AND (“active
charcoal”OR“activated charcoal”OR“active carbon”ORVomitingORemesisORemeticOR“gastric evacuation”OR“gastrointestinal
decontamination” OR ipecac OR cathartic OR cathartics OR purgative OR purgatives OR “bowel evacuant” OR “bowel evacuants”
OR sorbitol OR mannitol OR lactulose OR “magnesium sulphate” OR “magnesium sulfate” OR “magnesium citrate” OR “sodium
sulphate” OR “sodium sulfate” OR ((drinking OR drink OR intake OR consuming OR consumption OR ingestion OR ingesting)
AND water) OR “left side” OR “body position” OR “body positions” OR posture OR postures OR “lateral decubitus” OR Milk OR
“acetic acid” OR vinegar OR citrus OR citric OR orange OR oranges OR grapefruit OR grapefruits OR lemon OR lemons)
WHO International Clinical Trials Registry Platform (ICTRP)
Poison* OR toxic ingestion* OR intoxica* OR overdos*
Appendix 2. Syrup of ipecac + SDAC + cathartic versus SDAC + cathartic for first aid in patients
with acute oral poisoning
Syrup of ipecac + SDAC + cathartic versus SDAC + cathartic for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning (combination of different drugs or not specified)
Setting: hospital setting
Intervention: syrup of ipecac + single-dose activated charcoal (SDAC) + Cathartic
Comparison: SDAC + Cathartic
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
of
participants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Risk with
SDAC + cathar-
tic
Risk with syrup
of ipecac +
SDAC + cathar-
tic
Incidence of
mortality
- - 573
(2 RCTs)
⊕©©©
Very lowa,b,c
The
effect was not es-
timable due to
zero events in in-
tervention group
(0/300) and con-
trol group (0/
273). We are un-
certain about the
effect of syrup of
ipecac in addi-
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(Continued)
tion to SDAC +
cathartic on inci-
dence of mortal-
ity
Incidence of ad-
verse events
Study population RR 2.59
(1.37 to 4.91)
764
(3 RCTs)
⊕©©©
Very lowa,b,c
We are uncer-
tain about the ef-
fect of syrup of
ipecac in addi-
tion to SDAC +
cathartic on inci-
dence of adverse
events
41 per 1000 105 per 1000
(56 to 199)
Inci-
dence and sever-
ity of symptoms
of poisoning: in-
cidence of clini-
cal improvement
Study population RR 1.00
(0.83 to 1.21)
989
(3 RCTs)
⊕⊕©©
Lowa,b
Syrup of ipecac
in addition to
SDAC + cathar-
tic may make lit-
tle or no dif-
ference in inci-
dence of clinical
improvement
548 per 1000 548 per 1000
(455 to 663)
Duration of
toxic symptoms
No studies collected or reported this outcome
Drug absorption No studies collected or reported this outcome
Incidence of hos-
pitalization
76 per 1000 89 per 1000
(53 to 151)
PetoOR1.17 (0.
69 to 1.98)
746
(3 RCTs)
⊕©©©
Very lowa,b,d
We are uncer-
tain about the ef-
fect of Syrup of
ipecac in addi-
tion to SDAC +
cathartic on in-
cidence of hospi-
talization
Incidence of
ICU admission
47 per 1000 64 per 1000
(21 to 205)
RR 1.38 (0.44 to
4.38)
200
(1 RCT)
⊕©©©
Very lowa,b,d
We are uncer-
tain about the ef-
fect of Syrup of
ipecac in addi-
tion to SDAC +
cathartic on inci-
dence of ICU ad-
mission
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ICU: intensive care unit; RCT: randomized controlled trial; RR: risk ratio; OR: odds ratio; SDAC: single-
dose activated charcoal.
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(Continued)
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
Footnotes
aDowngraded one level for serious limitations in study design: high risk of selection bias and high or unclear risk of detection bias.
bDowngraded one level for serious indirectness: study conducted in a hospital setting.
cDowngraded one level for serious imprecision: low number of events.
dDowngraded one level for serious imprecision: low number of events and wide confidence interval.
Appendix 3. SDAC + cathartic versus SDAC for first aid in patients with acute oral poisoning
SDAC + cathartic versus SDAC for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning (not specified or a combination of different drugs)
Setting: hospital setting
Intervention: single-dose activated charcoal (SDAC) + cathartic
Comparison: SDAC
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
of
participants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Risk with
SDAC
Risk with
SDAC + cathar-
tic
Incidence of
mortality
No studies collected or reported this outcome
Incidence of ad-
verse events
Study population RR 1.46
(0.61 to 3.49)
180
(2 RCTs)
⊕©©©
Very lowa,b,c
We are uncer-
tain about the
effect of SDAC
+ cathartic, com-
pared to SDAC
alone on the inci-
dence of adverse
events
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119 per 1000 174 per 1000
(73 to 415)
Inci-
dence and sever-
ity of symptoms
of poisoning -
not reported
No studies looked at this outcome
Duration of
toxic symptoms
No studies collected or reported this outcome
Drug absorption No studies collected or reported this outcome
Incidence of hos-
pitalization
Study population RR 0.84
(0.09 to 7.46)
64
(1 RCT)
⊕©©©
Very lowa,b,c
We are uncer-
tain about the
effect of SDAC
+ cathartic, com-
pared to SDAC
alone on the inci-
dence of ICU ad-
mission
71 per 1000 60 per 1000
(6 to 533)
Incidence of
ICU admission
No studies collected or reported this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ICU: intensive care unit; RCT: randomized controlled trial; RR: risk ratio; SDAC: single-dose activated
charcoal.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
Footnotes
aDowngraded one level for serious study limitations: high risk of reporting bias.
bDowngraded one level for serious indirectness: study was conducted in a hospital setting.
cDowngraded one level for serious imprecision: low number of events and wide confidence intervals.
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Appendix 4. SDAC + cathartic compared to SDAC + cathartic (higher dose) for first aid in patients
with acute oral poisoning
SDAC + cathartic compared to SDAC + cathartic (higher dose) for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning (not specified)
Setting: hospital setting
Intervention: single-dose activated charcoal (SDAC) + Cathartic
Comparison: SDAC + Cathartic (higher dose)
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
of
participants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Risk with
SDAC + cathar-
tic (higher
dose)
Risk with
SDAC + cathar-
tic
Incidence of
mortality
No studies collected or reported this outcome
Incidence of ad-
verse events: 8
mLvs 4mLmag-
nesium citrate
- - 34
(1 RCT)
⊕©©©
Very lowa,b,c
The
effect was not es-
timable due to
zero events in in-
tervention group
(0/18) and con-
trol group (0/16)
We are uncer-
tain about the ef-
fects of SDAC +
cathartic (higher
dose) on the inci-
dence of adverse
events
Occurrence and
severity of symp-
toms of poison-
ing
No studies collected or reported this outcome
Duration of
toxic symptoms
No studies collected or reported this outcome
Drug absorption No studies collected or reported this outcome
In-
cidence of hospi-
talization (8 mL
control:0/16 and intervention 2/18
(PetoOR7.01, 95%CI 0.42 to 117.
63)
- 34
(1 RCT)
⊕©©©
Very lowa,b,d
We are uncer-
tain about the ef-
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(Continued)
vs 4 mL magne-
sium citrate)
fects of SDAC +
cathartic (higher
dose) on the in-
cidence of hospi-
talization
Incidence of
ICU admission
No studies collected or reported this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomized controlled trial; OR: odds ratio; SDAC: single-dose activated charcoal;
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
Footnotes
aDowngraded one level for serious limitations in study design: high risk of reporting bias.
bDowngraded one level for serious indirectness: study was conducted in a hospital setting.
cDowngraded one level for serious imprecision: low number of events.
dDowngraded one level for serious imprecision: low number of events and wide confidence intervals.
Appendix 5. SDAC + cathartic compared to SDAC + cathartic (different type) for first aid in
patients with acute oral poisoning
SDAC + cathartic compared to SDAC + cathartic (different type) for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning (combination of different drugs)
Setting: hospital setting
Intervention: single-dose activated charcoal (SDAC) + cathartic
Comparison: SDAC + cathartic (different type)
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
of
participants
(studies)
Certainty of the
evidence
(GRADE)
Comments
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(Continued)
Risk
with SDAC +
Cathartic (dif-
ferent type)
Risk
with SDAC +
Cathartic
Incidence of
mortality
No studies collected or reported this outcome
Inci-
dence of adverse
events: vomiting
(sorbitol vs mag-
nesium citrate)
Study population RR 2.23
(0.97 to 5.16)
65
(1 RCT)
⊕©©©
Very lowa,b,c
We are uncer-
tain about the ef-
fect of different
types of cathar-
tics combined
with SDAC on
the incidence of
adverse events
182 per 1000 405 per 1000
(176 to 938)
Inci-
dence and sever-
ity of symptoms
of poisoning -
not reported
No studies collected or reported this outcome
Duration of
toxic symptoms
No studies collected or reported this outcome
Drug absorption No studies collected or reported this outcome
Incidence of hos-
pitalization ad-
mission
No studies collected or reported this outcome
Incidence of
ICU admission
No studies collected or reported this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ICU: intensive care unit; RR: risk ratio; RCT: randomized controlled trial; SDAC: single-dose activated
charcoal.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
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Footnotes
aDowngraded one level for serious study limitations: high risk of reporting bias.
bDowngraded one level for serious indirectness: study was conducted in a hospital setting.
cDowngraded one level for serious imprecision: low number of events and wide confidence intervals.
Appendix 6. SDAC + cathartic + hospital intervention versus hospital intervention for first aid in
patients with acute oral poisoning
SDAC + cathartic + hospital intervention versus hospital intervention for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning
Setting: hospital setting
Intervention: SDAC + cathartic + hospital intervention
Comparison: hospital intervention
Outcomes Impact of participants
(studies)
Certainty of the evidence
(GRADE)
Incidence of mortality No studies collected or reported this outcome
Incidence of adverse events Control group: 0/16 and inter-
vention group: 5/16 (Peto OR
9.94, 95% CI 1.52 to 65.02).
We are uncertain of the effect of
SDAC + cathartic on the inci-
dence of adverse events
32
(1 RCT)
⊕©©©
Very lowa,b,c
Incidence and severity of symp-
toms of poisoning: level of
coma
assessed with: Glasgow Coma
Scale
Follow-up: 2 days
No numeric data were provided
about Glasgow Coma Scale
scores, but the course of the
scores was reported not to dif-
fer significantly between treat-
ments (P = 0.49). We are un-
certain of the effect of SDAC +
cathartic on the level of coma
32
(1 RCT)
⊕©©©
Very lowa,b,d
Duration of toxic symptoms No studies collected or reported this outcome
Drug absorption No studies collected or reported this outcome
Hospitalization No studies collected or reported this outcome
ICU admission No studies collected or reported this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ICU: intensive care unit; OR: odds ratio; RCT: randomized controlled trial; SDAC: single-dose activated
charcoal.
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(Continued)
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect
Footnotes
aDowngraded one level for serious study limitations: high risk of selection bias.
bDowngraded one level for serious indirectness: study conducted in a hospital setting.
cDowngraded one level for serious imprecision: low number of events and wide confidence intervals.
dDowngraded one level for serious imprecision: lack of data.
Appendix 7. MDAC + cathartic + hospital intervention versus hospital intervention for first aid in
patients with acute oral poisoning
MDAC + cathartic + hospital intervention versus hospital intervention for first aid in patients with acute oral poisoning
Patient or population: first aid in patients with acute oral poisoning (paracetamol)
Setting: hospital setting
Intervention: multiple dose of activated charcoal (MDAC) + Cathartic + Hospital intervention
Comparison: hospital intervention
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
of
participants
(studies)
Certainty of the
evidence
(GRADE)
Comments
Risk with hos-
pital interven-
tion
Risk
with MDAC +
cathartic + hos-
pital interven-
tion
Incidence of
mortality
No studies collected or reported this outcome
Incidence of ad-
verse events
- - 14
(1 RCT)
⊕©©©
Very lowa,b,c
The
effect was not es-
timable due to
the absence of
events in the in-
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(Continued)
tervention (0/7)
and the control
group (0/7)
We are uncertain
about the effect
of MDACwith a
cathartic on the
incidence of ad-
verse events
Inci-
dence and sever-
ity of symptoms
of poisoning
No studies collected or reported this outcome
Duration of
toxic symptoms
No studies collected or reported this outcome
Drug absorp-
tion: paraceta-
mol: elimination
half-life T1/2 (h)
The mean
drug absorption:
paracetamol:
elimination half-
life T1/2 (h) was
17 h
MD 7 h lower - 14
(1 RCT)
⊕©©©
Very lowa,b,d
The study re-
ported
no standard de-
viations or other
measures of data
spread
We are uncer-
tain about the ef-
fect of MDAC
with a cathartic
on paracetamol
elimination half-
life
Incidence of hos-
pitalization
No studies collected or reported this outcome
Incidence of
ICU admission
No studies collected or reported this outcome
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: confidence interval; ICU: intensive care unit; MD: mean difference; MDAC: multi-dose activated charcoal; RCT: randomized
controlled trial.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
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estimate of effect
Footnotes
aDowngraded one level due to serious limitations in study design: high risk of other bias: hepatic toxicity marker values suggest a
clinically meaningful difference between the two treatment groups.
bDowngraded one level due to serious indirectness: study conducted in a hospital setting.
cDowngraded one level due to serious imprecision: low number of events.
dDowngraded one level due to serious imprecision: lack of data.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Changes from the protocol
In the protocol, we stated that we would includ studies performed in poisoning patients as well as studies with healthy volunteers (Avau
2017). During screening of references, it became clear that there were sufficient patient studies available, which led to the decision
to only include these. We believe that studies performed in actual oral poisoning patients give better insight into the reality of oral
poisoning than studies performed in healthy volunteers, where poisoning is simulated in a controlled setting.
Furthermore, we described mult-dose activated charcoal as the same intervention as single-dose activated charcoal, but with multiple
doses of the same intervention. The identified studies made us aware that we should analyse them as different interventions, which we
did.
The pre-defined secondary outcome ’drug recovery rate from the body’ did not make it to the review, as we had anticipated finding this
outcome in studies in healthy volunteers, not in patient studies. As studies in healthy volunteers were no longer within scope of this
review, we did not report this outcome. Instead, we subdivided the primary outcome ’incidence and severity of symptoms of poisoning,
including mortality’ into two separate outcomes, ’incidence and severity of symptoms of poisoning’ and ’mortality’.
We also left out two other pre-defined secondary outcomes, ’length of hospital stay’ and ’length of ICU stay’. The Cochrane Injuries
review group does not consider these outcomes appropriate because they are prone to bias, as they depend on a lot of confounding factors,
such as time of death, insurance coverage, patient income, distance from a hospital, hospital admission policy and bed availability,
among other factors. As we extracted these outcomes, we present them in Table 4.
For some comparisons, we identified more than 7 outcomes. The outcomes as stated in the protocol were more generally described;
however, it became clear that outcomes such as occurrence and severity of poisoning symptoms could include a wide variety of specific
outcomes (e.g. incidence of clinical improvement, incidence of intubation requirement, incidence of convulsions) which we could not
combine in a meta-analysis due to the differences in the symptoms. As ’Summary of findings’ tables include only seven outcomes, we
decided, together with a clinical expert (PD), to choose the clinically most relevant outcomes.
For the assessment of the GRADE domain ’limitations in study design’, we decided to downgrade the level of the evidence if one of
the studies contributing to the outcome was classified as a having a high risk of bias in one or more of the following domains: selection
bias, detection bias, attrition bias or other bias. We did not consider domains with unclear risk of bias. The protocol did not clearly
state this. Furthermore, we have expanded explanations on our considerations for the assessment of the GRADE domain ’imprecision’.
During the analysis of our data, we encountered dichotomous outcomes with zero events. We decided to analyse these with the Peto
OR method instead of the Maentel-Haenzel method in cases where this method is appropriate, according to the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). In addition, we have further expanded our Methods section concerning the
interpretation of I² for the assessment of heterogeneity.
In the protocol we anticipated making subgroups of different drugs taken, single versus multiple doses of an intervention and different
time points of the interventions. Based on the identified evidence, we decided to create the following subgroups: different drugs taken,
different time points of the intervention, co-interventions administered and type of adverse event experienced. We performed no
subgroup analysis for single versus multiple doses of an intervention, as it became clear that these should be treated as two different
interventions and are therefore different analyses. As for the different time points of the interventions, we did not identify any studies
that compared against a control intervention, so we could not perform subgroup analyses.
For practical reasons, we decided to include an extra review author (AV) to help with data extraction of the studies. This person was
included as third author of this review.
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Methods not implemented
Selection of subsets of participants
Had we encountered a study where only a subset of participants met the eligibility criteria of our review, we would have only extracted
data for this relevant subset, if separate data for this subset were available or could be obtained.
Assessment of reporting biases
Had we identified more than 10 studies for the same outcome, we would have used funnel plots to assess possible publication bias. In
case of funnel plot asymmetry, we would have considered small-study effects in the meta-analysis (Higgins 2011).
Sensitivity analysis
We would have performed sensitivity analysis by excluding studies with high or unclear risk of bias for sequence generation, allocation
concealment, incomplete outcome reporting or other sources of bias and comparing results with the initial analysis, had more than two
studies been in the comparison.
We would also have carried out sensitivity analyses had we been required to impute data for some studies to be able to perform a meta-
analysis. We would then have excluded the studies with imputed data and compared the results to the initial analysis.
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